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 Exposure to the bacterium, Mycobacterium tuberculosis, only leads to the active form of 
tuberculosis disease (TB) in 5-10% of infected individuals.  The development of active TB, at 
any stage of infection, is often the result of a known TB risk factor, either intrinsic to the 
individual or acquired as a communicable or non-communicable disease. An association 
between diabetes and TB has long been recognized, but only recently was diabetes confirmed 
to increase the risk of developing active TB disease.  The convergence of a growing diabetes 
epidemic on regions with endemic TB has positioned diabetes as an emerging global threat to 
TB control. 
 Of particular importance is the rapidly growing incidence of type 2 diabetes, which 
accounts for up to 95% of the global diabetic population.  Since the potential impact of this 
growing comorbidity has only been recently emphasized, little is known regarding the 
mechanisms of dysregulated immune function and metabolism by which diabetes predisposes 
to active TB disease.  The current understanding of this comorbidity is further limited by the lack 
of appropriate animal models that replicate the pathogenesis of both human type 2 diabetes and 
TB.  The guinea pig is a well-established model of TB that replicates human pathology and 
disease progression.  This species was emphasized in this series of studies with the goal of 
better understanding the impact of type 2 diabetes on TB progression and the mechanisms that 
may change the host response to M. tuberculosis infection. 
 In Chapter 2, we investigated the impact of hyperglycemia alone, induced as post-
prandial hyperglycemia through daily administration of sucrose, on TB disease progression in 
non-diabetic guinea pigs.  Guinea pigs receiving daily sucrose developed both higher bacterial 
burdens in pulmonary and extrapulmonary tissue and also more severe pathology by day 60 of 
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infection.  This exacerbated disease manifestation was accompanied by the accumulation of 
advanced glycation end-products, which are inflammatory by-products of chronic hyperglycemia 
with known involvement in the development of diabetes-related complications.  Interestingly, by 
monitoring glucose and lipid metabolism in these guinea pigs, we learned that TB alone leads to 
severe metabolic disturbances, manifesting as hyperglycemia and accumulation of circulating 
total free fatty acids.  From this study, we were able to conclude that not only does mild post-
prandial hyperglycemia worsen the course of TB disease in guinea pigs, but also, infection with 
M. tuberculosis alone induces metabolic disease resembling diabetes, similar to what has been 
previously reported in human TB.  These conclusions rationalize the investigation of novel 
adjunctive therapies to restore metabolic homeostasis, which may improve the host response to 
infection, limit bacterial growth, and increase the efficacy of frontline antimicrobial drugs.  
 In Chapter 3, we developed a novel model of type 2 diabetes in the guinea pig to be 
used in future investigations of type 2 diabetes-TB comorbidity.  Previously, the guinea pig as a 
diabetic model has been described only in the context of β-cell cytotoxicity with the drug, 
streptozotocin (STZ), but with variable efficacy.  In this study, we initially optimized the dose 
response and STZ preparation to achieve an induction of hyperglycemia that was uniform with 
limited mortality.  This hyperglycemic response was transient but could be stabilized through 
continued β-cell stress, in the form of a high fat, high sugar diet.  Feeding of this modified diet 
led to impaired glucose tolerance and a compensatory β-cell response that could be abrogated 
with the use of a single optimized dose of STZ.  This novel model of type 2 diabetes develops 
both insulin resistance and β-cell failure, which replicate the typical progression of type 2 
diabetes in humans, all within a reasonable experimental timeframe.  From this study, two 
models emerged, a type 2 diabetic guinea pig as well as a model of impaired glucose tolerance, 
or prediabetes, that would be used to investigate the mechanisms of diabetes-TB comorbidity. 
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 In Chapter 4, the newly developed guinea pig models were used to investigate the 
overall impact of type 2 diabetes and impaired glucose tolerance on TB progression and the 
host immune response to M. tuberculosis infection.  Although impaired glucose tolerance alone 
had limited impact on TB progression with exacerbation of disease only at chronic end points, 
M. tuberculosis infected type 2 diabetic guinea pigs closely resembled the reported 
manifestations of human diabetes-TB comorbidity including more severe TB disease, higher 
bacterial burdens, and a robust innate and cell-mediated immune response.  Despite evidence 
of strong Th1 cell-mediated immunity, which is known to be critical for limiting bacterial growth 
and disease progression, diabetic guinea pigs were unable to control bacterial growth and 
developed damaging neutrophilic inflammation.  To better understand the immune mechanisms 
leading to uncontrolled bacterial growth and severe disease, in Chapter 5, we investigated the 
innate and adaptive immune response over the course of early infection in type 2 diabetic 
guinea pigs.  Diabetic guinea pigs were slow to develop early lesions with delayed bacterial 
transport to the lung draining lymph node, and a corresponding delay in antigen-specific Th1 
immunity.  Early alterations in cytokine expression were identified that may explain the delayed 
development of cell-mediated immunity and allow for substantial growth of M. tuberculosis in the 
lung of infected diabetic guinea pigs.  
 These data indicate that not only does type 2 diabetes increase the severity of TB but 
also that the chronic inflammatory process associated with TB itself may worsen diabetes.  This 
has important implications worthy of further investigation revolving around the diagnostic criteria 
for diabetes when associated with TB, the impact of active TB on medical management of 
diabetes, and the investigation of novel therapeutic targets, both metabolic and immunological, 
to enhance the host immune response to infection and limit TB disease severity in diabetics. 
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Review of the Literature 
 
Tuberculosis - Pathophysiology, Disease Diagnosis, and Treatment 
 
Tuberculosis Epidemiology. 
 Tuberculosis (TB), caused by the bacterium, Mycobacterium tuberculosis, is currently 
the second leading cause of mortality due to an infectious disease, behind human 
immunodeficiency virus (HIV).  TB has remained a global health priority since 1993, when a 
surge in HIV-related TB cases coincided with a rising overall TB prevalence and emergence of 
drug resistance1, 2.  The TB DOTS (directly observed treatment, short-course) strategy was 
adopted to improve treatment success and reduce transmission and mortality among TB 
patients, and through demonstrated success, led to a strategy to reverse the trend of rising TB 
prevalence by the year 20153.  The overall goal is to reduce the prevalence and mortality by 
50% compared to the baseline rates in 19904.  In 2012, progress toward this goal indicates that 
the prevalence of TB has been reduced by 37% since 1990 and the mortality reduced by 45%3.  
Although a slow but successful reduction in TB cases has been achieved, at approximately 2% 
per year, TB remains a major global health problem with 8.6 million new TB cases in 2012 and 
1.3 million deaths due to TB5. 
 The major factors that are contributing to the slow rate of decline in TB cases worldwide 
include the continual major contribution of HIV to new TB cases and mortality, the continuing 
expansion and inefficient detection of multidrug resistance, the lack of a vaccine that is 
uniformly effective across the entire population, and the emergence of new risk factors that 
impact TB prevalence and response to treatment5-7.  Of the 8.6 million new TB cases and 1.3 
million deaths in 2012, 1.1 million and 300,000, respectively, were associated with HIV.  As 
such, HIV remains the leading risk factor for the development of active TB disease5.  Globally in 
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2012, 3.6% of new cases, and 20.2% of previously treated TB cases were due to infection with 
multidrug resistant (MDR) strains of M. tuberculosis, which is defined as resistance to isoniazid 
and rifampicin, the two major frontline antimicrobials for TB treatment5, 8.  MDR-TB is associated 
with a significantly lower treatment success rate of 48%, compared to 87% in drug-susceptible 
TB5.  Considering the growing rate of MDR-TB cases, novel therapeutic approaches and new, 
well-tolerated antimicrobial compounds are urgently needed to limit this growing problem.   
 In addition, the true protective efficacy of BCG vaccination, the only current option for 
immunization against M. tuberculosis, remains uncertain7, 9.  The vaccine is frequently 
implemented as a strategy to reduce childhood mortality due to TB, for which it is effective10, 11.  
However, in high burden countries, efficacy of the vaccine in the adult population is variable and 
lends a limited overall efficacy of 50% based on risk reduction in recent meta-analyses, which is 
supported by the high TB burden that remains in countries that practice uniform immunization 
during infancy12, 13.  Hence, the growing rate of antimicrobial resistance, and new emerging risk 
factors, such as diabetes, raise concern that the current suboptimal treatment and preventive 
strategies are not sufficient to control the global tuberculosis burden3, 14. 
  
Transmission and Disease Progression in Tuberculosis. 
 Although TB can affect a variety of organs, this generally occurs via dissemination from 
the lung, which is the portal of entry in almost all cases. Exposure occurs upon encountering an 
infectious aerosol from a person with active pulmonary disease and capable of expelling 
bacteria into the upper airways.  Infectious individuals are generally though to have cavitary 
pulmonary TB with evidence of bacilli by sputum smear1.  Studies involving close contacts have 
shown an infection rate of only 25 - 50% even in the most crowded conditions15.  These data 
indicate that sustained close contact and/or intrinsic host susceptibility factors are important for 
successful transmission of the organism.  Additionally, it has become apparent that expelled 
organisms have adopted a specific phenotype not typical of in vitro culture, indicating that 
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organism specific factors may also play a role in transmission16.  An individual is deemed 
infected if they have detectable cell-mediated immunity.  Among infected individuals, only 
around 5-10% will develop active TB, which is the progressive form of disease and is most likely 
to manifest within five years after exposure15.  The other 90-95% are assumed to have 
developed the latent form of TB (LTBI), where there is no detectable clinical disease and the 
bacteria persist within a location that is not yet fully understood; however, successful 
sterilization by the immune response is possible, but the frequency of this remains unclear17. 
The development of recrudescing active TB from LTBI is known as reactivation and is expected 
to account for the majority of active TB cases, but the contribution of reinfection after successful 
clearance, either by the host response or through antimicrobial treatment, is becoming 
increasingly recognized18.  Most cases of active TB stem from reactivation of a latent infection 
state in areas with low prevalence. In areas of high endemnicity, recent exposure contributes 
greatly to the population with active TB disease19, 20. The factors that lead to LTBI reactivation or 
progression to active TB upon exposure are poorly understood but are at least partially 
attributable to acquired host risk factors21.     
 
Diagnosis of Tuberculosis. 
 Active TB can be diagnosed through a combination of radiographic evidence of active 
disease, detection of the bacterium in sputum by culture or molecular techniques, and acid-fast 
staining of the bacteria in sputum smears22, 23.  A patient with radiographic evidence of active TB 
does not necessarily manifest sputum smear or culture positivity, and alternatively, culture 
evidence may be present without identification of bacilli by direct smear techniques.  In contrast, 
the more frequent manifestation of LTBI poses a greater diagnostic challenge, as diagnosis 
often relies entirely on immunological evidence of infection, although additional strength is 
added by radiographic evidence of pulmonary scarring indicating previous active TB.  The 
tuberculin skin test (TST) remains the most widely used and available test for the immunological 
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diagnosis of M. tuberculosis infection, especially in resource poor communities24.  The TST is 
performed by intradermal injection of purified protein derivative (PPD), a protein preparation 
consisting of greater than 200 antigens precipitated from in vitro culture supernatant of M. 
tuberculosis25.  In individuals that have developed cell-mediated immunity to Mycobacterium 
spp., induration develops at the site of injection due to a T cell-mediated memory recall 
response26.  However, specificity of the TST is a significant issue, as people previously 
vaccinated with BCG will frequently be skin test positive.  Additionally, environmental exposure 
to non-tuberculous Mycobacteria, which have multiple cross-reactive antigens, may also 
develop a TST reaction, leading to false-positive results27, 28.   
 Although general rules exist to help differentiate skin test reactivity in BCG-vaccinated 
versus M. tuberculosis-infected individuals, the more recent implementation of antigen-specific 
blood assays have greatly improved the diagnostic specificity for TB29.  These IFNγ release 
assays (IGRAs) detect the production of IFNγ by antigen-specific memory T cells against the 
immunodominant antigens, ESAT-6 and CFP-10, which are specific to M. tuberculosis and M. 
bovis (as well as M. kansasii and M. marinum)24.  These antigens are products of the region of 
difference 1 (RD1) gene cluster, which is absent in M. bovis BCG as well as most non-
tuberculous mycobacteria.  Two commonly used assays exist for whole blood preparations with 
detection by either traditional ELISA, or by ELISPOT30.  In culture confirmed cases of active TB, 
these IGRA assays demonstrate a sensitivity and specificity exceeding 90%, compared to a 
TST sensitivity of 77%, while BCG vaccination has a large and variable effect on TST 
specificity31.  Accordingly, the IGRA has become an important tool for the diagnosis of LTBI.            
 
Treatment of Tuberculosis. 
 The difficulty in the treatment of tuberculosis lies in the inherent capacity for the 
organism to persist within the host where it is tolerant of antimicrobial therapy, as well as the 
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relatively frequent emergence of genotypic antimicrobial resistance.  The organism may exist 
within the host is essentially three states: extracellular amongst host-derived cellular debris 
(casseous necrosis) and actively replicating, extracellular amongst host casseous debris and in 
a slow or non-replicating state, or intracellular within professional phagocytes32.  The utility of 
antimicrobials targeting bacteria in the intracellular environment is limited by the slow-replicating 
state of the organism and the acidic intracellular environment.  The tolerance of bacteria is an 
extracellular state to antimicrobial therapy has been attributed to a non-replicating state adopted 
by the organism33.  The primary target of antimicrobials may be the rapidly growing extracellular 
compartment, which is readily reduced during antimicrobial therapy but is also the prime site for 
selection of point mutations leading to genotypic resistance.  It is due to this rapid emergence of 
resistance that monotherapy for the treatment of active TB is not utilized34.   
 The first line regimens for the treatment of active disease consist of a combination of 
isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA), with or without ethambutol.  In 
concert, these three drugs are bactericidal against the organism in its various locations and 
growth states within the host35.  The mechanisms of action target mycolic acid synthesis, DNA-
dependent RNA polymerase, and membrane transport systems for INH, RIF and PZA, 
respectively34, 36, 37.  The preferred treatment method is a standard 6-month course utilizing the 
DOTS standards of care.  The initial phase of treatment in patients with active disease, whether 
cavitary or not, involves 8 weeks of INH, RIF, and PZA therapy followed by a continuation phase 
of either 18 additional weeks with INH and RIF if sputum culture negative after initial phase, or 
31 weeks if sputum culture positive32.  The use of combination therapy and prolonged regimens 
are necessary both to prevent emergence of resistance and also to eliminate persistent 
bacterial populations, which are considered to be the source of disease relapse after incomplete 
therapy.  The long regimens are complicated by hepatotoxicity as the major adverse effect, 
which contributes to poor patient compliance and early termination of therapy in some cases38.  
  
 6 
The Immunopathogenesis of Tuberculosis 
 
 The majority of what we know about the immune response to M. tuberculosis and what 
constitutes a favorable response to infection has been investigated in the mouse model of 
tuberculosis39.  Furthermore, many of these investigations have been performed in a single 
inbred strain, C57BL/6, attributable to the readily available knockout and transgenic models on 
this background.  However, important contributions have been made from the guinea pig, rabbit 
and non-human primate models of TB.  From what has been learned in animal models, a central 
theory has emerged for optimal host protection, where the immune response to M. tuberculosis 
infection, particularly as chronic infection is established, is a balance between protection and 
pathology40.  The inflammation that mounts in response to infection should be just enough to 
control bacterial growth, but not so active as to result in host tissue injury.  In forming this 
balance during the immune response in animal models, an equilibrium between host and 
organism is thought to be established where the host response can contain the growth of the 
organism, but not eliminate it, thereby slowing the progression of disease41. Both the innate 
responses to infection as well as an appropriate adaptive T cell-mediated response are involved 
in the host's ability to slow disease progression.  
 
The Innate Response to Infection. 
 It has long been regarded that the primary cell type infected by M. tuberculosis is the 
mature myeloid cell collectively referred to as the macrophage42.  Although seemingly intuitive, 
only recently was it demonstrated that the alveolar macrophage is the first cell to be infected by 
this primarily pulmonary pathogen43.  Furthermore, it is also now recognized that the catch-all 
term of macrophage actually extends to a diversity of cell types that are infected from the 
myeloid cell lineage, and that the kinetics of this is dynamic.  While alveolar macrophages may 
be the first cell to be infected, the rate of infection is quickly exceeded by the rate of neutrophil 
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and dendritic cell infection43, 44.  As the inflammatory response progresses, macrophages that 
are recruited from the periphery to pulmonary sites of inflammation also become infected43, 44.  
One correlate for protection in animal models is the rate by which dendritic cells become 
infected because the establishment of adaptive immunity is dependent on presentation of 
antigens by dendritic cells in the lung-draining lymph nodes45.   
 While other pathogens may utilize mechanisms to evade phagocytosis as a virulence 
factor, M. tuberculosis is promiscuous in receptor binding on macrophages to encourage 
phagocytosis46.  M. tuberculosis has been shown to bind multiple receptors to gain access to 
myeloid cells where bacterial-mediated inhibition of phagolysosomal fusion effectively harbors 
the pathogen initially within the phagosome.  These receptors include complement receptors 
such as CR1 and CR3, transmembrane C-type lectins including the mannose receptor, and 
scavenger receptors including SR-A and CD3646.  In contrast, these receptors play less of a role 
in infecting dendritic cells in vitro, which is mediated predominately by DC-SIGN, a C-type lectin 
that recognizes mannose molecules47, 48.  Host innate pulmonary defense mechanisms such as 
surfactant D, which has an affinity for lipoarabinomannan of M. tuberculosis may enhance 
protection by promoting phagolysosomal fusion, while other surfactant proteins may enhance 
uptake of the bacterium46, 49.   
 Within the host cell the bacterium may exist in multiple intracellular compartments.  The 
recently recognized role of autophagy adds an additional factor to consider in the intracellular 
fate of the bacterium, beyond the long-accepted process of preventing phagosomal 
maturation46, 50, 51.  The type VII secretion system, ESX-1, of M. tuberculosis facilitates 
phagosomal degradation and escape, allowing the organism to replicate in the cytosol51, 52.  It is 
thought that this ESX-1 system allows for the initial recognition of the pathogen by gaining 
access to cytsolic pattern recognition receptors including NOD2, which occurs only if the ESX-1 
system is intact53, 54.  Organisms residing in the cytosol may become ubiquinated and 
sequestered further in an autophagosome, which facilitates antigen presentation, as has been 
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shown in M. marinum infected macrophages55.  However, M. tuberculosis is able to inhibit 
autophagy, leading to suppressed innate immune defenses56.  Therefore, M. tuberculosis 
follows a complex intracellular survival pattern that reduces host recognition of the organism 
and limits an effective immune response. 
 Some of the most recognized receptors participating in the early response to infection 
include NOD2, C-type lectins, and of the Toll-like receptors, TLR-2 is particularly recognized for 
initiating inflammation in response to M. tuberculosis infection. However, the critical role of the 
adaptor protein MyD88 in initiating the response to infection is not entirely TLR-dependent and 
is also heavily influenced by signaling through the IL-1 receptor57.  MyD88 and IL-1 receptor 
knock-out mice are capable of generating an antigen specific response in the lung but they 
develop acute, severe pneumonia, a process that has been attributed to reduced bactericidal 
capacity of phagocytes58.  The innate response to M. tuberculosis infection leads to synthesis of 
IL-12, which promotes a Th1-skewed T cell response.  The production of IL-12 is critical for 
dendritic cell migration to the tracheobronchial lymph nodes.  However, TLR signaling is linked 
to efficient induction of effector T cells and therefore may be involved in balancing the protection 
of the host59, 60.  
 The production of TNFα during the innate response to infection, similar to IFNγ during 
the adaptive response, is an indispensable cytokine61.  TNFα is a macrophage activation signal 
that synergizes with IFNγ.  The induction of apoptosis by TNFα is recognized in vitro, and the 
importance of inducing this cell death mechanism in vivo is becoming increasingly recognized61, 
62.  Recently, it has been demonstrated in the zebra fish model of M. marinum infection, that 
optimal TNFα levels are required because TNFα in reduced or excess concentration promotes 
necrosis, an unfavorable mechanism of cell death, and inflammation63.  Mice deficient in TNFα 
have been shown to develop a severe inflammatory response that does not necessarily 
correlate with high bacterial load, indicating that this cytokine has regulatory function as well64.   
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The Adaptive Response to Infection. 
 CD4 T cells are absolutely necessary for an effective response to M. tuberculosis 
infection, and more specifically a Th1-skewed response65.  This is most obvious in mouse 
models lacking IFNγ, which rapidly succumb to progressive TB, but also in human populations 
where a lack of CD4 T cells due to HIV infection is the major risk factor for the development of 
TB65-67.  The beneficial effects of adoptively transferring T cells to deficient hosts demonstrated 
the requirement of T cells in a successful response68.  Evidence from mice suggest that the 
development of classic casseous necrosis is dependent of the T cell population however this 
has been challenged in the guinea pig model where kinetic studies have demonstrated that 
casseous necrosis precedes the accumulation of T cells in the granuloma69, 70.  This 
dependency on a T cell response is related to the generation of IFNγ because cessation of 
bacterial growth correlates with the arrival of IFNγ-producing T cells in the lung in multiple 
studies39, 71, 72.   
 The generation of a functional adaptive response with antigen-specific T cells is notably 
delayed in tuberculosis when compared to other intracellular infections and the timing is the 
most critical aspect of the adaptive response to M. tuberculosis infection73.  If it is too slow, 
bacterial growth cannot be controlled, but in the presence of an already established cell-
mediated response, the host is much more successful in limiting the infection73.  However, the 
efficacy of an existing antigen-specific cell-mediated response is limited in its ability to induce 
bactericidal activity, since the adoptive transfer of primed effector CD4 T cells still cannot control 
the intracellular growth of bacteria in the first seven days of infection74.  This suggests that the 
organism is not recognized during this stage and provides insight into why prior BCG 
vaccination does not lead to sterilizing immunity even in animal models75.  This varying process 
is evident within the same infected host, where early granulomata display progressive bacterial 
growth, while disseminated granulomata, which contain antigen specific T cells, contain much 
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lower bacterial loads76, 77.  The genetic susceptibility of mice to M. tuberculosis, is at least in part 
due to the timing and strength of the adaptive response78.  The generation of adaptive immunity 
is further delayed in susceptible mouse strains, when compared to resistant strains79, 80.  This is 
potentially the result of failed migration of antigen presenting cells since lymph node initiation is 
essential and susceptible strains have delayed arrival of bacteria in the lung-draining lymph 
node43, 45, 71, 78.  Inhibition of apoptosis by M. tuberculosis may contribute significantly to this 
delay since dendritic cell acquisition of the bacteria or bacterial products is greatly enhanced by 
apoptosis44.  This is supported by a number of studies that have demonstrated enhanced 
adaptive immune function when animals are infected with pro-apoptotic strains of M. 
tuberculosis or M. bovis BCG81, 82.  Recent studies suggest that the balance of cell death 
between apoptosis and necrosis is related to eicosanoid production, where lipoxins promote 
necrosis and prostaglandins promote apoptosis83.  
 Although the events that occur immediately after low-dose aerosol infection remain 
poorly understood, the first evidence of bacterial dissemination is via the lymphatics to the lung 
draining lymph node by day 9 of infection at the earliest in resistant mouse strains45, 78.  
Interestingly, during this time, no mediators have been shown to accelerate the dissemination 
and earlier initiation of the response in the lymph node, which has been attempted with external 
inflammatory stimuli expected to enhance migratory activity, such as LPS45.  However, upon 
antigen arrival in the lymph node, activation of naive T cells and their accumulation in the lung 
occurs with anticipated kinetics and therefore, it is the early innate pulmonary response that 
accounts for delayed priming of an adaptive response84.   
 The protective effect of cell-mediated immunity has been attributed to the production of 
IFNγ.  Mice lacking this cytokine have uncontrolled bacterial growth and rapidly succumb to 
progressive TB disease66.  Part of the protective effect of IFNγ is through macrophage 
activation, which upregulates MHCII and CD80/86 co-stimulatory molecule surface expression 
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and activates microbicidal functions85.  In murine macrophages, inducible nitric oxide synthase 
(NOS2) is a potent bactericidal mechanism induced by IFNγ, which leads to production of 
reactive nitrogen intermediates that may be directly bactericidal although recently, the 
bactericidal effect of nitric oxide has been attributed to the induction of apoptosis86, 87.  However, 
the role of nitric oxide in human disease has been debated88. IFNγ also promotes phagosomal 
maturation and induces autophagy, which may both increase bactericidal capacity and promote 
antigen presentation89, 90. The impairment of autophagy even in the presence of IFNγ increases 
intracellular bacterial viability90.  In mice lacking functional CD4 T cells, there is a tendency 
toward heavy granulocytic inflammation, findings that suggest an anti-inflammatory component 
to CD4 T cells and IFNγ production, in addition to the classical paradigm of activating infected 
macrophages91.  This failure to develop the classical well developed granulomata with casseous 
necrosis in exchange for more neutrophil-mediated injury is also replicated in HIV-infected 
individuals with depleted CD4 T cell counts92.  More recently, it was demonstrated that this anti-
inflammatory property of IFNγ might result from reducing the production of IL-1β, a potent pro-
inflammatory cytokine involved in the recruitment of neutrophils93.  However, the opposite is true 
in lymphopenic HIV-TB patients receiving antiretroviral therapy that develop immune 
reconstitution inflammatory syndrome (IRIS), which is a highly suppurative process dependent 
on restoration of CD4 T cell help94, 95.  In αβTCR-deletion mice infected with M. avium, adoptive 
transfer of functional antigen-specific T cells into mice with high pulmonary bacterial burden, 
leads to massive exacerbation of the innate cellular response resulting in injurious tissue 
pathology96.   These data indicate that although T cells are generally thought to be protective, 
there is a balance between anti- and pro-inflammatory functions of T cells.  
 Although the majority of research on the adaptive response to M. tuberculosis heavily 
emphasizes the protective role of the CD4 T cell, CD8 T cells also play a critical, but 
independent role.  Evidence suggests that CD1-mediated antigen presentation of lipids are 
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involved in CD8 T cell immunity against M. tuberculosis as well as CD1-restricted T cells97. To 
date, there is limited evidence of the importance of CD8 T cells in human TB, but multiple 
animal models demonstrate their importance46.  Mice lacking CD8 T cells have reduced survival 
that is intermediate compared to a lack of CD4 T cells98.  Non-human primates with antibody-
mediated depletion of CD8 T cells develop more severe disease and higher bacterial burdens 
earlier in infection99.  Depletion of these cells in NHPs exposed and cleared with antimicrobials 
resulted in a complete loss of protective immunity upon reinfection99, results which provide 
rationale for targeting CD8 T cell memory during vaccination against M. tuberculosis.  Recently, 
the priming of CD8 T cell immunity during infection and with BCG vaccination has demonstrated 
a critical role for dendritic cell cross-presentation, a process significantly enhanced by 
apoptosis, as indicated by pro-apoptotic mutants of both M. tuberculosis and M. bovis BCG100, 
101, data which suggests that a CD8 T cell response may be enhanced by improving the rate of 
apoptosis compared to necrosis of infected cells102.  
 The generation of antigen-specific regulatory T cells (Treg) occurs simultaneously with the 
onset of CD4 and CD8 effector T cell responses and subsequently, their accumulation in the 
lung parallels that of the Th1 effector response103.  Regulatory T cells are expected to delay 
priming of newly activated T cells through several potential mechanisms including 
downregulation of co-stimulatory molecules on dendritic cells and macrophages, or impairment 
of the effector response through IL-10 or TGF-β40.  It has been demonstrated that regulatory T 
cells in TB develop to specific M. tuberculosis antigens and that their development delays the 
onset of protective pulmonary immunity104.  Elimination of this cell population can improve the 
effector T cell response and result in a modest reduction in bacterial burden103, 105.  Thus, while 
it appears that expansion of regulatory T cells is an unfavorable natural response, the true role 
of this population in regulating the response to chronic infection requires further investigation.  
An additional regulatory cytokine prominently expressed during tuberculosis is IL-10.  The 
propensity for production of IL-10 in the innate response in humans is associated with a 
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tendency toward development of active TB disease, but the strength of this association has 
been challenged106, 107.  This negative impact of IL-10 is also supported by the observation that 
certain strains of M. tuberculosis susceptible mice produce higher levels of IL-10108. Production 
is not limited to regulatory T cells but the impairment of CD4 T cell response is supported by 
improved migration of IFNγ-producing cells to the lung in IL-10 deficient mice and an improved 
response to BCG vaccination109, 110.      
 The production of the cytokine IL-17 represents an additional critical mediator of the 
response to M. tuberculosis but may also have a detrimental impact on disease progression 
when present in persistently high concentrations.  IL-17 is produced very early in infection prior 
to the onset of the adaptive response and comes predominately from the residing γδ T cell 
population in the lung111. Neutrophils are among the first cells to arrive to the site of infection, as 
with any other bacterial infection, but this response is hindered in the mouse in the absence of 
IL-17112.  Depleting neutrophils early in infection is known to reduce IFNγ production in organs 
later in disease, indicating an important role for neutrophils early in infection113.  IL-17 production 
from antigen specific Th17 cells does occur later in the course of infection.  It has been 
demonstrated that this population is important for a memory T cell response in experimental 
vaccine studies, which is dependent on production of IL-23 and IL-17, and that an accelerated 
recall response is hindered in the absence of these cells114.   
 
The Influence of TB Risk Factors on the Immune Response to M. tuberculosis. 
 The response to infection with M. tuberculosis is infrequently modeled in the context of 
known acquired risk factors, although these are well recognized to promote active or 
reactivation TB disease115.  HIV is the leading risk factor for TB and the immune defect of low 
CD4 T cell counts is well-established67.  Beyond HIV, malnutrition is among the most significant 
risk factors for TB and has been previously modeled in guinea pigs fed a protein-poor diet116.  
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Overall, protein malnourished guinea pigs demonstrated a compromised immune response with 
inability to control bacterial growth in infected macrophages, impaired lymphoproliferation in 
response to PPD, and a reduced production of TNFα.  Smoking, also a TB risk factor, has 
recently been evaluated in a mouse model of cigarette smoke exposure and in vitro in human 
cells.  Data suggested impaired killing of bacteria in human primary macrophages and reduced 
tissue influx of TNFα and IFNγ producing cells.  Additionally, IL-12 and TNFα production by 
dendritic cells was reduced in mice, which may be related to the lower IFNγ production in 
tissue117.  These data indicate that cigarette smoke suppresses the protective immune response 
to M. tuberculosis infection.  Diabetes, described in greater detail in the following sections, is a 
known risk factor for developing active TB with growing importance.  Similar to other risk factors, 
the mechanisms that lead to increased susceptibility to TB in diabetic humans remain poorly 
defined and the validation of animal models for this comorbidity has been limited14.  
 
Diabetes Mellitus - Diagnosis and Pathogenesis 
 
General Classification and Diagnosis of Diabetes. 
 Diabetes mellitus, in general, is a disease caused by a lack or dysfunction of the 
hormone insulin, whose most important physiologic function is to maintain glucose homeostasis. 
Elevated glucose, or hyperglycemia, is the hallmark feature of diabetes mellitus.  As recognized 
by the American Diabetes Association, diabetes mellitus can generally be divided into two forms 
based on etiopathogenesis, either type 1 or type 2118.  Type 1 diabetes is an autoimmune 
disease associated with specific destruction of β-cells, that ultimately, leads to absolute insulin 
deficiency, thereby requiring insulin therapy for treatment.  Thus, this form has been previously 
referred to as insulin-dependent diabetes; however, the convention is to no longer use this 
terminology since it refers simply to treatment requirements rather than disease pathogenesis.  
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Approximately, 5-10% of the diabetic population has type 1 diabetes and in approximately 90%, 
one or more autoantibodies to islet cell antigens, insulin, GAD, and tyrosine phosphatases IA-2 
and IA-2β can be detected concurrently with fasting hyperglycemia118, 119.    
 Type 2 diabetes accounts for 90-95% of the diabetic population and has previously been 
referred to as non-insulin dependent diabetes, since most type 2 diabetes patients do not 
progress to a stage of absolute insulin deficiency that would require insulin replacement 
therapy.  This form of the disease encompasses any range of a syndrome known as insulin 
resistance, along with a relative, rather than absolute, insulin deficiency.  Most often, patients 
with this form are obese, but some type 2 diabetes patients that are not obese may have a 
disproportionate distribution of fat within the abdomen, as opposed to a subcutaneous location.  
A genetic predisposition for abdominal adiposity is recognized in Indian and Asian populations, 
a feature that has been attributed to the rapidly rising incidence of type 2 diabetes in these 
global regions120, 121.  A recent study demonstrated a much higher prevalence of diabetes in 
people of Asian heritage (23%) when compared to Caucasian descent (6%), which may be a 
reflection of generally lower β-cell function in this population122.  The type 2 form of diabetes is 
insidious in onset and often remains undiagnosed for years because classical clinical signs of 
diabetes do not develop with the severity that is typical of type 1 diabetes118, 123.  
 Additionally, two other forms of diabetes are recognized including gestational diabetes 
and those attributed to specific genetic defects in insulin-producing β-cells.  Gestational 
diabetes is a temporal state of diabetes associated with approximately 7% of pregnancies and 
most often resolves after birth, although it can contribute to progressive loss of beta cell function 
and ultimately lead to overt diabetes118, 124.  Patients with genetic defects in β-cell function are 
referred to as having monogenic diabetes or maturity-onset diabetes of the young (MODY) and 
generally develop diabetes around the age of 20 years.  Six genetic defects have been 
identified to date that relate to glucose sensing, or insulin production/secretion defects118, 125.     
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 A diagnosis of diabetes is based on criteria of glucose metabolism with evidence of 
hyperglycemia.  The American Diabetes Association has provided guidelines for the diagnosis 
of overt diabetes as well as those at risk for developing diabetes, based on multiple analyses of 
glucose metabolism including fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) 
and glycated hemoglobin (HbA1c), with any one or more being abnormal in a diabetic individual.  
The 75-gram OGTT is the most common and most sensitive of routine methods for the 
diagnosis of diabetes123.  This is likely reflective of the inherent strengths of this test in 
evaluating post-prandial glucose utilization, a time when glucose levels are at their physiologic 
peak and when the functional demand of β-cells is at its highest.  Additionally, an oral route of 
administration also evaluates the axis of glucose-sensitive incretin hormones, such as GIP and 
GLP-1, which are produced by the GI tract postprandially and act to increase insulin secretion 
and insulin sensitivity126.  In this test, a patient is fasted overnight; glucose measured prior to 
initiating the test, and then administered an oral bolus of glucose solution (75 g).  Glucose is 
measured over time through 120 minutes post glucose administration.  Fasting plasma glucose 
(FPG) at the start of the test and at the 2-hour time point is used for diabetes diagnosis.  The 
criteria for a diagnosis of diabetes are FPG ≥ 126 mg/dl and 2-hour OGTT ≥ 200 mg/dl118.  More 
recently, it has been suggested that the 1-hour OGTT time point may also be beneficial in 
identifying patients at risk of developing diabetes, which can be defined as having a syndrome 
known as prediabetes127.   
 An additional criterion has recently been set that reflects the degree of hyperglycemia 
over time, as measured by HbA1c118.  This test is based on the level by which the hemoglobin 
protein is modified by circulating glucose, which measures the level of Amadori product 
formation.  Amadori products are the rearrangement of Schiff bases, which is the chemical 
modification by a sugar molecule on a free amine group, such as that contained on the N-
terminus of proteins or on amino acids with free amine groups, including lysine and arginine. 
Glucose present in higher circulating concentrations for an extended period of time yields more 
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Amadori modified hemoglobin and is the basis for this test.  The HbA1c test specifically targets 
modifications of the N-terminal valine residue on the alpha chain and is reported most 
commonly as percent modified hemoglobin, with the ADA cut-off value for a diagnosis of 
diabetes being ≥ 6.5%.  However, the measurement of A1c is only around 66% sensitive when 
compared to the 2-hour OGTT123.  Arguments can be made regarding the benefit of HbA1c as a 
diagnostic tool but the OGTT remains the primary standard for diagnosis and it is generally 
recommended that HbA1c be utilized as a tool to monitor the level of hyperglycemic control in 
diabetic patients128.  
 
The Pathogenesis of Insulin Resistance and Contribution to Type 2 Diabetes. 
 Insulin resistance is defined as the inability of insulin to exhibit biologic activity at normal 
physiologic concentrations.  Obesity is the greatest predictor of insulin resistance and type 2 
diabetes; and insulin resistance both precedes and predicts the development of type 2 diabetes.  
While insulin resistance contributes directly to the progression of type 2 diabetes, it is not 
sufficient to induce overt diabetes when β-cells of the pancreatic islets are functioning at normal 
capacity.  The development of type 2 diabetes represents a continuum of insulin resistance and 
progressive β-cell loss until compensation by insulin secretion is no longer capable of 
restraining diabetic levels of hyperglycemia, a process that generally spans a period of years.      
 In the context of glucose metabolism, insulin resistance leads to both a failure to 
suppress endogenous glucose production by the liver in basal and post-prandial states, as well 
as reduced peripheral uptake of glucose in insulin-dependent target cells such as skeletal 
muscle and adipose tissue129.  Alterations in lipid metabolism in both liver and adipose make the 
most significant contribution to the development of systemic insulin resistance, while impaired 
insulin signaling in skeletal muscle makes the greatest contribution to impaired peripheral 
glucose clearance.  The storage of lipid as triglycerides in adipose tissue is highly dependent on 
 18 
a functional insulin-signaling pathway.  Therefore, in states of insulin resistance, a higher basal 
level of adipose tissue lipolysis is present, leading to increased circulating fatty acids with 
downstream effects on other organs and further impairment of the insulin response130.    
 The development of hepatic insulin resistance is linked to accumulation of excess fat 
within the liver131.  Hepatic lipid accumulation in obesity is the result of both an increased rate of 
lipolysis from adipose tissue and from de novo synthesis in the liver, which is markedly 
increased in type 2 diabetic patients and is linked to excess consumption of carbohydrates132, 
133.  Recent research in the pathogenesis of type 2 diabetes has revealed that lipid accumulation 
in the liver is a critical mediator of insulin resistance and that when extreme hypocaloric dietary 
interventions are employed, there is a drastic reduction in liver fat, improved insulin production 
in β-cells, and a return to a basal euglycemic state comparable to non-diabetic individuals134.  
This marked and rapid improvement in glucose and lipid metabolism, and restoration of normal 
glucose tolerance is also consistently demonstrated in patients undergoing bariatric surgery, 
often with improvement over what can be achieved with medical interventions135.  These data 
indicate that insulin resistance and type 2 diabetes are reversible, assuming that sufficient 
insulin-producing capacity remains.  
 It is well documented now that the activation of inflammatory pathways in adipose tissue 
is responsible, at least in part, for the development of systemic insulin resistance136.  Elevated 
serum levels of IL-1β, IL-6 and the acute phase protein, C-reactive protein, are predictive of type 
2 diabetes in humans137, 138.  As fat mass increases, a distinct polarization of pro- and anti-
inflammatory mediator expression develops with a balance shifted toward local adipose 
inflammation, which has systemic effects139, 140.  Evidence for an inflammation-mediated 
pathogenesis of insulin resistance was first documented nearly a century ago when anti-
inflammatory salicylates were noted to completely reverse hyperglycemia in diabetic patients141.  
Several studies have since documented this further, and recently have been pursued in clinical 
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trials as a type 2 diabetes treatment option142.  However, the concept of an inflammatory-
mediated pathogenesis was initiated by experiments that first demonstrated adipose tissue-
derived TNFα as an inducer of systemic insulin resistance in mouse models of obesity143-146. 
 Macrophages are a normal constituent of adipose tissue but in non-obese, metabolically 
healthy individuals, these are present in low numbers.  However, as lipid-mediated inflammatory 
signals are activated, there is recruitment of additional macrophages and a shift toward the pro-
inflammatory M1 phenotype of adipose-associated macrophages147, 148.  In obesity-related 
insulin resistance, adipose tissue macrophages can account for up to 50% of visceral adipose 
mass149, 150. This accumulation of macrophages has been linked to production of MCP-1 (CCL2) 
in adipose tissue151 and accompanies the expression of other pro-inflammatory cytokines that 
are produced exclusively by adipose such as leptin, known as adipokines, as well as mediators 
that may be produced by both adipocytes and macrophages, including IL-6, TNFα, IL-1β, and 
resistin152, 153.  Anti-TNFα and IL-1β targeted therapy have been shown to restore insulin 
sensitivity and although the role of IL-6 has been controversial, the specific deletion of IL-6 in 
adipose, protects against insulin resistance specifically by promoting hepatic insulin sensitivity 
136, 154-156.  In contrast, anti-inflammatory mediators produced in adipose such as the adipokine, 
adiponectin, and IL-10 are significantly reduced in states of obesity and insulin resistance.  
 High fat diet and excessive accumulation of lipid in adipocytes activates inflammation 
through JNK and IKKβ/NFkB pathways via signaling through pattern recognition receptors, 
induction of ROS and ER stress, and via activation of protein kinase C isoforms.  Although this 
may be initiated by both adipocytes and resident adipose-associated macrophages, it is the 
accumulating macrophages that account for the majority of the inflammatory response as 
disease progresses.  JNK activation mediates insulin resistance through serine phosphorylation 
and inactivation of insulin receptor substrate 1, a major adaptor protein required in the insulin 
receptor signaling pathway139.  The mechanisms of direct NFkB induction of cellular insulin 
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resistance are less well understood, but the inflammatory-mediated induction of lipolysis in 
adipose tissue leads to free fatty acid mediated insulin resistance through similar interference 
with insulin receptor signaling in skeletal myocytes and hepatocytes157, 158.                
 The resulting increase in circulating free fatty acids, which correlate with human obesity 
and insulin resistance, are known mediators of insulin resistance, particularly in skeletal 
muscle130, 159.  Free fatty acids are metabolized within skeletal myocytes, leading to 
accumulation of diacylglycerol, which activate protein kinase C isoforms capable of serine 
phosphorylation, which inactivates insulin receptor substrate proteins and reduces transport of 
GLUT4 transporters to the cell surface160, 161.  Free fatty acids may also directly signal through 
pattern recognition receptors TLR2 and TLR4 on myocytes, adipocytes and macrophages to 
induce JNK and IKKβ signaling pathways, both of which may inactivate IRS proteins by serine 
phosphorylation.  The manifestation of this is reduced insulin signaling and glucose transport, 
which translates to systemic insulin resistance162-164.  In the liver, downstream activation of 
glycogen synthase is lost, leading to decreased glycogen synthesis and failure to suppress the 
hepatic gluconeogenesis159.   
 
Beta Cell Dysfunction in Type 2 Diabetes. 
 Insulin resistance both precedes and coincides with type 2 diabetes; however, not all 
people with insulin resistance will develop type 2 diabetes.  The disease pathogenesis also 
requires a defect in β-cell function.  While previously, the defect in β-cell function was attributed 
to persistent stress on the cells as a result of insulin resistance, more recent evidence suggests 
that these two critical components likely develop independently, then synergize to promote the 
onset of type 2 diabetes165.  Individuals with normal beta cell function have the capacity to fully 
compensate for the presence of insulin resistance and it has been shown that β-cell dysfunction 
can be demonstrated in people even before the development of insulin resistance, suggesting 
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that this is a preceding and independent process166, 167.  β-cell dysfunction is predictive of 
developing type 2 diabetes, and is more likely attributable to polygenetic factors, in contrast to 
insulin resistance, which develops as a result of environmental influences168, 169.  
 There is approximately a 50% reduction in total β-cell mass in patients with type 2 
diabetes, indicating that loss of cells contributes to the pathogenesis in addition to 
dysfunction170, 171.  The failure of β-cells can be attributed to a number of mechanisms, which 
generally derive from metabolic stress of high glucose and fatty acids, known as glucotoxicity 
and lipotoxicity.  This process dampens the normal compensatory response of β-cells and leads 
to cell death.  The compensatory mechanisms of β-cells, beyond hypersecretion of insulin, are 
to; 1) proliferate and increase in number, which occurs in humans but to a lesser degree than 
that seen in rodent models; or 2) through derivation of new β-cells, termed neogenesis.  
Proliferation is thought to contribute more than neogenesis to the compensatory response172.  
However, in response to diabetic stressors including hyperglycemia, increased fatty acids, 
oxidative stress and induction of cytokines, particularly IL-1β173, the cells are reduced in their 
ability to proliferate and convert proinsulin to active insulin, and are also prone to undergoing 
apoptosis174-176.  Apoptosis is thought to be a major contributor to the overall reduction in β-cell 
mass that is typical of type 2 diabetes177.  Additionally, there is evidence in rodents that 
dedifferentiation of β-cells may play a role in cellular loss by transformation into glucagon-
producing α-cells, which has also been demonstrated in isolated human islets from diabetic 
patients178, 179.  This may further worsen metabolic defects associated with diabetes and also 






Treatment Options for Insulin Resistance and Type 2 Diabetes. 
 An abundance of metabolic targets exist as therapeutic options for the treatment of type 
2 diabetes; however, those most commonly utilized as frontline therapy for glucose control in 
people newly diagnosed with type 2 diabetes also provide the opportunity to validate new type 2 
diabetes models with these compounds. The most common frontline drugs for the treatment of 
type 2 diabetes include the biguanide, thiazolidinedione (TZD), sulfonylurea, and GLP-1 classes 
of drugs.  Based on recommendations from the American Diabetes Association, the level of 
hyperglycemic control should be monitored through HbA1c, and monotherapy initiated with the 
biguanide, metformin, in addition to lifestyle interventions such as dietary restriction and 
increased physical activity.  After 3 months, if HbA1c is not improved, dual therapy with either a 
sulfonylurea, TZD, or GLP-1 agonist may be added to the metformin regimen123.  Additional 
drugs might be further considered if hyperglycemic control is still not achieved; however, the use 
of insulin in type 2 diabetes is generally reserved as a final approach to glucose control. 
 Metformin is the frontline drug of choice for initial therapy of type 2 diabetes and belongs 
to the biguanide class of compounds.  The primary mechanism of action and glucose-lowering 
effect of metformin is through activation of AMPK in hepatocytes, leading to reduced 
gluconeogenesis in a manner independent of insulin181.  The TZD class of drugs includes the 
most commonly used member, rosiglitazone, as well as troglitazone.  These compounds are 
agonists for the PPARγ nuclear receptor expressed in adipocytes, in which activation leads to 
enhanced uptake and storage of lipids in adipose tissue182.  The sulfonylureas, such as glipizide 
and glipuride, bind to the sulfonylurea receptor on β-cells and promote insulin release via 





Risk for Infection as a Complication of Diabetes. 
 Diabetes, in general, is frequently linked to a higher risk for infection; however, due to a 
frequency of conflicting results, the mechanisms of this increased risk are not fully 
understood184.   A recent epidemiological study demonstrated that people with both type 1 and 
type 2 diabetes are, in general, at greater risk of infections of the respiratory tract, urinary tract, 
and skin/mucous membranes185.  Diabetic foot infection is the most common example of an 
infectious complication, and is often paired with additional diabetic complications of the 
peripheral nerves and microvasculature, indicating that the underlying mechanisms of diabetic 
infections likely extend beyond an impairment of the immune system alone186.  Diabetic patients 
were demonstrated to be 2.17- and 1.92-times more likely to suffer hospitalization or death, 
respectively from an infectious etiology187.  This increased risk is likely to be both a 
manifestation of host and organism specific factors that occur under diabetic conditions.  The 
fact that hyperglycemic control greatly improves the response to treatment and outcome is 
evidence that elevated glucose may be among the more important diabetic factors contributing 
to higher risk of infection185.    
 Cellular defects have been described in neutrophils, macrophages and T cells in 
association with diabetes. The defects in innate cell function are more consistently reported, 
including impaired chemotaxis, adhesion, phagocytosis, and bactericidal activity against 
intracellular pathogens.  Neutrophils from diabetic patients are reported to display enhanced 
adhesion to vascular endothelium, which correlates with increased leukocyte integrin expression 
along with higher adhesion molecule expression on the endothelial surface188, 189.  Despite 
higher adhesion, several reports of impaired neutrophil chemotaxis and transmigration in vitro 
are reported, both with and without correlation to hyperglycemia and glycation190-192.  Similar 
impaired chemotaxis has also been reported in peripheral blood monocytes from patients with 
diabetes193.  In contrast, in hyperinsulinemic patients, an improvement in neutrophil chemotaxis 
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has been demonstrated, which suggests that the glucose lowering effects of insulin therapy may 
not be the only benefit in improving the course of infection194.   
 Contrasting results also exist among studies evaluating neutrophil phagocytic capacity.  
Studies have shown both defective and normal phagocytosis of opsonized bacteria in diabetes 
and no difference in the ability of diabetic neutrophils to phagocytize opsonized latex beads192. 
Additionally, impaired phagocytic activity has been demonstrated in monocytes and alveolar 
macrophages from diabetic patients as well as peritoneal macrophages in mice195-197.  More 
consistently, a reduced ability to generate a respiratory burst in response to pathogens has 
been described, which is attributed to hyperglycemic induction of the polyol pathway198-200.  This 
leads to consumption of NADPH, the necessary substrate for oxidative burst, by the enzyme 
aldose reductase.  This defect has been confirmed by improved neutrophil superoxide 
generation from diabetic cells in the presence of aldose reductase inhibitors201, 202.  However, an 
increase in respiratory burst in neutrophils from type 2 diabetic patients has also been 
observed203.  
 Altered T cell function is the most commonly reported defect in the adaptive response of 
individuals with diabetes.  In diabetic patients with relatively controlled hyperglycemia, studies 
have shown both impaired proliferation in response to specific antigens, as well as a robust 
antigen-specific T cell responses equivalent to non-diabetic patients204, 205.  Impaired 
proliferation has also been demonstrated in mice with STZ-induced diabetes and in mouse 
lymphocytes cultured in the presence of high glucose206.   In a separate study investigating T 
cell response to M. tuberculosis antigens, it was found that the antigen-specific response was 
unaltered but that diabetic T cells had an impaired ability to proliferate in the presence of non-
specific stimulation with phytohemagglutinin207.  Although antibody production in response to 
vaccination does not appear to be impaired in diabetic people, antibodies produced may be 
modified by non-enzymatic glycation, which parallels the level of HbA1c208-211.  However, since 
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the humoral response appears to be equivalent regardless of the diabetic state, the clinical 
relevance of this is uncertain.         
 From these studies investigating mechanistic defects in immune function, it is apparent 
that variable and often contrasting results exist.  This may be a reflection of differences in 
experimental conditions or the level of hyperglycemic control in the sampled populations.  
Additionally, there may be differences in critical pathways needed for protection against specific 
agents, and thus, the deviations in host response must be taken into context of what is 
protective for a given pathogen.  It is known that virulence is enhanced in the presence of high 
glucose for pathogens such as Candida and Klebsiella; and Klebsiella and Burkholderia 
pseudomallei both have a disproportionately high prevalence in people with diabetes. This 
suggests that specific pathogens may take advantage of "excess nutrients" in the host and 
indicates that both host and pathogen response may need consideration for each disease 
studied.  Whether this is also the case for M. tuberculosis under diabetic conditions is unknown.   
 
Mechanisms of Diabetic Complications and Potential Contributions to TB Susceptibility. 
 Hyperglycemia is a major contributor to the onset and progression of diabetic 
complications, which account for the majority of diabetes-related morbidity and mortality. The 
pathogenesis of diabetic complications involves a combination of oxidative stress and 
inflammatory mediators, which promote microvascular dysfunction, the major underlying factor 
of these complications.  The DCCT/EDIC (type 1) and UKPDS (type 2) represent large 
prospective studies that have followed diabetic patients in their control of hyperglycemia, split 
into intensively managed versus those conventionally managed, and the development of 
complications over multiple years.  These studies have demonstrated that prolonged exposure 
to high glucose is a predictor of diabetic complications and that glucose control can significantly 
delay their onset212, 213.  However, follow up in these studies indicated that despite convergence 
of HbA1c between previously controlled treatment groups, the emergence of complications 
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continued on a similar path.  This indicates that there are lasting effects from previous chronic 
elevations in glucose, which has been termed "glycemic memory".  This has important 
implications in the early diagnosis and management of hyperglycemia, the continued monitoring 
for complications even if hyperglycemia becomes well controlled, and the need for a better 
understanding of the underlying mechanisms of glycemic memory.  
 The pathobiology of diabetic complications is linked to biochemical abnormalities in the 
glycolysis pathway that result from elevated glucose concentrations.  As described by Brownlee, 
five major mechanisms by which hyperglycemia causes diabetic complications are supported by 
an abundance of literature214.  These five pathways include; 1) increased glucose flux in the 
polyol pathway; 2) Increased formation of intracellular dicarbonyl-derived advanced glycation 
end-products (AGEs); 3) Increased signaling through the receptor for advanced glycation end 
products (RAGE) and increased expression of its ligands; 4) Activation of isoforms of protein 
kinase C (PKC); and 5) A hyperactive hexosamine pathway.  Evidence from Brownlee et al. 
supports an oxidative stress origin of all five mechanisms around the overproduction of 
mitochondrial superoxide due to intracellular hyperglycemia, which inhibits the glycolytic 
enzyme, GAPDH.  As a result, metabolic by-products of glucose are shunted into alternative 
and detrimental pathways215, 216.    
 Evidence from TB patients with diabetes suggests that, similar to the more typical 
diabetes complications, TB may also represent a "complication" of chronic hyperglycemia.  Both 
human and animal studies have shown that poorly controlled and chronic hyperglycemia is an 
important factor in the increased risk of TB in diabetic individuals217-219.  The unifying mechanism 
of oxidative stress and superoxide production in diabetic complications may also have a 
significant impact on immune function.  Activation of protein kinase C isoforms through 
diacylglycerol accumulation not only impacts liver and skeletal muscle in type 2 diabetes, but 
also may have significant effects on T cell function220.  Hyperglycemia-mediated oxidative stress 
activates the redox sensitive, pro-inflammatory transcription factor, NFkB, leading to sustained 
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inflammatory effects, as well as the depletion of the major intracellular antioxidant, reduced 
glutathione (GSH)221.  Additionally, the consumption of NADPH in the polyol pathway due to 
diabetes reduces the availability of this necessary substrate for regeneration of GSH, leading to 
an overall intracellular depletion of GSH.  This depletion has been confirmed in PBMCs of type 
2 diabetic patients and is linked to reduced synthesis of the IL-12 cytokine, which is regulated by 
GSH222.  Restoration of intracellular GSH in diabetic PBMCs has been shown to improve IL-12 
production and improve bactericidal activity against intracellular bacteria, including M. 
tuberculosis223.                  
 Of the defined pathways involved in the pathogenesis of diabetic complications, RAGE 
receptor signaling has been the most extensively studied in leukocytes, immune function, and 
response to infection.  The RAGE receptor is a multiligand pattern recognition receptor of the 
immunoglobulin superfamily and signals through binding of not only AGEs, as the name implies, 
but also the A8 and A9 members of S100 proteins, the cellular stress signaling protein, high 
mobility group box-1 (HMGB-1), and β-amyloid sheets.  All of these ligands are either direct 
products of high glucose, or are induced by the cellular stress of hyperglycemia216.  The 
formation of AGEs is of particular interest in the comorbidity of diabetes and TB because AGEs 
are known to accumulate to a higher level with diabetes and also in the presence of chronic 
inflammation, such as that which occurs in TB224.  A recent study has demonstrated that 
methylglyoxal, an AGE precursor, accumulates during M. tuberculosis infection and contributes 
to macrophages apoptosis225.  It is possible that AGEs may accumulate at a faster rate in 
people with M. tuberculosis infection and diabetes, given the convergence of hyperglycemia and 
chronic inflammation.  AGE accumulation may alter immune cell function and lead to a 
sustained proinflammatory response through their activation of NFkB via RAGE receptor 
signaling226, 227.         
 The RAGE receptor is expressed on many different immune cell types including 
macrophages, neutrophils and lymphocytes, but the site of greatest expression is on the 
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pulmonary epithelium228.  Accordingly, multiple investigations into the role of RAGE in 
pulmonary infections have been reported, which may correlate with TB since it is predominately 
a pulmonary disease.  However, it should be noted that the role of RAGE or accumulation of 
AGE ligands specifically in the context of diabetes-related pulmonary infection has not been 
previously studied.  Since diabetes has a significant influence on RAGE ligand expression as 
well as expression of the receptor itself, the role of RAGE signaling in infection may differ under 
diabetic conditions.      
 The impact of RAGE signaling on acute bacterial infections in a non-diabetic state has 
been previously investigated.  A lack of RAGE has been shown to attenuate the inflammatory 
response to both LPS stimulation and E. coli pneumonia in mice and also significantly improves 
survival during bacterial sepsis229, 230.  Additionally, the infusion of AGE-modified proteins during 
sepsis worsens the disease course in a manner dependent on RAGE231.  However, the 
evidence for RAGE involvement in M. tuberculosis infection is conflicting since one study has 
demonstrated more severe TB disease in RAGE-null mice infected with a high intranasal dose, 
whereas another study noted similar TB disease in RAGE-null and wild type mice infected via a 
more physiologically relevant low-dose aerosol route232, 233.  In general, previous data implicate 
RAGE in the promotion of damaging inflammation, a process that is well recognized in diabetes, 
and therefore can also be rationally implicated in the comorbidity of diabetes and infectious 
disease.  
 
Animal Models of Diabetes. 
 The mouse, rat, and non-human primate are the most commonly used models in 
experimental diabetes studies and generally manifest features of diabetes either through the 
induction of obesity or loss of β-cells.  These models can be separated into those with pure 
hyperglycemia and type 1 diabetes, or those of diet- and obesity-induced insulin resistance and 
type 2 diabetes.  Streptozotocin (STZ) and alloxan are glucose analog compounds with a 
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cytotoxic nitrosurea group that are utilized to induce acute beta cell death.  Streptozotocin is 
used more commonly for this purpose and with a full, multiday dosing regimen, leads to 
complete β-cell ablation and insulin-dependent diabetes in mice.  Due to absolute-insulin 
deficiency, this is often designated as a model of type 1 diabetes; however, these models lack 
the autoimmune inflammatory pathogenesis that leads to β-cell loss in type 1 diabetes and also 
tend to develop severe and persistent hyperglycemia requiring insulin therapy for extended 
survival234. The non-obese diabetic (NOD) mouse is the most common model of type 1 diabetes 
and manifests spontaneous autoimmune insulitis, however, certain strains of the rat, such as 
the BBdp (diabetes prone), also develop spontaneous insulitis235.   
 Diet-induced obesity in mice (DIO), particularly C57/BL6, and less commonly in rats, is 
the most frequent method for investigating insulin resistance and β-cell responses234, 236.  
However, this model fails to progress to overt diabetes within a reasonable experimental 
timeframe and does not manifest the beta cell loss that is characteristic of human type 2 
diabetes patients237.  Alternative models with more severe manifestations of insulin resistance 
are often therefore utilized with or without a high-fat diet.  The ob/ob mouse, which is obesity 
prone due to an inactive leptin molecule, suffers from extreme overeating.  Disruption of the 
leptin receptor in db/db mice also targets this same obesity pathway.  However, alternative 
polygenic models have been developed in the mice that manifest diabetic phenotypes more 
rapidly and are also more consistent with the typical obesity-associated form of type 2 diabetes 
in humans, including the NON/ShiLtJ and NONcNZO10 mice238.  Analagous to the db/db mice, 
the Zucker diabetic fatty rat is a model of obesity due to a spontaneous genetic defect in the 
leptin receptor.  A hybrid model of diet-induced insulin resistance and STZ-induced β-cell 
cytotoxicity has been described in the rat, which manifests both the features of impaired glucose 
tolerance and response to insulin, along with reduced insulin-producing capacity due to β-cell 
loss239.  
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 The guinea pig has been previously utilized as a model of diabetes, although with far 
less frequency, never as a diet-induced or obesity-based model of insulin resistance, and with 
significant variations in the utilization, route and dose of either streptozotocin or alloxan.  Pure 
streptozotocin-induced hyperglycemia in the guinea pig is essentially the only model described 
in the guinea pig with any frequency.  In these studies, methods describe various routes of 
administration including intraperitoneal, intravenous and intracardiac administration at doses 
ranging from 180 to 350 mg/kg.  The level of mortality reported from acute toxicity is high, 
ranging from 50-90%234.  Optimized methods for route of administration and effective diabetes 
induction while minimizing the level of toxicity are not reported in the guinea pig, as they are in 
the mouse and rat.  
   
The Comorbidity of Tuberculosis and Diabetes - Current Knowledge 
 
Risk Factors for Tuberculosis. 
 Many recognized risk factors exist for tuberculosis, which may be attributed to increased 
risk of developing active TB disease either upon exposure or as reactivation TB.  Beyond host 
genetic factors, the majority of TB risk factors are non-communicable diseases often linked to 
socioeconomic factors and environmental influences.  Among the greatest recognized risk 
factors for TB include HIV infection, immunosuppressive therapies, smoking, air pollution, 
alcoholism, malnutrition, chronic kidney disease, and diabetes115.  HIV is, by far, the greatest 
recognized risk factor for TB, with a relative risk of nearly 30-fold over uninfected individuals240-
242.  The contribution of malnutrition as a risk factor is the result of the high global prevalence of 
this problem in underdeveloped countries where TB is also prevalent, leading to a high 
population attributable risk240-242.  While these risk factors are well recognized, the mechanisms 
underlying predisposition for active TB disease are poorly understood, with the exception of HIV 
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infection, which may be, in part, due to the infrequent modeling of such comorbidities in animal 
species116. 
 
The Driving Epidemiology of Diabetes-Tuberculosis Comorbidity. 
 An association between TB and diabetes has been recognized for multiple centuries243, 
244.  However, the importance has been previously underemphasized because a convergence of 
diabetes on regions of high tuberculosis prevalence was not a growing concern245.  It was not 
until recently that diabetes was confirmed as a significant risk factor for TB and a potential threat 
to public health.  The emerging emphasis on this comorbidity stems from the rapidly growing 
diabetic population worldwide.  Driven by urbanization, Western diet, and lack of physical 
exercise, as well as phenotypic predispositions in certain populations246, an epidemic of 
diabetes is affecting predominately countries that also have endemic tuberculosis247.  For 
example, India, a country with among the highest tuberculosis burden worldwide, also contains 
the highest prevalence of type 2 diabetes worldwide.   Up to 95% of the global diabetic 
population is affected by type 2 diabetes, a form of the disease with a rapidly growing 
incidence247.  Less than 10% of the diabetic population is affected by autoimmune, type 1 
diabetes, a population that has increased but not nearly at the rate recently seen with type 2 
diabetes.  However, both types 1 and 2 diabetes are associated with increased risk for TB248. 
 In 2012, the number of people with type 2 diabetes worldwide was estimated at 371 
million individuals249.  Approximately 80% of this population resides in developing countries 
where risk for exposure to M. tuberculosis is significantly higher.  It is estimated that this 
population will continue to grow rapidly and will exceed 550 million affected by the year 2030, 
with the majority of growth occurring in densely populated developing countries.  Of this 
population, up to 50% of diabetic patients remain undiagnosed in the most remote areas, where 
access to the necessary health care and diagnostic capabilities is lacking249.  Therefore, a large 
proportion of the diabetic population is unknowingly affected by uncontrolled hyperglycemia and 
 32 
may be at even higher risk of developing TB.  In addition to patients with diagnostic criteria 
consistent with diabetes, it is estimated that 70% of people affected by prediabetes also reside 
in countries with the highest TB burdens249.    
 In considering the impact that the emergence of HIV had on the incidence of 
tuberculosis, global TB control, and emergence of drug resistance, correlations with diabetes as 
a risk factor for tuberculosis highlights the urgency and importance of controlling the growing 
comorbidity in order to maintain a slow but steady decline in global TB incidence5.  Although the 
relative risk for TB in HIV patients far surpasses that of diabetes at 30-fold compared to 
approximately 3-fold, respectively, the prevalence of diabetes far surpasses that of HIV, making 
the attributable risk for TB potentially greater than that of HIV14. This is reflected in the 8% of all 
new TB cases attributed to diabetes, which amounts to >700,000 cases14, 250, 251.  Moreover, in 8 
of the 22 countries with the highest TB prevalence, diabetes accounts for more TB cases than 
HIV. India is a dramatic example where between 20 and 40% of TB can be attributed to 
diabetes compared to 5% attributed to HIV14, 252.  This high prevalence of comorbidity justifies 
the need for bidirectional screening, which would increase the rate at which new cases of either 
disease may be identified.   
 
The Human Comorbidity of Diabetes and Tuberculosis. 
 A review of 13 appropriately conducted observational studies by Jeon and Murray has 
definitively linked diabetes with increased risk of TB and specifically the active form of disease, 
with a relative risk of 3.1253.  The differentiation between risk in type 1 compared to type 2 
diabetes has not been formally addressed, but two studies have demonstrated that insulin-
dependent diabetes yields an even greater risk than non-insulin dependent diabetes, which 
suggests that severity of diabetes, in the form of residual β-cell function, may be a predictor of 
higher tuberculosis risk254, 255.  Beyond this, it has been demonstrated that poorly controlled 
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diabetic hyperglycemia (HbA1c >7%) additionally increases TB risk and raises the question of 
the importance of chronic hyperglycemia in susceptibility to develop active TB disease217.  
 However, epidemiological data suggests an increased risk from prediabetes as well 
based on bidirectional screening.  A recent study in India by Vijay et al. has demonstrated a 
prediabetes prevalence of 24.5% in patients diagnosed with TB256.  Because an association with 
TB and the presence of uncontrolled hyperglycemia has not been identified, the association of 
prediabetes with TB is unexpected.  This may be due to altered lipid metabolism and 
generalized pro-inflammatory conditions that are strongly linked with the development of insulin 
resistance, but currently no animal models representative of human TB pathogenesis or 
development of insulin resistance have been pursued to investigate this susceptibility.  
 However, an additional confounding factor that should be considered is the impact that 
active TB disease has on glucose metabolism257, 258.  As previously demonstrated, a high 
proportion of new diabetes diagnoses can be identified through screening for TB, but the 
contribution that TB might be making to impaired glucose tolerance is not yet known.  Since 
treatment with antimicrobial therapy in diabetic patients with active TB improves glucose 
tolerance, a contribution from TB associated disease is implicated262, 264.  This may be 
significant in the diagnosis of TB-diabetes comorbidity for adjustment of diabetes diagnostic 
criteria in comorbid patients.  Perhaps higher thresholds on the oral glucose tolerance test or 
combined use with glycated hemoglobin (HbA1c) is necessary to differentiate these two 
mechanisms of impaired glucose tolerance but this remains to be investigated in human 
patients.   
 The importance of chronic hyperglycemia has been demonstrated based on indices of 
glycation as measured by HbA1c.  In patients with HbA1c greater than 7%, a higher risk of 
active disease is recognized217, 219.  An additional factor that remains unknown but is critical to 
the implementation of both diagnostic and therapeutic strategies is whether diabetes increases 
initial susceptibility to M. tuberculosis infection or whether it is more likely to develop reactivation 
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TB in latently infected individuals that become infected.  A general lack of representative animal 
models of this comorbidity makes this a difficult question to investigate, but may be overcome 
with a model that is representative of the human diabetes-TB comorbidity.      
 Whether the severity of active TB is increased or the pathological manifestations of TB 
are altered in comorbid individuals remains to be fully elucidated.  While there is evidence that 
radiographic features of TB disease are altered in patients with diabetes, including more 
frequent lower lung or multiple lobe involvement and higher frequency of cavitary disease259-261, 
these are not consistent findings262.  Additionally, pathological investigations in cases of 
diabetes-TB mortality are limited to a single series performed in 1934 by Root, where a 
manifestation of TB unique to the diabetic individuals was not appreciated263.  However, studies 
suggest that death attributable to TB is more likely in comorbid individuals after initiating 
antimycobacterial therapy, with a reported risk 5 - 7 fold increased risk overall and 17% mortality 
after 1 year compared to 7% in patients with TB alone264-266.   Additionally, failure of 
antimicrobial treatment in diabetic patients has been reported with frequencies of up to 40%, 
which are not attributable to resistance or poor adherence267, 268, along with delayed sputum 
culture conversion rates265, 269.  
 Mounting evidence is leaning towards a hyperactive and proinflammatory immune 
response profile in diabetic patients with active TB, which has been performed in antigen-
stimulated and unstimulated peripheral blood mononuclear cells.  Two studies in particular have 
demonstrated this concept in populations in Mexico and India270, 271. Restrepo et al. 
demonstrated that stimulated PBMCs from diabetic patients consistently produced higher levels 
of IFNγ, IL-1β and TNFα compared to those without diabetes, and that this change was 
proportionately higher in diabetic individuals with high HbA1c270.  This study implicates, again, 
the potential role for uncontrolled hyperglycemia in altered response to M. tuberculosis infection.  
Similarly, Kumar et al. demonstrated higher frequencies of antigen responsive Th1 and Th17 
CD4 T cells in comorbid patients with poorly controlled diabetes, which correlated with higher 
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levels of IFNγ, and IL-17 in plasma, but a reduction in the regulatory T cell population271.   In one 
additional study, although no difference was noted in stimulated IFNγ production or other innate 
pro-inflammatory cytokines from whole blood samples of diabetic TB patients compared to 
those without diabetes, a shift toward a pro-inflammatory response in diabetic TB patients was 
suggested by reduced IL-10 production207.   
 Despite evidence of unfavorable outcomes in diabetic patients, the basis for this is not 
yet understood.  Whether higher mortality and treatment failure result from complications with 
TB and bacterial load, from complications with diabetes, or from a combination of both, remains 
to be determined.  Currently, there is little information regarding the impact of glucose control on 
TB treatment and whether intensive diabetes management prior to initiation of combination 
antimicrobial therapy would improve outcome272, 273.  Additionally, evidence suggests that 
pharmacokinetics of type 2 diabetes drugs would be altered and efficacy reduced particularly in 
the presence of rifampicin, which induces p450 enzyme activation and metabolism of T2DM 
hypoglycemic agents such as sulfonylureas and TZDs274, 275.  Alternatively, it is possible that in 
the presence of pre-existing hepatic alterations typical of type 2 diabetes, the hepatotoxicity that 
is characteristic of anti-TB drugs may be worsened.  Similarly, the efficacy of current preventive 
strategies in the face of diabetes, including BCG vaccination or isoniazid preventive therapy, is 
uncertain.  Many questions exist regarding BCG efficacy in the non-diabetic population, and 
whether a protective response can be established or maintained in BCG vaccinated individuals. 
The influence that diabetes has on BCG efficacy will be important to address since diabetes is 
most prevalent in developing countries where BCG vaccination during infancy is a standard of 
care.   Additionally, considering the higher risk of active disease in diabetic patients, IPT has 
been recommended for those meeting the classification of latent TB; however, the efficacy of 
currently recommended IPT regimens in diabetic patients has not been established. However, in 
order to determine IPT efficacy, it must first be known if diabetes truly leads to increased 
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progression from latent to active TB disease or if it leads to increased susceptibility to initial 
infection250, 262, 273. Many of these treatment questions could be effectively addressed 
experimentally in preclinical models that closely mimic the manifestations of type 2 diabetes and 
tuberculosis, particularly in models with demonstrable response to the hypoglycemic drugs used 
to treat type 2 diabetes, as opposed to insulin dependent models of diabetes that lack features 
of insulin resistance.   
 
Animal Models of Diabetes-Tuberculosis Comorbidity. 
 Experimental investigations into diabetes-TB comorbidity, to this point, have been limited 
to studies in the rat, a species highly resistant to TB, and in mice with hyperglycemia due to 
absolute insulin deficiency.  While this mouse model is often cited as a model of type 1 
diabetes, it is more appropriate to describe this as a model of insulin-dependent diabetes, since 
the hyperglycemia is a reflection of total insulin deficiency and lacks the autoimmune 
component that is the pathognomonic feature of type 1 diabetes234.  However, an animal model 
that not only more closely reflects the pathogenesis and pathology of TB in humans, but also 
develops the inflammatory, metabolic, and endocrine alterations typical of insulin resistance and 
type 2 diabetes has not been previously developed.  Additionally, there is a need for a model 
that more closely mimics the physiologically relevant fasting and post-prandial hyperglycemia 
characteristic of a type 2 diabetic patient, rather than extreme and persistent hyperglycemia 
typical of STZ-induced insulin-dependent diabetes in mice.   
 The C57BL/6 mouse model of STZ-induced diabetes demonstrates more severe TB 
disease, which occurs in the presence of 1.5 log higher pulmonary bacterial burdens, higher 
production of IFNγ, IL-1β and TNFα, and increased numbers of neutrophils.  In this model, the 
heightened susceptibility was noted only in mice infected 16 weeks after STZ treatment, with no 
difference in mice infected 4 weeks after induction of diabetes218.  This requirement for 
persistent and chronic hyperglycemia in the susceptibility of this mouse model highlights the 
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importance of hyperglycemia in the pathogenesis of this comorbidity, similar to what has been 
demonstrated in humans with poorly controlled diabetes.  Additionally, earlier in the course of 
infection in this mouse model, antigen specific IFNγ production is reduced during the phase of 
logarithmic bacterial growth276.  Rat models of diabetes previously used to carry out diabetes-TB 
comorbidity studies, including STZ-treated (similar to the mouse model) and goto-kakizaki 
spontaneously diabetic rats, have also demonstrated a similar lower expression of IFNγ and 
higher bacterial burdens277, 278.  These models demonstrate an apparent difference in Th1-
related cytokine expression when compared to the previously described human studies, where 
human samples have demonstrated increased IFNγ production.  This may be a reflection of the 
controlled time point of disease when samples are assayed, or a difference in the organs of 
primary infection sampled for animal models versus reliance on peripheral blood samples in 
human patients.      
 Alternative mouse models could be considered that are frequently used in type 2 
diabetes research, however, there are some unavoidable pitfalls.  The most established model 
of diet-induced obesity is in C57Bl6 mice, which as described above are inherently TB resistant 
among the characterized strains of mice.  Additionally, these mice fail to develop overt type 2 
diabetes within a reasonable experimental time frame.  The use of mice with leptin pathway 
defects harbors important considerations as well since this deficient leptin signaling pathway 
may affect the response to M. tuberculosis infection even in the absence of obesity and insulin 
resistance. Leptin has been demonstrated to have immunomodulatory effects on response to 
infection and overall susceptibility to M. tuberculosis infection, with leptin deficiency manifesting 
in chronic stages of human TB279.  The non-obese diabetic (NOD) mouse spontaneously 
develops autoimmune insulitis and therefore serves as a representative model of type 1 
diabetes, however, it remains unknown how type 1 diabetes in the context of autoimmune 
inflammation impacts the response to infection with M. tuberculosis.  
 38 
The Guinea Pig Model of Tuberculosis 
 
Historical Significance. 
 The guinea pig is the oldest animal model used to study tuberculosis.  If not for the 
guinea pig, Robert Koch would not have been able to demonstrate that tuberculosis results from 
an infectious etiology, fulfilling in 1882 what is now known as the Koch-Henle Postulates280.  
After this time, it was observed that growth of the infectious agent could be inhibited chemically 
with streptomycin and again to demonstrate the efficacy of isoniazid and ethambutol still used to 
this day as front line anti-tuberculosis drugs281, 282.  Since, the guinea pig has been regarded 
largely as the most optimal animal species for studying the pathogenesis of tuberculosis, 
response to treatment, and strategies for immunization283, 284.    
  
General Strengths of the Guinea Pig Model of Tuberculosis. 
 Among the largest contributions to tuberculosis research provided by the guinea pig 
have come from evaluation of preventive and therapeutic strategies.  The guinea pig is often 
regarded as the most appropriate species for vaccine investigation and validation of novel 
preventive measures against TB7.  As indicated below, the guinea pig responds similar to 
people with M. bovis BCG immunization, the only currently available vaccine for TB, which fails 
to prevent infection and disease progression in adults but limits bacterial dissemination in young 
children13.  Similar to humans, the guinea pig develops a delayed-type hypersensitivity reaction 
to purified protein derivative, a multi-antigen preparation derived from mycobacterial culture 
supernatant.  Upon intradermal injection, skin induration develops at the injection site in 
exposed or vaccinated animals, which is also the basis of a PPD skin test in people285.   
 Recently, a detailed evaluation of the guinea pig response to the frontline chemotherapy 
regimen of isoniazid, rifampicin, and pyrazinamide has been demonstrated in response to 
infection with the clinical isolate Erdman K01286.  This prototypical response may serve as a 
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baseline for comparison of newly developed chemotherapeutics as well as evaluation of optimal 
regimens since it is likely that multiple drugs rather than a single compound are necessary for 
sterilizing activity to eliminate persistent bacilli and prevent relapse of infection. Also, given the 
exceedingly long duration of treatment required with frontline antimicrobials, there is a growing 
need for optimization of drug regimens that reduce the time course required for effective 
treatment287, 288.    
 The benefits of utilizing the guinea pig for treatment and prevention strategies may be a 
reflection of the similarities of guinea pig and human TB disease.  Utilizing the guinea pig allows 
for evaluation in a species that develops granulomata with morphology remarkably similar to 
humans and when paired with the high susceptibility of this species to biologically relevant 
infectious doses and route, creates an optimal model for assessing treatment interventions289.  
Additionally, the guinea pig displays disease progression similar to that of humans.  In 
particular, the development of lymphangitis in draining lymphatic vessels in the lung leads 
ultimately to granulomatous lymphadenitis, a common feature of human disease particularly in 
infants and younger children290.  The guinea pig is highly susceptible to M. tuberculosis infection 
and therefore, serves as an optimal model for experimental infection utilizing a biologically 
relevant experimental dose and route.  The guinea pig develops uniform pulmonary infection at 
low dose aerosol exposure of less than 50 CFUs per animal284.  However, the high susceptibility 
of this species also lends to its weaknesses as a TB model, since all experimentally-infected 
animals develop progressive TB disease and a true latent infection is not established in this 
species291.  Additionally, the guinea pig rarely develops cavitary TB disease, the end-stage 
progression of human disease, which is a feature of the rabbit and non-human primate 
models292.  
 The guinea pig also mimics some important physiological similarities to humans that are 
absent in other rodent species. The guinea pig shares similar lipid and cholesterol metabolism 
to humans with a higher ratio of the pro-atherogenic, low-density lipoproteins to high-density 
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lipoproteins in blood293, 294. The guinea pig displays high lipoprotein lipase and cholesterol 
transport activity similar to humans, allowing for transfer of cholesterol rich lipid particles 
between blood and tissue, and has been shown to respond similar to humans during 
experimental manipulation of dietary fat intake294, 295.  Additionally, guinea pigs manifest 
metabolic disturbances including insulin resistance and hyperglycemia as a result of active TB 
infection296, which have been previously described in humans257, 258, and also develop 
dyslipidemia during active infection with evidence of severe lipolysis and an increase in 
circulating free fatty acids296.  These metabolic features in this species may have important 
relevance to TB pathogenesis given the recent evidence of bacilli acquisition and utilization of 
host-derived fatty acids, the ability of M. tuberculosis bacilli to utilize host cholesterol as a 
source for metabolism, as well as accumulation of intracellular lipid within bacilli during states of 
dormancy that are expected to reflect the metabolic state of the bacteria during latency16, 297-299.  
All of these factors, combined with the evidence of dyslipidemia that mimic human related 
manifestations resulting from M. tuberculosis infection in the guinea pig make this species 
suitable for evaluating metabolic interventions during M. tuberculosis infection.  
 
The Guinea Pig Model for Preclinical Antimicrobial Drug Development. 
 While the mouse has largely been used in the evaluation of new chemotherapy 
strategies, the guinea pig offers the strength of evaluating new approaches in a model with 
pathology similar to human TB.  The relative benefit of assessing novel chemotherapeutic 
strategies in the guinea pig, in contrast to mice, relates to the development of casseous 
necrosis in granulomas, as described in detail below.  Careful assessment of drug regimens in 
the guinea pig and comparison with the mouse model has revealed that responses differ 
significantly between species.  
 The importance of representative pathology in the animal model used for drug studies 
was highlighted using experimental compound TMC207 (now FDA-approved), which was highly 
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effective in nearly eradicating bacilli within granulomatous lesions300, 301.  Importantly however, 
this study indicated that the location of bacteria poorly responsive to treatment was extracellular 
and confined to a hypoxic, acellular rim within the area of central necrosis.  Further studies in 
guinea pigs have indicated that this small subpopulation of bacilli that survive antimicrobial 
therapy are not the result of emergence of genotypic antimicrobial resistance, specifically using 
isoniazid in this study, but rather occurs with the selection of phenotypic resistance302.  
Therefore, this has been referred to as antimicrobial tolerance, rather than resistance, and the 
bacteria as persistent bacilli303. 
 Despite these findings, there is also evidence that residual tolerant bacilli develop in 
mice lacking casseous necrosis304. Some studies indicate that the use of the standard 
antituberculosis regimen in guinea pigs has greater sterilizing activity than in the mouse with 
reduced relapse in guinea pigs as compared to mice.  These findings have suggested that 
casseous necrosis does not impair the sterilizing activity of RHZ304 and has important 
implications in the choice of animal model for testing novel drug therapies. Differences among 
mouse strains in response to treatment, particularly in those which develop necrotic lesions, as 
well as species differences provides further support for the importance of selecting models 
which develop appropriate pathology when assessing preclinical efficacy of new drugs and that 
the use of multiple species/strains may be of particular benefit305, 306.  
 A particular strength of more recent antimicrobial studies in guinea pigs has been the 
use of pharmacokinetics to establish human equivalent doses of antituberculosis drugs in the 
guinea pig.  As a result, appropriate guinea pig doses have been developed for isoniazid, 
rifampin, pyrazinamide, moxifloxacin and streptomycin, as well as other investigational 
compounds303, 307-309.  The growing incidence of drug-resistant TB cases highlights the 
importance of developing not only new antimicrobial compounds but also for the development of 
new regimens with shorter periods of administration and are better tolerated than the toxicity 
associated with frontline combinations including rifampicin and isoniazid.  This is especially 
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important in the case of multidrug resistant infections requiring up to 24 months of continuous 
treatment.  The value of the guinea pig in chemotherapy studies is reflected in the recent 
comparisons of efficacy between rifampicin and rifapentine.  It has been suggested that 
rifapentine, as a substitute for rifampicin, may eliminate toxicity due to reduced activation of 
hepatic microsomal metabolic pathways.  Studies in mice indicated more potent sterilizing 
activity and reduced relapse rate when treated with rifapentine compared to rifampicin309, 310.  
However, a lack of therapeutic advantage demonstrated in the guinea pig model backs up a 
recent evaluation in human patients also demonstrating no significant advantage of this 
substitution311. These findings suggest that although the mouse often closely resembles the 
success in human chemotherapy trials, the guinea pig is a reasonable model to confirm 
promising results that derive from the more economically feasible and statistically powerful 
murine preclinical studies. Guinea pigs also demonstrate differences in their response to 
treatment with pyrazinamide. Although there is synergy with rifampin, as is also the case in 
mouse and human, higher PZA doses when administered alone, provide a greater bacillary 
reduction in guinea pigs than is seen in mice312.  If this translates to humans, further 
investigation of higher PZA dosing may be warranted.      
 
Pathology of Tuberculosis in the Guinea Pig. 
 A key feature of TB pathogenesis in the guinea pig is the pattern of pulmonary infection, 
which is followed by systemic hematogenous dissemination76, 289.  Linking these two events is 
involvement of lymphatic drainage and formation of granulomatous lymphadenitis around 10 to 
14 days after infection290.  Logarithmic growth of bacteria in pulmonary lesions occurs up to 3 
weeks post-infection after which, onset of adaptive immunity is associated with a stationary 
phase313.  All of these processes are consistently replicated in the guinea pig, making this 
species an ideal model for studying kinetics of the response to M. tuberculosis infection.  Lesion 
dissemination is most often demonstrated in the spleen, followed by involvement of the liver in 
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guinea pigs.  However, more distant or less commonly involved organs, including adrenal gland, 
heart, pancreas and abdominal lymph nodes, may develop TB lesions during infection with 
highly virulent clinical strains such as HN878 or CDC1551314.     
 Guinea pigs develop classical pulmonary granulomas that are characterized by central 
casseous necrosis and a thick wall of epithelioid macrophages69.  A characteristic feature of 
these primary casseous granulomas, which occur upon initial aerogenous exposure, is the 
confinement of lymphocytes to a circumferential and peripheral rim around the granuloma.  In 
primary granulomas, the majority of lymphocytes fail to penetrate the lesion 69, 315. This is in 
contrast to post-primary, or otherwise described as secondary, granulomas, which occur upon 
hematogenous reseeding of the lung and consist of evenly admixed lymphocytes and 
macrophages76. It has been demonstrated that the formation of primary granulomas, and the 
associated casseous necrosis, most likely precedes the onset of adaptive immunity in the 
guinea pig69.  While the secondary pulmonary lesions are readily amenable to combination 
antimicrobial therapy with isoniazid, rifampicin and pyrazinamide, primary lesion necrosis 
persists after treatment and has been shown to harbor persistent extracellular bacilli that are 
resistant to antimicrobial drugs286, 300.         
 After initial aerogenous infection, the first cell to infiltrate pulmonary alveoli is the 
heterophil (neutrophil), first noticeable around day 11 of infection, and is accompanied by poorly 
organized infiltrates of macrophages285. The dynamics of macrophages types within the guinea 
pig lesions remains unknown. Central necrosis appears before day 21 of infection, at a time 
when minimal detectable CD4 or CD8 lymphocytes can be identified at the site of developing 
granulomata69.  This finding challenges the hypothesis that granuloma necrosis is mediated by 
high IFNγ production in a delayed type hypersensitivity reaction which would require antigen-
specific T cell immunity69.  However, true demonstration of this lack of antigen specific immunity 
remains to be demonstrated with new and developing techniques such as the IFNγ ELISPOT316. 
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Hematogenous reseeding of the lung coincides with onset of adaptive immune function around 
3 weeks post-infection317.  In contrast to primary TB granulomas, these secondary lesions 
contain up to 2 log10 fewer CFUs, likely due to a very different immune microenvironment, which 
forms after immune stimulation and leads to restriction of bacterial replication318, 319.  The 
difference in immune function between primary and secondary TB lesions has been confirmed, 
and equates to a response in the pre-immune phase for primary granulomas, while secondary, 
consolidating lesions occur with cytokine evidence of exposure, indicating their occurrence in 
post-immune phase of infection317.     
 One important development in particular in the guinea pig model is a growing span of 
studies evaluating the response of guinea pigs to infection with clinical M. tuberculosis 
isolates314.  The contribution from these studies may significantly impact vaccine development in 
that efficacy of a candidate vaccine must certainly be capable of providing protection against 
these highly virulent and more medically relevant strains, rather than the standard H37Rv or 
Erdman laboratory strains frequently used in animal studies, which displays attenuated 
virulence75.  Importantly, infection with clinical isolates, as opposed to the laboratory strains, 
imparts a wide variation in disease severity and manifestation, where clinical isolates of Beijing 
as well as non-Beijing lineage produced more severe pathology and extrapulmonary 
disseminated disease.  In contrast, guinea pigs infected with MDR strains developed reduced 
pathology and bacillary burdens, suggesting reduced bacterial fitness of the genotypically 
resistant bacteria in a susceptible host species, although progressive, active TB was uniformly 
manifested among infected animals 320.  This is consistent with the notion that virulence is lost or 
reduced in drug-resistant strains of M. tuberculosis321, 322.  Previously, it was indicated that the 
severity of disease dissemination and in particular, the degree of necrosis as measured by 
emerging stereologic methods, is a better predictor of strain virulence than recovery of viable 
bacilli counts from tissue.  These findings support the use of area quantification in pathology 
assessment, in addition to CFU assays or survival measurements, for the identification of new 
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chemotherapeutic or vaccine candidates with improved efficacy314.  Because disease 
manifestations from clinical isolates are so variable, it remains important to evaluate new 
vaccine candidates against these isolates to determine if the level of protection provided by a 
vaccine is equivalent to that from a laboratory strain challenge7.  Additionally, evaluation of 
organs infrequently assessed for dissemination, including heart, adrenal gland, and distant 
lymph nodes may provide an advantage in evaluating vaccine efficacy against clinical isolates.  
 Because the pathology of TB in the guinea pig so closely mimics that of human TB, this 
species has also been utilized to evaluate bacterial proteomics in early and chronic stages of 
disease as well as host metabolomics during infection with clinical W-Beijing strains of M. 
tuberculosis. Importantly, hypoxia is feature of the guinea pig lesions, which is presumed to 
trigger metabolic changes in bacilli associated with latency323-325.  Using the guinea pig, it is 
apparent that bacilli alter their protein expression significantly between acute and chronic 
infection.  Bacilli isolated from granulomas on day 30 or day 90 of infection had only 28% and 
27% overlap of identified proteins at each time point, respectively326.  These methods have 
identified the most abundant classes of proteins expressed during infection as those involved in 
cell wall biosynthesis and intermediary metabolism and respiration, and importantly, have 
identified some potential significant differences between day 30 and 90 of infection that support 
metabolic adaptation of M. tuberculosis over time. This in vivo approach has allowed for 
identification of a large protein population, which can be mined for potential therapeutic and 
vaccine targets against the bacterium. 
 Evaluation of the metabolomic profile in the guinea pig also identified distinct metabolic 
patterns in guinea pigs that were able to differentiate naive from infected animals and also those 
that change with progression of infection327, 328.  These findings have important implications 
toward identification of biomarkers with predictive or diagnostic potential that can be further 
investigated from this defined pool of molecules.  Additionally, these techniques could 
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potentially be applied to antimicrobial treated or vaccinated guinea pigs to predict correlates of 
protection or effective treatment.  
 
Manifestations of Tuberculosis in Guinea Pigs Under Natural Exposure Conditions.  
 Until recently, the true susceptibility of an individual to TB exposure had been 
extrapolated from the downstream disease manifestations in people because all studies utilizing 
animal models had been performed with experimental infections.  While this has obvious 
benefits for controlled experimental conditions, the majority of animal models of experimental 
infection fail to replicate the diverse manifestations of TB that are characteristic of naturally 
occurring human TB.  A new platform combining the controlled conditions of timed and evenly 
distributed exposure by aerosol route with the source of exposure being infected human 
patients has recently been developed.  Although the highly susceptible guinea pig develops 
uniformly progressive TB disease after experimental aerosol infection, it has recently been 
shown that this is not the case when guinea pigs are naturally exposed to infectious aerosols.  
In a hospital setting where airflow from a multi-drug resistant human TB ward is routed to 
individual guinea pig cages, guinea pigs developed a spectrum of TB disease responses similar 
to what is expected in a human population.  
 In guinea pigs exposed over a period of 4 months to air exhausted from an inpatient 
MDR/XDR-TB ward, the majority of animals became skin test positive.  Importantly, however, 
TST responses were diverse with many guinea pigs reverting to TST negative status only later 
to display positive TST recurrence.  This high level of TST reactivity over the course of the 
experiment is indicative of a high rate of exposure to viable M. tuberculosis bacilli.  However, 
unlike with experimental infections largely accompanied by a 100% rate of infection and 
progressive, active TB, only a minority of guinea pigs actually developed active TB disease.  
Given an unlikely role of establishing latency in these non-progressors that maintained TST 
reactivity since corticosteroid-induced immunosuppression failed to reactivate disease, these 
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findings suggest the ability to clear infection.  The loss of TST reactivity followed by recurrence 
suggests that first, even in a uniformly susceptible model, not all exposures lead to progressive 
disease and that spontaneous sterilization by host immunity is possible, and second, that 
recurrence of TST reactivity are likely due to reexposure and reinfection events.     
 Importantly, guinea pigs manifesting the greater delayed-type hypersensitivity response, 
and likely the strongest T cell response, as measured by a TST of >19mm, were the animals 
with the greatest rate of protection and clearance of infection.  Histologic analysis of the lungs 
from these guinea pigs confirmed infection but lesions in these animals were predominated by 
healing indicators such as fibrosis with reduced active inflammation and dystrophic calcification. 
Whether the development of a robust TST response represents a protective correlate is worthy 
of further investigation. 
 Perhaps one of the most intriguing findings from this study is the apparent role of 
reinfection, suggesting that clearance of the bacillus may actually occur with greater frequency 
than previously assumed but also indicating that the immune response acquired from initial 
infection is insufficient to prevent infection upon reexposure.  The fact that a uniformly 
susceptible species failed to develop active disease also suggests that experimental infection 
doses may be relatively high compared to what is naturally transmitted, in addition to the 
possibility of significant differences in the state of host-transmitted and artificially cultivated 
bacteria16, 329.  The concept that a waning TST response may indicate a failure to initiate long-
term memory T cell function poses an intriguing question regarding the true efficacy of BCG 
vaccination, which previously has only been assessed under experimental conditions.  Little is 
understood about how the BCG vaccine actually works and what the protective correlates are, 
making it difficult to interpret the significance of responses to novel vaccine candidates7, 75.  This 
natural exposure setting may provide an optimal environment for better understanding the BCG 
mechanisms of protection and also as a strategy for testing new vaccines in general.  The 
guinea pig may also be valuable in evaluating methods for reducing transmission of the bacilli.  
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A recent study from this same group has indicated that simply wearing surgical masks 
significantly reduces the transmission of M. tuberculosis as evidenced by reduced guinea pig 
tuberculin skin test reactivity as a marker of exposure330.  
 
The Immune Response to Mycobacterium tuberculosis Experimental Infection by Aerosol 
Exposure. 
 Due to limited reagent availability for cytokine analysis in the guinea pig species, the 
majority of investigations into cytokine kinetics have been measured through relative gene 
expression.  An advantage to this approach is that the measured responses are lesion specific 
due to the employment of laser capture microdissection317, 331.  Innate cytokines dominate the 
early cytokine response at 3 weeks of infection with overwhelming expression of TNFα that 
persists through 6 weeks of infection in non-vaccinated guinea pigs.  In contrast, BCG-
vaccinated guinea pigs develop an early type 1 response at 3 weeks of infection, with high IFNγ 
and IL-12p40 expression which transitions to a response dominated by the antiinflammatory 
cytokine TGFβ.   
 Further investigations into the cytokine response by McMurray et al. have taken 
advantage of the primary and secondary lesion manifestations in the guinea pig.  A very similar 
expression profile to BCG vaccinated guinea pigs in microdissected secondary lesions indicates 
that hematogenous reseeding of the lung does occur in the post-immune phase of infection as 
was anticipated by previous studies69.  In contrast, primary TB lesions are dominated by TNFα 
with lesser contribution from IL-12p40 and barely detectable IFNγ expression317. This indicates 
that the initial granulomas formed are dominated by an innate pro-inflammatory immune 
response. 
 The development of flow cytometry methods using guinea pig surface markers for 
specific immune cell types and fine tuning of appropriate gating strategies has allowed for 
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characterization of the cellular immune response to infection in the guinea pig315, 332.  Although 
CD4 and CD8 T cells can be identified early in infection in low numbers, their appearance does 
not peak until around day 30 of infection and are generally confined to the rim of the granuloma 
based on immunohistochemistry.  In contrast, the lesion necrosis, which precedes lymphocyte 
accumulation, has no apparent association with the adaptive response, suggesting innate 
mechanisms that lead to the development of lesion necrosis.  Further investigations also 
employing flow cytometry have indicated that granulocytes are the first immune cell type to 
increase in the guinea pig lung and that their infiltration may be associated with the 
development of lesion necrosis315.  Using CD45 high surface expression as an indicator of 
activation, it is also apparent that while activated CD4+ and CD8+ lymphocytes peak around 
day 30 of infection, this state is not maintained and there is a significant reduction in the number 
activated T cells through day 90 of infection, suggesting loss of an ongoing T cell-mediated 
response315.   
 In evaluating the cytokine response to infection and modulation by BCG vaccination in 
the guinea pig, TNFα is the most well studied to date.  McMurray et al. have evaluated the role 
of TNFα in the guinea pig using recombinant guinea pig TNFα as well as anti-guinea pig TNFα 
neutralizing antibodies.  Ex vivo studies from isolated guinea pig macrophages, either alveolar 
or peritoneal, have revealed the antimicrobial properties of this cytokine, where neutralization of 
TNFα in BCG vaccinated animals leads to enhanced bacterial growth333.  Additionally, from ex 
vivo studies it is apparent that TNFα acts synergistically with the T cell response, enhancing the 
proliferative capacity of T cells as well as increasing IL-12p40 and IFNγ expression333-335.  
Additional studies have indicated that neutrophils may be an important source of TNFα early in 
infection, leading to enhanced macrophage activation336.  However, this cytokine may also be 
detrimental through enhancing bacterial growth in non-vaccinated guinea pigs as well as 
through perpetuating an active and destructive inflammatory response337.  
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 In recent development of guinea pig reagents, a custom micro-array with targets limited 
to immune evaluation (86 transcripts) has been developed as a method for evaluating response 
to vaccination338.  With this microarray, a protective response was most associated with Th1-
related cytokines.  Even more recently, a larger microarray has allowed for determination of an 
immune transcriptome response signature to infectious agents in the guinea pig, using M. 
tuberculosis as the model infectious agent.  Further use of these new assays will aid in 
identification of better protective correlates that can be measured in vaccine efficacy trials.  
Additionally, the ability to study and better understand TB pathogenesis in this highly relevant 
species will be significantly improved by the growing number of immunologic reagents available 
for the guinea pig.  In particular, McMurray and colleagues have made a significant contribution 
to the reagent pool, initially through the use of relative gene expression but more recently by the 
generation of eukaryotic recombinant guinea pig cytokines and chemokines including IL-17, 
MCP-1, IL-10, TNFα, and IL-4339-342.  Also, recent evidence that guinea pig macrophages 
displaying functional pinocytotic and phagocytic activity can be derived from bone marrow using 
human M-CSF (but not GM-CSF or either murine counterpart), will promote in vitro studies 
using infected cells of guinea pig origin343.   
 Although genetic investigations into the guinea pig are continually growing, the studies 
performed to date have identified a number of important immunological similarities between this 
species and humans284.  Several important similarities in the guinea pig should be noted.  The 
sequence encoding for both CXCL8 (IL-8) and its receptor CXCR1, both of which are absent in 
the mouse, are present in the guinea pig344, 345.  Additionally, although the mouse lacks all CD1 
proteins except for the group 2 homologue, CD1d, the guinea pig genome encodes homologues 
of group1 CD1b and c, as well as group 2 CD1d and intermediary, CD1e346, 347.  CD1 molecules 
are similar to MHC but are restricted to presentation of lipid antigen and these serve to present 
mycobacterial lipid antigens including mycolic acids and LAM348, 349.  The guinea pig is the most 
suitable small animal model for studying the role of lipid antigen presentation as well as CD1-
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restricted T cell function during TB because mycobacterial lipid antigens are presented by group 
1 rather than group 2 CD1 molecules346. 
 
The Guinea Pig Model for Evaluation of New Tuberculosis Vaccines. 
 BCG vaccination remains the only available option for protection against tuberculosis but 
still does not protect adults from infection of active TB disease.  Therefore, all new vaccines 
being developed must display a significant improvement in protection exceeding that of BCG in 
preclinical models in order to proceed to human clinical trials.  The two strategies for 
immunization improvements are either the replacement of BCG with a more effective vaccine or 
a modification of the BCG vaccine regimen with a recombinant form or a boosting immunization 
that improves upon the protection9, 75.  Lessons learned from the most recent human efficacy 
trials of a new vaccine BCG-MVAAg85a performed in infants, which failed to demonstrate 
significant improvement upon BCG-only immunization, indicate a strong need for identification 
of protective correlates in animal models that mirror human data as well as the more careful 
design of preclinical studies to improve statistical power and a demonstration of efficacy 
equivalent to that expected from vaccines in human clinical trials350.  Despite the results of the 
phase II trials, some protective efficacy from this vaccine was apparent in guinea pigs in terms 
of enhancing survival, while evaluation at a fixed end-point and with a lower challenge dose did 
not indicate a protective advantage over BCG351, 352.  The guinea pig has been utilized to 
evaluate the efficacy of other vaccine candidates in the form of attenuated live mutants of M. 
tuberculosis such as the SO2 mutant with a disrupted phoP gene and reduced virulence as well 
as a pro-apoptotic secA2 deletion mutant7, 353.  
 One of the important criteria in evaluation of new vaccine candidates in preclinical 
models is the challenge strain that is used.  The majority of all new vaccine candidates are 
tested in animals against the laboratory strains H37Rv or Erdman.  However, the virulence of 
these strains is not representative of clinical TB isolates, and therefore the use of clinical strains 
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may provide a more stringent basis for evaluation of vaccines and their improvement upon 
BCG75. The two criteria used for evaluation of vaccine efficacy in the guinea pig (as well as 
other animal model species) is a reduction in bacterial load after the acute phase of bacterial 
growth and the improvement of TB disease as indicated by longer survival intervals in 
vaccinated animals75, 354, 355. 
 The guinea pig has been a useful model for evaluating the disease features associated 
with more relevant clinical strains320.  Previous studies have indicated that guinea pigs infected 
with both Beijing and non-Beijing clinical strains develop rapidly more progressive pulmonary 
and extrapulmonary disease.  Additional studies have indicated variability among Beijing 
sublineages with those of higher pathogenicity tending toward greater induction of regulatory T 
cell responses and reduced T cell activation over the disease course356.  Although reduced 
efficacy of BCG against Beijing clinical strains has been observed in mice during establishment 
of chronic disease, the impact of the Beijing strains on BCG vaccine efficacy in guinea pigs is 
unknown357.  Evidence that reduced efficacy from BCG vaccination against clinical strains is 
evident however from infection studies with Erdman K01358.  The emergence of regulatory T 
cells seen in mice, which may counteract protective immunity conferred by BCG, has also been 
suggested in guinea pigs infected with W-Beijing strains, which demonstrated elevated 
expression of the Foxp3 transcription factor359.  
 As an alternative to BCG vaccination, the use of non-tuberculous mycobacteria for 
immunization has been evaluated for protective effects in the guinea pig.  Specifically, 
evaluation of M. indicus pranii was demonstrated to provide a heightened Th1 response as 
compared to the BCG group, as well as reduced bacterial burden and improved pathology360.  
Evaluation of immunization through aerosol route was shown to provide superior protection and 
overall, data suggested better protection with MIP over BCG.  
 Another facet of vaccine evaluation is post-exposure prophylaxis, rather than pre-
exposure immunization. Post-exposure immunization with immunodominant antigens Ag85a 
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and ESAT6 as well as fusion protein F36, consisting of TLR2 agonist fused to ESAT6, was able 
to provide early protection by day 40 of infection but this effect was transient with no significant 
improvement in survival intervals361.  More recently, further investigations into post-exposure 
therapeutic vaccination, using a TLR4 and TLR9 agonist adjuvant, have indicated that although 
a reduction in bacterial burden is not achieved with these methods, a large reduction in 
consolidating secondary lesions resulted in significantly improved pulmonary pathology in 
guinea pigs infected with clinical isolates.  An improvement in survival could be achieved using 
a priming immunization followed by a single boost362.  
 
Response to BCG Vaccination in the Guinea Pig. 
 The response of guinea pigs to BCG vaccination closely replicates the efficacy of this 
vaccine in humans. BCG effectively prolongs survival in experimentally infected guinea pigs and 
because this vaccine is sufficiently protective, it can be used for comparison to candidate 
vaccines. Although immunization slows the progression of pulmonary and extrapulmonary TB 
disease, this vaccine does not prevent infection nor does it prevent dissemination of the bacilli 
to commonly involved organs.  Also, BCG vaccination in guinea pigs does not prevent the 
development of casseous necrosis in granulomas. These findings indicate that regardless of 
timing of adaptive immune function, whether pre-existing or not, this response cannot prevent 
the classical primary granuloma formation that is characteristic of the guinea pig model358. In 
contrast, the primary purpose of BCG vaccination in infants is to prevent severe multi-organ 
dissemination, to which young children are predisposed, but this is less effective in the guinea 
pig model.  In addition, it was recently shown that BCG vaccination does not prevent 
reactivation of latent or persistent TB disease in a guinea pig model of reactivation TB358. 
Whether the response to BCG vaccination accurately reflects the efficacy seen in humans under 
the previously described natural exposure conditions remains to be evaluated363.  
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 The immune response in BCG vaccinated guinea pigs differs significantly from that of 
non-vaccinated guinea pigs.  Vaccination significantly increases antigen specific IFNγ 
production in ex vivo stimulation assays by 10 weeks post-vaccination and leads to higher IFNγ 
expression, but reduced TNFα expression, post-infection in the lungs364.  There is also evidence 
that BCG vaccination promotes a functional T cell response to infection in the lungs based on 
higher numbers of CD4, but not CD8, positive T cells with low CD62L surface expression, as an 
indicator of T cell activation364.  Additional evidence CD4 T cell activation is enhanced over the 
course of disease by BCG vaccination indicated by upregulated surface expression of CD45365 
and homing receptor CT4358.  BCG also reduces heterophil/neutrophil influx into the lungs and is 
associated with an earlier B cell response365.  This primed response in the lung has been 
confirmed by laser capture microdissection of lesions from lungs of BCG vaccinated guinea 
pigs.  Based on qRT-PCR methods for relative gene expression in laser-capture microdissected 
pulmonary lesions, primary lesions in BCG vaccinated guinea pigs are dominated by the anti-
inflammatory cytokine TGFβ, with lesser contributions from IFNγ and IL-12p40, and have a 
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Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis 
infected guinea pigs1 
 
Rationale: Diabetes is a poorly understood but recognized risk factor for TB and the incidence 
is rising at an epidemic rate globally. Hyperglycemia is the hallmark feature of diabetes and 
epidemiological evidence suggests that hyperglycemia may be an important contributor to 
diabetic susceptibility to TB because diabetic individuals with adequate blood glucose control 
have a risk of developing TB equivalent to that of non-diabetic individuals.  Chronic 
hyperglycemia leads to non-enzymatic glycation of host macromolecules, which serves as the 
basis for glycated hemoglobin (HbA1c), an indicator of blood glucose levels over time.  In the 
presence of chronic hyperglycemia, advanced glycation end products (AGEs) are formed, which 
are inflammatory molecules linked to the development of diabetic complications, and also may 
influence the chronic inflammatory response to infection. Previously we identified that sucrose 
increases the severity of TB disease based on the results from carrier control guinea pigs in a 
study utilizing sucrose as a carrier solution for antimicrobial drug administration, indicating that 
the guinea pig may be an ideal model to study the impact of hyperglycemia and diabetes as a 
risk factor for TB.  Because little is understood regarding the pathogenesis of diabetes-TB 
comorbidity, we used the sucrose-fed guinea pig model to investigate the impact of 
hyperglycemia alone on progression of TB disease in association with the formation of AGEs.  
 
Hypothesis: Hyperglycemia, induced by daily feeding of sucrose, worsens TB disease in 
guinea pigs in association with increasing the formation of AGEs. 
                                                
1 This chapter is published in PLOS ONE as: 
Podell BK, Ackart DF, Kirk N, Eck S, Bell C, Basaraba RJ. (2012). Non-diabetic hyperglycemia 






 Hyperglycemia, the diagnostic feature of diabetes also occurs in non-diabetics 
associated with chronic inflammation and systemic insulin resistance. Since the increased risk 
of active TB in diabetics has been linked to the severity and duration of hyperglycemia, we 
investigated what effect diet-induced hyperglycemia had on the severity of Mycobacterium 
tuberculosis infection in non-diabetic guinea pigs.  Post-prandial hyperglycemia was induced in 
guinea pigs on normal chow by feeding a 40% sucrose solution daily or water as a carrier 
control. Sucrose feeding was initiated on the day of aerosol exposure to the H37Rv strain of M. 
tuberculosis and continued for 30 or 60 days of infection. Despite more severe hyperglycemia in 
sucrose-fed animals on day 30, there was no significant difference in lung bacterial or lesion 
burden until day 60. However the higher spleen and lymph node bacterial and lesion burden at 
day 30 indicated earlier and more severe extrapulmonary TB in sucrose-fed animals. In both 
sucrose- and water-fed animals, serum free fatty acids, important mediators of insulin 
resistance, were increased by day 30 and remained elevated until day 60 of infection. 
Hyperglycemia mediated by M. tuberculosis infection resulted in accumulation of advanced 
glycation end products (AGEs) in lung granulomas, which was exacerbated by sucrose feeding. 
However, tissue and serum AGEs were elevated in both sucrose and water-fed guinea pigs by 
day 60. These data indicate that M. tuberculosis infection alone induces insulin resistance and 
chronic hyperglycemia, which is exacerbated by sucrose feeding. Moreover, M. tuberculosis 
infection alone resulted in the accumulation tissue and serum AGEs, which are also central to 
the pathogenesis of diabetes and diabetic complications. The exacerbation of insulin resistance 
and hyperglycemia by M. tuberculosis infection alone may explain why TB is more severe in 
diabetics with poorly controlled hyperglycemia compared to non-diabetics and patients with 





 Historically the risk factors most frequently linked to TB are HIV infection, tobacco use, 
extremes in age, alcoholism, malnutrition, chronic kidney disease and both type 1 and type 2 
diabetes1. How these conditions increase the susceptibility to M. tuberculosis infection is poorly 
understood but is generally thought to be associated with altered cellular immune responses.   
Even though diabetes has been known for centuries to increase the risk of active TB2, 3, the 
current diabetes epidemic has the potential to significantly hamper efforts to control the spread 
of TB especially in parts of the world where M. tuberculosis is endemic4, 5.  It is estimated that 
80% of the global diabetic population is concentrated in developing countries with the incidence 
estimated to increase from 285 million currently to 439 million by the year 20306. In regions 
where the incidence of diabetes surpasses HIV the cumulative TB risk associated with diabetes 
has the potential to equal or exceed that linked to HIV infection despite the lower relative risk of 
TB in diabetic individuals compared to HIV1, 7.  
 The link between diabetes and TB susceptibility has been recently reaffirmed through 
retrospective review of clinical and observational studies, which show that regardless of study 
design and population, diabetes increases the risk of active TB8. These clinical studies have 
revealed that diabetic patients with active TB have more frequent radiographic evidence of 
multilobar disease 9, an increased incidence of cavitary lesions10, 11, increased risk of 
extrapulmonary dissemination12, 13, increased sputum bacterial counts14, and more frequent TB 
drug treatment failures and higher mortality compared to those without diabetes15, 16. 
 Recent studies have shown that despite the numerous metabolic derangements 
associated with type 2 diabetes, chronically elevated blood glucose (hyperglycemia) especially, 
is linked to the increased risk of active TB.  Patients with glycated hemoglobin (HbA1c) levels 
exceeding 7%, indicating poorly regulated blood glucose, have a higher risk of developing TB 
than diabetic patients with properly controlled blood glucose levels17, 18. However 
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hyperglycemia, the diagnostic feature of both type-1 and type-2 diabetes, can also occur in the 
absence of diabetes and can presumably also increase the risk of active TB. The relationship 
between non-diabetic hyperglycemia and the susceptibility to M. tuberculosis has not been 
adequately investigated yet is an important consideration since it is estimated that the pre-
diabetic population worldwide currently exceeds 280 million people and is rapidly growing19. 
Non-diabetic hyperglycemia as a TB risk factor was prioritized as important and in need of more 
research by a panel of experts commissioned to develop a research agenda addressing how 
the growing diabetes epidemic impacts TB treatment responses and thus global TB control 
measures20.  
 In individuals with type 2 diabetes or pre-diabetes, hyperglycemia is due in part to 
decreased responsiveness of tissues to the hormone insulin, a phenomenon known as insulin 
resistance. How hyperglycemia or insulin resistance increases the susceptibility to TB whether 
due to diabetes or not is unknown21. One possibility may be related to the chemical interaction 
of reducing sugars including glucose, with proteins and other host macromolecules known as 
the Maillard reaction. The non-enzymatic and therefore unregulated binding of sugar residues to 
proteins (glycation) is associated with the normal aging process but is exacerbated by chronic 
elevations in blood glucose in individuals with poorly controlled diabetes. Glycation and the 
intermediate formation of Amadori products is a reversible reaction, which precedes the 
formation of irreversibly modified adducts referred to as advanced glycation end products 
(AGEs)22. The accelerated accumulation of AGEs during diabetes is implicated in the pro-
inflammatory responses directly linking hyperglycemia to debilitating and life-threatening 
complications including nephropathy, neuropathy, retinopathy and atherosclerosis23-25.  
Because diabetes is an important TB risk factor and little is known about how 
hyperglycemia alone increases the risk of M. tuberculosis infection, we investigated the impact 
diet-induced hyperglycemia had on the severity of experimental M. tuberculosis infection and 
AGE accumulation in non-diabetic guinea pigs. The design of this study was based on the 
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hypothesis that the consequences of hyperglycemia and TB share a common pathogenesis 
involving chronic inflammation and the formation of AGEs and that combining the two conditions 
exacerbates TB severity even in hyperglycemic, non-diabetic guinea pigs.  
  
Materials and Methods. 
 
Animal treatments. 
A total of 60 guinea pigs (Charles River Laboratories; North Wilmington, MA) were 
randomly assigned to 4 treatment groups split between two separate experiments: M. 
tuberculosis infected and sucrose-fed (n=20), M. tuberculosis infected and water-fed (n=20), 
uninfected and sucrose-fed (sucrose control, n=10) and uninfected and water-fed (uninfected 
control, n=10).  All animals treated with sucrose were given 400 mg of sucrose as a 40% w/v 
solution per os daily beginning on the day of infection based on an unpublished observation that 
this dose of sucrose increases the severity of TB in guinea pigs when used as a carrier control 
in anti-TB drug treatment studies. In addition, a slightly lower dose of sucrose induces post-
prandial hyperglycemia and insulin resistance in the rat 26.  This 400 mg dose effectively 
increases post-prandial blood glucose levels with a peak average of 2.14 fold above baseline in 
the guinea pig (Figure S1). The mock-treated, water-fed animals were given an equivalent 
volume of water per os daily also beginning on the day of infection.   
 
Aerosol infection of guinea pigs with M. tuberculosis. 
Culture stocks of Mycobacterium tuberculosis strain H37Rv (TMC #102, Trudeau 
Institute; Saranac Lake, NY) collected at mid-log phase of growth in Proskauer-Beck liquid 
medium containing 0.05% Tween-80 were diluted to 1 x 106 CFU/ml and delivered by low-dose 
aerosol infection using a Madison chamber aerosol generation device calibrated to deliver 
approximately 20 bacilli to each animal.  
 88 
Euthanasia and Sample Collection. 
 At days 30 and 60 of infection, 10 guinea pigs from each infected treatment group and 5 
guinea pigs from each uninfected group were anesthetized by intramuscular injection of 
ketamine (20 mg) and diazepam (1 mg) prior to humane euthanasia with an overdose of sodium 
pentobarbital by intraperitoneal injection (1.5 ml/kg).  Lung, spleen and mediastinal lymph node 
was collected either for histopathology and fixed in 4% paraformaldehyde or for Mycobacterial 
culture and weighed prior to homogenization and plating of serial dilutions. All 
paraformaldehyde fixed tissue was removed after 72 hours and placed in 70% ethanol for 
storage.  
 
Tissue CFU Quantification. 
Bacterial burden in the lung, spleen, and mediastinal lymph nodes was determined by 
plating serial dilutions of tissue homogenates on nutrient 7H11 agar followed by counting 
colony-forming units after incubation at 37°C for 3-6 weeks.  Data was expressed as CFUs per 
gram of tissue.  
 
Histopathology and lesion analysis.  
Either on day 30 or day 60 of infection, lung, spleen, and mediastinal lymph node were 
collected and fixed in buffered 4% paraformaldehyde for 3 days then stored permanently in 70% 
ethanol.  Tissues were paraffin embedded, sectioned at 5 µm and stained with hematoxylin and 
eosin by standard methods.     
Total lung, lymph node and spleen tissue area for each organ was quantified using the 
Stereo Investigator software version 10.02 (MBF Bioscience; Williston, VT) and the Nikon 
Eclipse 80i microscope.  Total lesion area was compared to total tissue area of lung, lymph 
node or spleen respectively to yield total lesion burden expressed as a percentage of lesion to 
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total tissue area using the area fraction fractionator as previously described27.  Similarly, area 
ratio quantification was performed comparing necrosis to lesion area.  
 
Serum glucose and oral glucose tolerance test. 
Serum was collected from guinea pigs at the time of euthanasia on either day 30 or day 
60 of infection.  Glucose was measured using the glucose oxidase enzymatic method (Cayman 
Chemical; Ann Arbor, MI) at an absorbance of 500 nm on a microplate spectrophotometer.  The 
oral glucose tolerance test was performed on the animals after 12 hours of overnight fasting.  At 
time 0 each guinea pig was administered an oral dose of D-glucose (Sigma-Aldrich; St. Louis, 
MO) of 1g/kg.  Percutaneous whole blood obtained from an ear pinna prick site was used for 
sequential glucose measurements performed at 0, 60, and 120 minutes post-glucose 
administration with a handheld glucometer (Freestyle Lite, Abbott Diabetes Care; Alameda, CA) 
validated against the glucose oxidase assay.   
 
Immunohistochemistry for AGEs. 
Immunohistochemistry was performed on paraformaldehyde-fixed, paraffin-embedded 5 
µm sections of lung from the sucrose-fed and water-fed guinea pigs targeting AGEs.  Slides 
containing tissue sections were deparaffinized and rehydrated followed by antigen retrieval (PT 
Module Buffer 4, Thermo Scientific; Rockford, IL) at an incubation temperature of 95°C for 30 
minutes.  Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide 
treatment for 10 min, rinsed in Tris-buffered saline with 1% Tween-20 (TTBS), and followed by 
two blocking steps: (i) 15 min incubation with 0.15 mM glycine in PBS, and (ii) 30 min incubation 
with 10% fetal bovine serum and 1% bovine serum albumin. The slides were then incubated for 
30 minutes with rabbit polyclonal antibody to AGE (ab23722, AbCam; Cambridge, MA) or rabbit 
polyclonal IgG (ab27478, AbCam; Cambridge, MA) at a 1:400 or 1:100 dilution, respectively, in 
blocking buffer.  After rinsing, the slides were incubated for 30 minutes with biotinylated goat-
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anti rabbit IgG antibody (Vector Laboratories; Burlingame, CA).  Horseradish peroxidase was 
added followed by diaminobenzidine substrate to visualize bound antibody.  Hematoxylin was 
used as a counterstain.    
Evaluation of immunohistochemical reactivity within TB lesions of lung tissue was based 
on a 4-point scoring system and performed by a pathologist blinded to the study groups.  Areas 
of lung containing primary lesions with or without necrosis were separated from lesion-free lung 
and scored based on the following 2 criteria: (i) Percent of lesion inflammatory cells displaying 
immunoreactivity: 0- No immunoreactivity is evident, 1- Up to 25% of cells are reactive, 2- Up to 
50% of cells are reactive, 3- Up to 75% of cells are reactive, 4- Greater than 75% of cells are 
reactive. (ii) Intensity of immunoreactivity was assessed as follows: 0- none, 1- mild, 2- 
moderate, 3- severe.  The maximum possible score for AGE IHC is 7.     
 The specificity of anti-AGE antibodies for AGE-modified guinea pig proteins was 
validated by competitive inhibition of tissue binding utilizing AGE-modified bovine serum 
albumin (ab51995, Abcam; Cambridge, MA) at an antibody:antigen ratio of 1:100 prior to adding 
the primary antibody to each tissue section.  Specificity was confirmed by loss or lack of 
immunoreactivity in tissue sections indicating effective blocking of anti-AGE antibodies to guinea 
pig lung tissue.  Purified polyclonal rabbit IgG was applied as a primary antibody for a negative 
control. 
 
Quantification of serum AGE levels. 
Protein content of serum was measured using the BCA assay (Thermo Scientific; 
Rockford, IL) and samples were diluted to a concentration of 10 µg/ml.  AGE levels were 
measured in diluted serum samples by ELISA (Cell Biolabs; San Diego, CA).  Serum samples 
were analyzed on a standard curve of AGE-modified bovine serum albumin as directed by the 
manufacturer and expressed as the mass of AGE-modified serum protein per 10 µg analyzed.  
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This assay detects AGE structures formed on proteins in the presence of glycolaldehyde 
including two of the most prevalent, carboxymethyllysine and pentosidine. 
 
Quantification of serum free fatty acid levels. 
 Serum free fatty acid levels were measured by fluorescence in an assay utilizing a 
coupled enzymatic reaction (Cayman Chemical; Ann Arbor MI).  Briefly, acyl CoA synthetase 
catalyzes fatty acid acylation of coenzyme A.  The acyl CoA generated is oxidized by acyl CoA 
oxidase to generate hydrogen peroxide, which in the presence of horseradish peroxidase and 
10-aceyl-3,7-dihydroxyphenoxazine (ADHP) generates fluorescence that is measured 
spectrophotometrically at an excitation wavelength of 530 nm and an emission wavelength of 
585 nm. 
 
Data Analysis.  
 Statistical analyses and graphic expression of the data was by the use of the statistical 
package in GraphPad Prism 5. Bacterial tissue burden was log10 transformed and normalized to 
per gram of tissue prior to analysis to ensure approximate normal distribution with a common 
variance. Comparison of paired observations based on a single treatment was performed by 
paired t test.  The differences between treatment groups of the remaining data was compared 
using a two-way ANOVA followed by Bonferroni post-test for pair-wise comparison of means 










Serum glucose and glucose tolerance tests. 
  At day 30 of infection, serum glucose levels (Fig 2.1) were elevated with a mean value 
of 132.6 mg/dl in infected water-fed control guinea pigs but this increase was not statistically 
significant (p>0.05). In contrast, hyperglycemia was further exacerbated by sucrose feeding at 
30 days of infection with a mean value of 147.6 mg/dl (p≤0.01). Interestingly, similar 
hyperglycemia was evident by 60 days of infection in both the water- and sucrose-fed groups 
with mean values of 196.3 and 197.4 mg/dl, respectively (p≤0.01).   
Oral glucose tolerance tests (OGTT) were performed prior to euthanasia at both days 30 
(Appendix Fig 2A) and 60 (Appendix Fig 2B) of infection to confirm that sucrose feeding or 
infection alone or in combination did not induce a diabetic type response to oral glucose 
challenge.  A response similar to that of normal water-fed controls was present in all groups 
independent of sucrose feeding or infection with a peak glucose concentration of approximately 
2 fold at 60 minutes and a return to <1.5 fold by 120 minutes post-challenge.  
 
Histopathology. 
 Pulmonary pathology showed no statistically significant quantitative differences between 
the sucrose-fed animals compared to water-fed controls on day 30 of infection (p>0.05) but was 
more severe in the sucrose-fed group by day 60 (p≤0.05) (Fig 2.2A).  More striking was the 
increase in size and frequency of the extrapulmonary lesions in the spleen (Fig 2.2B) and lymph 
node (Fig 2.2C) of sucrose-fed guinea pigs compared to the water-fed controls.  In the spleen, 
the lesion burden was significantly higher in sucrose-fed guinea pigs by day 30 of infection 
(p≤0.05) with an even greater difference in severity by day 60 (p≤0.05). At day 30 of infection, 
the lesion burden in mediastinal lymph nodes was significantly higher in the sucrose-fed group 
(p≤0.05), which progressed in both groups such that there were no differences between water  
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Figure 2.1.  Hyperglycemia resulting from M. tuberculosis infection was exacerbated early by 
sucrose treatment. Random sampling of serum glucose values were compared to the mean glucose 
level of guinea pigs prior to sucrose feeding or infection (Pre-infection, n=20) and served as the normal 
reference value. Serum glucose values of uninfected guinea pigs are similar to normal pre-infection 
values. Despite a mild increase in serum glucose associated with M. tuberculosis infection in the water-
fed controls, significant exacerbation of hyperglycemia was only induced in sucrose-fed guinea pigs on 
day 30 of infection (n=10). However, this difference was independent of sucrose feeding by day 60 (n=9) 


































Figure 2.2.  Sucrose fed guinea pigs had significantly higher lung and extrapulmonary TB lesion 
burden.  The lung and lesion area was determined from hematoxylin and eosin stained tissue sections 
for each animal and the data expressed as mean percent involvement for each treatment group.  The 
sucrose-fed guinea pigs had a significantly higher lesion burden compared to the water-fed control group 
in the lung (A) on day 60 of infection, spleen (B) on days 30 and 60 of infection, and mediastinal lymph 
node (C) on day 30 of infection. n=10, *p≤0.05.   
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and sucrose-fed groups by day 60 of infection (Fig 2.2C).  The degree of necrosis, measured as 
percent necrosis area to lesion area, was not significantly different between water and sucrose-
treatment in any organ at either day 30 or day 60 of infection (p≤0.05) (Appendix Fig 3). 
 The qualitative differences of lesions for each treatment group are depicted in 
representative photomicrographs of lung in Figure 2.3 and spleen in Figure 2.4. Individual 
lesions were represented by well-delineated granulomas consisting of epithelioid macrophages 
and scattered multinucleated giant cells with fewer lymphocytes in sections of lung, lymph node 
and spleen of both treatment groups by day 30 of infection with necrosis and central 
accumulations of infiltrating granulocytes. By day 60 of infection the granulomas had expanded 
in size, as did the extent of central lesion necrosis, peripheral lymphocytic infiltration, 
circumferential fibrosis and central dystrophic mineralization. Non-necrotic secondary pulmonary 
lesions indicative of hematogenous reinfection of the lung in sucrose-fed animals were more 
pronounced by day 30 of infection and progressed in size and number by day 60 of infection. 
Based on histologic examination the cellular constituents were similar between treatment 
groups however the size and frequency of lesions were more severe in the sucrose-fed groups.   
  
Tissue bacterial burden.  
On day 30 of infection similar numbers of viable bacilli were cultured from the lungs of 
water- and sucrose-fed groups (p>0.05, data not shown). There was a significant increase in the 
lung and spleen bacterial burden by day 60 of infection (p≤0.05) (Fig 2.5). Bacterial numbers in 
the mediastinal lymph node on day 60 of infection were not statistically different between 
sucrose- and water-fed, infected groups (p>0.05). While the difference in bacterial numbers in 
the lung of sucrose-fed animals was significant, the differences between treatment groups as 






Figure 2.3.  Sucrose feeding resulted in a more severe pulmonary lesion burden in M. tuberculosis 
infected guinea pigs. Images represent the animals closest to the mean values for severity of lesion 
burden as determined by measuring lesion and normal lung area using morphometric analysis (see 
Figure 2).  Pulmonary lesion severity was similar between water-  (A) and sucrose-fed (B) guinea pigs at 
day 30 of infection but was more severe in the sucrose-fed animals by 60 days of infection (D) compared 
to the water-fed controls (C). Bar = 1000µm. Hematoxylin and eosin stain. Insets: High magnification 














Figure 2.4.  Spleen lesions from extrapulmonary dissemination of M. tuberculosis were more 
severe and more numerous in sucrose-treated guinea pigs. Images represent the animals closest to 
the mean severity of lesion burden as determined by measuring lesion and normal spleen area using 
morphometric analysis (see Figure 2).  Splenic involvement was mild in the sucrose-fed guinea pigs at 30 
days of infection (A) which was even less in the water-fed controls (B).  However, splenic lesions were 
significantly more severe in the sucrose-fed animals by day 60 of infection (D) compared to the water-fed 
control group (C). Bar = 1000µm. Hematoxylin and eosin stain. Insets: High magnification views of the TB 

























Figure 2.5.  Sucrose treatment resulted in higher bacterial burden in lung and spleen of M. 
tuberculosis infected guinea pigs. Yield of viable bacilli from the lung was significantly higher in 
sucrose-fed guinea pigs on day 60 of infection compared to water-fed control animals.  Even higher yields 
of bacilli were recovered from the spleens of sucrose-fed guinea pigs on day 60 of infection. No 
















Serum Free Fatty Acid Levels. 
 Total free fatty acids were measured in serum from guinea pigs of all treatment groups 
at days 30 and 60 of infection (Fig 2.6).  Elevated mean FFA levels were present in both water-
and sucrose-fed, M. tuberculosis infected groups at both days 30 and 60 of infection (p≤0.001). 
Compared to mean values of 102.8 µM and 107.2 µM at day 30 of infection in uninfected 
sucrose- and water-fed guinea pigs, respectively, FFAs were elevated with mean values of 
207.6 µM and 204.3 µM in the infected groups. Serum FFAs remained elevated at day 60 of 
infection with mean values of 205.4 µM and 202.3 µM in sucrose- and water-fed, infected 
guinea pigs, respectively while uninfected mean values were minimally reduced at 67.2 µM and 
65.03 µM. Sucrose feeding alone in uninfected guinea pigs did not result in alterations of serum 
FFAs compared to water-fed controls (p>0.05).  
 
Serum AGE Levels. 
The differences in serum AGEs between treatment groups at days 30 and 60 of infection 
are illustrated in Figure 2.7. Elevated serum AGEs were present in a single guinea pig in the 
sucrose-fed, infected group at day 30 of infection with no reflective increase in mean serum 
AGEs for that group (p>0.05). All remaining guinea pigs of sucrose- and water-fed, infected 
groups were similar to uninfected, water-fed controls. In contrast, by day 60 serum AGEs were 
similarly elevated in both the water- and sucrose-fed infected groups compared to the water-fed 
uninfected control group (p≤0.05). There was no evidence of increased AGEs due to sucrose 




































Figure 2.6.  Elevated total serum free fatty acids occurred as a result of M. tuberculosis infection 
and not due to sucrose treatment. Serum free fatty acids are similarly elevated between sucrose- (n=9) 
and water-fed (n=10) M. tuberculosis infected guinea pigs at day 30 of infection (A).  The levels remain 
similarly elevated in sucrose- (n=10) and water-fed (n=10) M. tuberculosis infected guinea pigs at day 60 
of infection with no increase in the mean values over time (B). Serum free fatty acid levels in sucrose-fed 
uninfected animals (day 30, n=5; day 60, n=5) are comparable to water-fed controls (day 30, n=5; day 60, 







Immunoreactivity for AGEs was seen specifically in the pulmonary TB lesions, within the 
serum and lymph fluid of all blood and lymphatic vessels and associated with extracellular 
matrix surrounding airways and blood vessels. There was no immunoreactivity seen in other 
normal microanatomic structures of the lung parenchyma. In both sucrose- and water-fed, 
uninfected animals, immunoreactivity was limited to intravascular serum, lymph fluid and 
extracellular matrix and were not significantly different. Immunoreactivity specifically colocalized 
with cells of the pulmonary TB lesions and most strikingly within the areas of central necrosis of 
the primary lesions. Occasionally, AGE-positive macrophages were in the lumen exudate, which 
frequently accumulates within bronchioles in the chronic stages of M. tuberculosis infection.   
The number and immunostaining intensity of macrophages within lesions was 
significantly different between treatment groups (Fig 2.8). The sucrose-fed guinea pigs had a 
marked accumulation of AGEs within lesions on both days 30 and 60 of infection compared to 
water-fed guinea pigs (p≤0.001 and p≤0.05, respectively) with elevated but little difference in the 
sucrose-fed group between days 30 and 60. Interestingly, pulmonary AGEs increased in the 
water-fed group between days 30 and 60 of infection but did not increase to a level comparable 
to that of the sucrose-fed animals.  However, this increase in the water-fed group was not 
statistically significant (p>0.05).  The differences in IHC scores were due to morphologic 
differences in macrophage or necrosis localization, frequency of immunoreactivity, and signal 
intensity in lungs between sucrose- and water-fed guinea pigs (Fig 2.9).  Lungs from sucrose-
fed guinea pigs had greater numbers of inflammatory cells with more intense immunoreactivity 
compared to water-fed guinea pigs.  Additionally, there was increased intensity of 
immunoreactivity present within areas of lesion necrosis in the sucrose-fed compared to water-




Figure 2.7.  M. tuberculosis infection induces the formation and accumulation of AGEs in serum 
from guinea pigs independent of sucrose feeding. Levels of serum AGEs were analyzed in sucrose- 
or water-fed guinea pigs with and without M. tuberculosis infection at both 30 and 60 days of infection.  At 
30 days of infection (A), mean serum AGEs are not elevated by either sucrose feeding or M. tuberculosis 
infection with levels remaining similar to uninfected controls.  However, elevations in serum AGEs were 
present at 60 days due to M. tuberculosis infection (B) (sucrose-infected n=10, water-infected n=9) and 
were not exacerbated by sucrose feeding.  AGE levels in uninfected, sucrose- and water-fed controls 
















Figure 2.8.  Sucrose feeding of M. tuberculosis infected guinea pigs significantly increased tissue 
AGEs by day 30 of infection. The mean score of AGE immunohistochemistry on lung is depicted in 
water- and sucrose-fed guinea pigs on days 30 and 60 of infection.  Significantly increased AGE 
formation and accumulation was present within TB lesions by day 30 of infection in the sucrose-fed group 
compared to the water-fed controls. AGE levels at day 30 were similar to day 60 in the sucrose-fed group 
but additional AGEs accumulated within lesions by day 60 of the water-fed controls, which was not 








Figure 2.9.  Sucrose feeding of M. tuberculosis infected guinea pigs increased lesion associated 
AGEs on day 30 and 60 of infection. AGEs are evaluated by immunohistochemistry on lung tissue 
sections of M. tuberculosis infected guinea pigs.  The majority of strong immunoreactivity was associated 
with TB lesions. Immunoreactivity was evident within the cytoplasm of macrophages forming 
granulomatous lesions and was also strongly present within central necrosis (N) of primary TB pulmonary 
lesions.  (A) Minimal reactivity was confined to the serum, rare macrophages in the lesions (arrow) and 
minimally within areas of necrosis (N) of the water-fed control group at 30 days of infection. (B) In 
contrast, at 30 days of infection, the sucrose-fed animals had strong immunoreactivity in the majority of 
lesion macrophages (arrow) and in areas of necrosis (N). (C) By day 60 of infection, AGEs began to 
accumulate within macrophages (arrow) in the water-fed controls but minimal reactivity was present in 
areas of necrosis (N). (D) The sucrose-fed animals had strong immunoreactivity within the majority of 
macrophages (arrow) and in areas of necrosis (N) at day 60 of infection. All tissue sections depicted are 
representative of the mean AGE IHC score for each treatment group at each time point (see Figure 8). 











 In this study we show that daily feeding of a relatively small amount of sucrose in non-
diabetic guinea pigs exacerbated M. tuberculosis infection-associated hyperglycemia, which 
significantly increased TB disease severity. Most notable was not only increased lung lesion and 
bacterial burden but also earlier hematogenous dissemination of bacilli in sucrose-fed animals, 
which resulted in earlier and more severe extrapulmonary TB. These studies were initiated 
following a fortuitous observation showing that the use of sucrose as an oral anti-TB drug carrier 
in guinea pigs resulted in more severe disease compared to non-sucrose fed controls. The 
importance of these data is that inducing post-prandial hyperglycemia in guinea pigs by 
supplementing a normal chow diet with sucrose had a significant negative impact on the 
severity of experimental M. tuberculosis infection. These data are significant since it has been 
shown that hyperglycemia is a TB risk factor and diabetics with uncontrolled hyperglycemia are 
at greater risk for active TB compared to those who have successfully maintained near normal 
blood glucose levels17, 18.  What remains unknown however, is whether hyperglycemia in non-
diabetic humans also increases the risk and severity of TB as suggested by these data.  
Invariably preceding the development of overt type 2 diabetes, there is a decrease in 
systemic insulin sensitivity referred to as insulin resistance, which is also a feature of chronic 
inflammatory conditions in non-diabetic individuals. Our results show that hyperglycemia in M. 
tuberculosis infected guinea pigs fed sucrose was largely driven by infection associated 
inflammation and sucrose feeding contributed to hyperglycemia in the early stages of infection. 
Therefore, these data suggest that the persistent hyperglycemia was more likely due to insulin 
resistance associated with chronic M. tuberculosis infection.  However, sucrose feeding 
lengthened the duration and severity of hyperglycemia as was evident by increased clinical 
disease severity and the formation and accumulation of tissue and serum AGEs.  
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One possible explanation for how chronic M. tuberculosis infection increases blood 
glucose levels is through the elevation of pro-inflammatory cytokines, specifically TNF-α. TNF-α 
rapidly induces insulin resistance by stimulating free fatty acid (FFA) synthesis and secretion, 
which interferes with post insulin receptor signaling via altered phosphorylation of insulin 
receptor substrates28-30. Our data are consistent with FFA mediated insulin resistance in M. 
tuberculosis infected guinea pigs since FFA levels were elevated in both the water- and 
sucrose-fed animals, with similar elevations present at both days 30 and 60 of infection.  
Although significant glucose intolerance was not demonstrated by OGTT, significant 
post-prandial hyperglycemia was confirmed 60 minutes after administration of 1 g/kg of glucose 
administered during the test. However, even a short interval of post-prandial hyperglycemia is 
known to result in significant oxidative stress in humans31. Additionally, oral supplementation of 
sucrose has been shown to model insulin-resistance in rats as early as 2 weeks after initiation 
of treatment while persistent hyperglycemia does not manifest until 9 weeks after treatment26.  
In this study, a comparatively low dose of 400mg of sucrose daily was utilized to mimic the 
original observation made when sucrose was used as an anti-TB drug carrier. Compared to 
water-fed controls, this treatment induced more severe hyperglycemia by 30 days when 
combined with M. tuberculosis infection. We showed, however, that combining sucrose feeding 
and M. tuberculosis infection did not induce diabetes since oral glucose tolerance tests did not 
show any evidence of elevated fasting glucose or glucose intolerance typical of type 2 diabetes. 
The degree of hyperglycemia, in particular non-diabetic hyperglycemia, has not been 
previously investigated as a risk factor for TB in humans and experimentally in animal models.  
In this study, non-diabetic guinea pigs with hyperglycemia had more severe and earlier onset of 
extrapulmonary TB as evident by higher lesion burden in the mediastinal lymph nodes at 30 
days of infection followed by an increased bacterial burden and increased severity of spleen 
lesions on both days 30 and 60 of infection. Immunosuppression has been implicated as the 
mechanism by which diabetes and other TB risk factors increase the susceptibility to M. 
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tuberculosis infection or exacerbate active TB disease1. While suppression of the adaptive 
immune response potentially explains the increased numbers of viable bacilli isolated from both 
lung and spleen of sucrose-fed animals on day 60 of infection there are alternative explanations. 
The delay in the adaptive immune response as demonstrated in diabetic mouse models of M. 
tuberculosis infection combined with a pro-inflammatory innate response associated with 
hyperglycemia could also explain our findings32. In addition, chronic hyperglycemia and free 
fatty acids may represent a readily available carbon source for rapidly replicating bacilli33. 
The extrapulmonary spread of bacilli to the regional lymph nodes is a consistent feature 
of the experimental M. tuberculosis infections in animal models including the guinea pig34. The 
rate of dissemination and severity of extrapulmonary lesions is an indicator of increased 
susceptibility of the host or increased virulence of the challenge strain of M. tuberculosis35, 36. 
Studies performed in our laboratory and others have demonstrated an increased resistance to 
extrapulmonary TB in guinea pigs vaccinated with BCG prior to challenge, but few studies have 
demonstrated a decreased resistance in this model34, 36.  Disseminated extrapulmonary TB in 
humans is associated with HIV infection and the risk increases proportionally with severity of 
immunosuppression37, 38.  Similarly, diabetes, a condition known to alter immune function, is 
associated with increased risk of developing extrapulmonary dissemination of M. tuberculosis in 
humans12, 13.  In this study, we show that non-diabetic hyperglycemia had a significant negative 
impact on disease progression resulting in earlier and more severe dissemination of bacilli. A 
potential mechanism leading to more extensive M. tuberculosis dissemination may be related to 
microvascular damage, a direct consequence of hyperglycemia, which is central to the 
pathogenesis of diabetic complications39. 
A potential link tying together high carbohydrate diet and a maladaptive pro-inflammatory 
state is the increased formation of circulating and tissue-associated AGEs.  The presence of 
increased AGEs is tied to both a pro-oxidative and pro-inflammatory state where oxidative 
stress mediates the persistent inflammatory response40, 41. In patients with poorly controlled 
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diabetes and increased glycated hemoglobin (HbA1c), peripheral blood leukocytes express 
increased innate and type 1 cytokines indicative of a pro-inflammatory phenotype42, 43.  In this 
study, sucrose-fed guinea pigs developed more severe pulmonary and splenic inflammation, 
which corresponded to increased AGE formation in the TB lesions. The specific localization and 
accumulation of AGEs in TB lesions even in water-fed controls implicates AGEs as a potential 
driving force for the pro-inflammatory state in TB as well, which is exacerbated by diabetic or 
non-diabetic hyperglycemia.  In part, this may be due to increased oxidative stress, which we 
have shown to be important in the pathogenesis of TB. Interestingly, this pathogenic mechanism 
is further supported by our findings that treatment of M. tuberculosis infected guinea pigs with 
the antioxidant drug N-acetyl cysteine significantly reduces disease burden including the extent 
of extrapulmonary dissemination44. 
There are multiple potential mechanisms for AGE formation in this study. Hyperglycemia 
may induce AGEs via direct interactions between glucose and serum or extracellular matrix 
proteins.  Alternatively, increased intracellular glucose under hyperglycemic conditions 
promotes rapid formation of dicarbonyl intermediates of glycolysis including glyoxal, 3-
deoxyglucasone and methylglyoxal, all potent inducers of AGE formation45-47.  Accumulation of 
AGEs associated with chronic inflammation has been shown to occur48 and methylglyoxal49, as 
well as its precursor dihydroxyacetone50, have been identified in association with TB lesions.  
This demonstrates the potential for at least localized AGE formation even in euglycemic animals 
infected with M. tuberculosis. AGE formation associated with M. tuberculosis infection was a 
prominent feature in this study where AGE accumulation increased in TB lesions between day 
30 and 60 of infection even in water-fed guinea pigs.  Additionally, elevated serum AGEs at day 
60 of infection were equally elevated in both sucrose-fed and water-fed guinea pigs. Recently 
AGE formation and secretion by bacteria has been shown in vitro and may represent a third 
source of AGEs in M. tuberculosis infection51.  However, the significant increase in tissue AGEs, 
which resulted from sucrose feeding, suggests that while bacteria and local tissue metabolism 
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may be a source for AGEs during M. tuberculosis infection, the accumulation is greatly 
exacerbated by hyperglycemia.  
 The importance of understanding the impact diabetes and hyperglycemia have on TB 
pathogenesis and treatment has been highlighted as a global priority7. Aside from overt clinical 
diabetes, the results herein indicate the potential for hyperglycemia in a non-diabetic state to 
significantly worsen active TB. These data emphasize the potential impact of stringent 
screening of glycemic responses in TB patients at the time of diagnosis even if diagnostic 
criteria for diabetes are not met20, 52. Our data indicate that inflammation-associated insulin 
resistance during M. tuberculosis infection may be an additional factor contributing to 
hyperglycemia. Based on our data, impaired control of M. tuberculosis infection, amplification of 
the inflammatory response and exacerbated extrapulmonary dissemination are evident in 
association with hyperglycemia-mediated AGE accumulation, which may represent a central 
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Developing a Model of Diet-Induced Glucose Intolerance and Type 2 Diabetes in the 
Guinea Pig 
 
Rationale:  An overall goal of this project is to advance the current understanding of the 
relationship between DM and TB with an animal model that accurately reflects the pathogenesis 
of both diseases in humans. The guinea pig is well regarded as a tuberculosis model due to 
remarkable similarities to human granuloma development and morphology. As such, the guinea 
pig has been relied upon for the preclinical evaluation of both new therapeutic and preventive 
strategies for TB.  However, the use of the guinea pig species as model of diabetes, in general, 
is limited.  Since the overwhelming majority of diabetes cases worldwide, as well as diabetes-
associated cases of TB are due to type 2 diabetes, a model of type 2 diabetes is critical for 
understanding the mechanisms of this rapidly emerging comorbidity.  This chapter describes the 
development of the first model of diet-induced insulin resistance and type 2 diabetes in the 
guinea pig.  In the chapters to follow, the use of this novel diabetes model will represent the first 
use of a representative animal model of type 2 diabetes and TB to study to study the two 
diseases combined. 
 
Hypothesis:  A guinea pig model that closely replicates the human pathogenesis of type 2 
diabetes can be generated through a two-stage process first involving induction of insulin 
resistance by dietary manipulation and second, through β-cell decompensation by subtotal 







The goal of this study was to develop a model of type 2 diabetes in outbred guinea pigs 
that closely replicates the typical pathogenesis of human type 2 diabetes associated obesity and 
insulin resistance.  Previously, the guinea pig has never been used as a model of type 2 
diabetes and has infrequently been reported as a diabetic model using chemical-mediated β-cell 
cytotoxicity with the compound streptozotocin (STZ), but with significant variability and a high 
level of mortality.  To optimize the dose and efficacy of hyperglycemic induction, while 
minimizing mortality with STZ, guinea pigs were treated with a range of STZ doses either by 
subcutaneous or intraperitoneal route, with or without pretreatment with the α2 adrenergic 
antagonist, yohimbine, and with STZ prepared as an anomer equilibrated solution.  In this study, 
guinea pigs responded to STZ doses of 200 and 250 mg/kg while minimizing mortality and 
anomer-equilibration was found to have a similar hyperglycemic induction rate of 25-50%.  
Complete hyperglycemic conversion occurred in all animals when administered yohimbine prior 
to STZ at a dose of 250 mg/kg. However, this hyperglycemic effect was transient and 
diminished along with glucose intolerance by 21 days after treatment.  To induce insulin 
resistance, guinea pigs were fed a high fat, high carbohydrate diet, which led to impaired 
glucose tolerance within eight weeks alongside compensatory hyperinsulinemia and normal 
fasting glucose.  To eliminate the capacity for compensation, guinea pigs were treated with an 
optimized STZ treatment of 200 mg/kg after yohimbine administration, which yielded a reduction 
in plasma insulin and a stable level of glucose intolerance consistent with type 2 diabetes.  In 
conclusion, we have demonstrated that the effect of STZ alone in the guinea pig is transient and 
that a steady diabetic state can be achieved through dietary induction of glucose intolerance 
and an optimized STZ treatment protocol to reduce β-cell mass, methodology that mimics the 




 The development of type 2 diabetes requires the presence of both peripheral insulin 
resistance and impaired β-cell function1. During a state of insulin resistance, insulin-mediated 
glucose disposal is impaired and leads to a compensatory hypersecretion of insulin by 
pancreatic β-cells to maintain a state of euglycemia2.  The typical progression of obesity-
associated, polygenic type 2 diabetes spans a period of years where impaired glucose 
tolerance, detectable by an oral glucose tolerance test, progressively worsens to a diabetic 
state, as the β-cell compensatory response is lost and often, the severity of insulin resistance 
increases3.  Consequently, the lower circulating insulin concentrations and associated reduced 
β-cell mass of type 2 diabetes patients is unable to maintain a euglycemic state4.  To better 
mimic the growing trend in poor diet, reduced physical activity and obesity, this typical 
pathogenesis involving insulin resistance and hyperinsulinemia is often replicated in rodents 
through dietary manipulation.  
 A number of well-characterized rodent models of type 2 diabetes exist involving either 
high fat diet-induced glucose intolerance in mice and rats5, 6 as well as spontaneous or targeted 
mutations either directly disrupting insulin signaling or leading to alterations in lipid metabolism4.  
Many of the models involving genetic defects develop severe obesity and metabolic 
disturbances, which typically mimic the most severe manifestations of diabetes.  In contrast, the 
use of high-fat diet in guinea pigs specifically for the induction of glucose intolerance and insulin 
resistance has not been previously described.  Guinea pigs fed a high carbohydrate diet or a 
diet high in saturated fat; however, have been emphasized as models of dietary-associated 
inflammation, dyslipidemia and atherosclerosis7, 8.  The cardiovascular risks and atherogenic 
susceptibility of this species can be attributed to lipid metabolism that is comparable to humans.  
Unlike all other laboratory rodent species that have serum lipoprotein profiles dominated by 
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high-density lipoproteins, the majority of guinea pig lipoproteins are the low-density type, similar 
to humans9-11.  Guinea pigs fed a high carbohydrate diet develop evidence of systemic 
inflammation including high TNFα and IL-6 production12, 13, which are also characteristic 
features of the inflammatory pathogenesis of insulin resistance and type 2 diabetes in humans14, 
15.  Therefore, guinea pigs are a suitable species for studying the impact of dietary-induced 
alterations in lipid metabolism, the primary factor contributing to the development of insulin 
resistance.   
 Previously, induction of diabetes in the guinea pig has been limited to the use of the β-
cell cytotoxic compound streptozotocin (STZ) alone, with the goal of obtaining a model of 
absolute insulin deficiency that is more reflective of insulin-dependent or type 1 diabetes.  The 
use of STZ to induce diabetic hyperglycemia in guinea pigs has been reported with variable 
efficacy, dose, and route of administration, and often involves significant levels of mortality in 
the acute stages after STZ administration16-20.  However, the degree of mortality associated with 
STZ toxicity, compared to severe diabetic hyperglycemia has not been specifically addressed 
and an optimized model for the use of STZ in guinea pigs has not been developed.  
Furthermore, previous studies have suggested that the guinea pig is resistant to the 
hyperglycemic effects of β-cell cytotoxins, including both STZ and alloxan21.  As a result, the 
degree of variability in the literature lends limited credibility to the guinea pig as a suitable model 
of chemical-induced, insulin-dependent diabetes.   
 In this study, we have developed a guinea pig model that mimics the two stages typical 
of human type 2 diabetes, initial insulin resistance followed by reduced beta cell function.  A 
high fat, high carbohydrate diet was used initially to induce glucose intolerance and followed by 
STZ treatment to induce a partial decline in insulin secretory capacity by reducing overall β-cell 
mass.  The goal of combining STZ with diet-induced glucose intolerance was to abolish the 
hyperinsulinemic compensatory response and unmask hyperglycemia consistent with type 2 
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diabetes.  Herein, we describe a guinea pig model that demonstrates evidence of insulin 
resistance and β-cell loss, the two principle components in the natural progression of type 2 
diabetes in humans. 
 
Materials and Methods. 
 
Animal care and sample collection.   
Female, outbred Dunkin-Hartley guinea pigs, weighing between 250 and 300 grams, 
were purchased from Charles River Laboratories and diabetogenic treatments were initiated at 
a weight of approximately 300 grams in mixed gender guinea pigs.  Guinea pigs with various 
dietary and diabetogenic interventions were monitored by weight change, water intake and food 
consumption.  For collection of serum, guinea pigs were anesthetized via isoflurane inhalation, 
placed in dorsal recumbency, and blood collected from the cranial vena cava percutaneously at 
the junction of the manubrium and the first rib.  Fasting was performed by removal of food 
overnight for a period of 12 hours.  Glucose was measured routinely using the Freestyle Lite 
glucometer (Abbot, Alameda, CA) from a skin prick site adjacent to the most peripheral vein on 
the pinna.  At the time of euthanasia, guinea pigs were administered 40 mg of ketamine and 0.5 
mg of diazepam via intramusclar route for anesthetic induction.  Anesthetized guinea pigs were 
administered a 750 mg dose of pentobarbital via intraperitoneal route for euthanasia. 
 
Preparation of Streptozotocin (STZ) solution for injection.   
All STZ preparations were dissolved in sodium citrate buffer at a pH of 4.5.  Sodium 
citrate buffer for injection was prepared initially as a 40mM citric acid solution (pH 2.9).  A 
solution of 40mM sodium citrate was titrated into the 40mM citric acid until a pH of 4.5 was 
reached.  STZ, >75% α-anomer purity (Sigma, St. Louis, MO), was dissolved in the freshly 
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prepared sodium citrate buffer at a concentration of 100 mg/ml.  The STZ solution was passed 
through a 0.22 micron filter to sterilize and administered either freshly prepared or as an 
equilibrated solution.  
 
Optimization of STZ treatment for induction of diabetic hyperglycemia.   
Various doses of STZ and routes of administration were evaluated for diabetogenic 
efficacy and level of mortality in guinea pigs initially fed a normal diet and subsequently in 
guinea pigs with diet-induced impaired glucose tolerance.  Dunkin-Hartley guinea pigs (n=4 or 
5) were administered STZ via subcutaneous or intraperitoneal route, at doses of 300 mg/kg, 250 
mg/kg, or 200 mg/kg; or as multiple daily consecutive doses of 50 mg/kg for four or six days.  In 
a separate experiment, STZ was prepared either fresh in citrate buffer or allowed to equilibrate 
between α and β anomers for two hours at 4°C and protected from light.  Fresh or anomer-
equilibrated STZ was administered via subcutaneous route at a dose of 200 mg/kg.  
Additionally, the diabetogenic efficacy of STZ was investigated for enhancement by pre-treating 
guinea pigs with 0.5 mg/kg of yohimbine, and α2 adrenergic receptor antagonist, intramuscularly 
20-30 minutes prior to STZ injection to increase the induction of hyperglycemia. For the 
depletion of β-cell mass in HFHC-fed guinea pigs, individuals with evidence of impaired glucose 
tolerance were administered a single 200 mg/kg dose of anomer-equilibrated STZ after pre-
treatment with 0.5 mg/kg yohimbine administered by intramuscular route.      
 
Custom Diet Formulation.   
Guinea pigs were fed a custom formulated high fat and high carbohydrate (HFHC) diet 
(Dyets Inc., Bethlehem, PA).  The custom formulated diet consisted of total calories as 30% fat, 
52% carbohydrate, and 18% protein, where calories from fat were derived equally from Primex 
vegetable shortening and beef tallow, and carbohydrate calories were composed of 55% 
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fructose and 45% sucrose.  For comparison, control guinea pigs were fed a conventional guinea 
pig diet containing 3% fat, 18% protein and 55% carbohydrates as fiber (Harlan-Teklad #2040).   
 
Evaluation of insulin resistance and impaired glucose tolerance.   
To evaluate the glucose-lowering effects of insulin in guinea pigs fed either normal or 
HFHC diet, regular acting human recombinant insulin (Humulin-R, Eli Lilly, Indianapolis, IN) was 
administered as a subcutaneous injection at a dose of 0.5 units/kg.  At the time of injection, 
glucose was measured in unfasted guinea pigs using the Freestyle Lite glucometer then 
measured at 25, 50, 75, and 100 minutes after administration.  To determine glucose tolerance 
in normal diet control, HFHC-fed and HFHC/STZ diabetic guinea pigs, a standardized oral 
glucose challenge consisting of a 2 g/kg bolus of D-glucose (0.5g/ml) was administered after a 
12-hour fasting period (oral glucose tolerance test, OGTT). Glucose levels were measured at 
times 0, 60, 90, 120 or 150 minutes post-administration with the Freestyle Lite glucometer 
validated for accuracy in the guinea pig against the glucose oxidase method for quantification of 
glucose in serum. 
 
Quantification of lipid parameters.   
Total serum free fatty acid levels were measured by fluorescence in an assay utilizing a 
coupled enzymatic reaction (Cayman Chemical; Ann Arbor MI).  Briefly, acyl CoA synthetase 
catalyzes fatty acid acylation of coenzyme A.  The acyl CoA generated is oxidized by acyl CoA 
oxidase to generate hydrogen peroxide, which in the presence of horseradish peroxidase and 
10-aceyl-3,7-dihydroxyphenoxazine (ADHP) generates fluorescence that is measured 
spectrophotometrically at an excitation wavelength of 530 nm and an emission wavelength of 
585 nm.  Total serum triglycerides were quantified by sequential enzymatic conversion with 
lipoprotein lipase, glycerol kinase and glycerol phosphate oxidase followed by peroxidase 
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mediated colorimetric change (Cayman Chemical, Ann Arbor, MI) measured 
spectrophotometrically at an absorbance of 450 nm.  
 
Quantification of serum insulin.   
The C-terminal decapeptide of the guinea pig insulin beta chain, amino acid sequence 
DDGFFYIPKD, was conjugated to the c-terminus of bovine serum albumin through custom 
synthesis (Bio-Synthesis Inc., Lewisville, TX).  Four Balb/C mice were immunized with 100 µg of 
this conjugated protein initially in TiterMax adjuvant (Sigma, St. Louis, MO), then twice 
additionally at three-week intervals in Freund's Incomplete adjuvant (Sigma, St. Louis, MO).  
Serum titers were then evaluated by direct ELISA.  Briefly, high binding polystyrene 96-well 
plates were coated with 50 µg of the target insulin peptide.  Serum from each mouse, collected 
via submandibular vein, was diluted in a 2-fold serial dilution, beginning with a dilution of 1:8 and 
ending at 1:32,768.  Specific serum antibodies were detected with HRP-conjugated, goat anti-
mouse IgG and 3,3,5,5-Tetramethylbenzidine (TMB) substrate.  All mice produced antibody at a 
titer of at least 16,384.  Mice were euthanized and serum was collected.  For the detection of 
guinea pig insulin, blood was collected from fasted guinea pigs, corresponding fasting glucose 
levels measured, and serum was coated on high-binding polystyrene plates overnight at 4°C at 
a 1:10 dilution in sodium bicarbonate buffer (pH 9.0).   Guinea pig insulin was detected with 
pooled polyclonal mouse anti-serum (1:1000), followed by HRP-goat anti-mouse IgG antibody 
(1:1000) and TMB substrate.  This assay was optimized with a detectable linear range of 0.1 - 7 
ng/ml of insulin (APPENDIX Figure 3).     
 
Treatment with oral antihyperglycemic therapy.   
Beginning at 3 weeks after STZ treatment, diabetic guinea pigs were treated with a 
combination of metformin (25 mg daily) and glipizide (0.25 mg daily) in combination.  Efficacy of 
 122 
treatment was assessed after 14 days of daily therapy based on improvement in glucose 
tolerance by OGTT.  Guinea pigs, either normal non-diabetic controls, diabetic mock-treated, or 
diabetic and treated with metformin and glipizide in combination, were followed for survival for 
140 days with daily treatment five days per week.   
 
Histology and area morphometry of guinea pig pancreas.   
Tissues were removed at necropsy and fixed in 4% buffered paraformaldehyde.  
Sections of pancreas were sampled from either end of the pancreatic limbs or at the center of 
the organ.  The tissues were paraffin embedded and 5 µm sections were stained with 
hematoxylin and eosin for histopathologic evaluation using routine methods.  Morphometric 
analysis was performed using a Nikon 80i Eclipse microscope and StereoInvestigator software, 
version 10.02 (MBF bioscience, Williston, VT) with tissue area estimated using the area fraction 
fractionator method.  The frequencies of islets within the quantified area were counted to 
determine a ratio of islets per mm2 of pancreatic tissue.   
 
Immunofluorescent detection of insulin in pancreatic tissue.   
Paraffin embedded 5 µm sections of pancreas were deparaffinized and rehydrated in 
serial ethanol washes followed by antigen retrieval by boiling in target retrieval buffer (Dako, 
Carpinteria, CA) for 30 minutes.  Endogenous peroxidase activity was quenched with 0.3% 
H2O2 and blocking performed in 0.15mM glycine and 10% FBS, 1%BSA in PBS.  Tissue 
sections were incubated with anti-proinsulin antibody, clone K36AC10 (Abcam, Cambridge, 
MA), at a 1:500 dilution overnight at 4°C.  After 3 washes in tween-TBS, tissue sections were 
incubated with HRP conjugated anti-mouse IgG (Vector Laboratories, Burlingame, CA) for 60 
minutes at room temperature, washed 3 times in tween-TBS, and the signal amplified with the 
tyramide signal amplification kit (Life Technologies, Grand Island, NY) employing AlexaFluor 
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488-labeled tyramide, as directed by the manufacturer.  Purified murine IgG1 was applied as a 




Optimized STZ dosing minimizes toxicity-associated mortality in the guinea pig model.  
 In developing a guinea pig model of STZ-induced hyperglycemia, three parameters were 
identified as being critical for a successful response to STZ without adverse effects, including 
dose, route, and preparation of the STZ-solution.  We evaluated a range of STZ doses from 100 
to 300 mg/kg, administered either IP or SC, and as a single dose or multiple daily injections of 
50 mg/kg.  In guinea pigs receiving 300 mg/kg, regardless of SC or IP route, or single versus 
multiple dosing, a high level mortality occurred within days after completing the treatment.  
Mortality in 300 mg/kg dosed guinea pigs ranged from 80% in those receiving a single dose by 
SC route (n=5), 75% in those receiving a single dose by IP route (n=4), and 100% in those 
receiving six consecutive daily doses of 50 mg/kg IP (n=4), using a multidose schedule shown 
to be effective in mice22 (Fig 3.1).   
 At the time of euthanasia, morbidity was often accompanied by hypoglycemia and only a 
single guinea pig out of the 13 receiving a cumulative dose of 300 mg/kg ever developed 
evidence of hyperglycemia (Table 3.1).  Evaluation of histopathology revealed that mortality in 
guinea pigs was the result of acute STZ-mediated toxicity.  The most severe and frequent 
manifestation of acute STZ toxicity was acute necrosis of the intestinal mucosal epithelium 
followed by acute necrosis of renal tubular epithelium (Fig 3.2).  There was no evidence of 
differences in toxicity-related pathology between route of administration and frequency of dosing 












Figure 3.1. A Dose-related trend in mortality is associated with higher doses of STZ.  The greatest 
proportion of survival is observed at doses of STZ equal to 200 mg/kg, while still achieving some 
hyperglycemic effect in the guinea pig.  Intermediate survival is observed at a dose of 250 mg/kg but high 
levels of mortality occur at a dose of 300 mg/kg, whether administered as a single dose or a combination 
of multiple 50mg/kg doses. 100% survival was observed at doses of 50mg/kg x 4, 100mg/kg, and 













































Figure 3.2. Acute toxicity associated with STZ in guinea pigs involves acute necrosis of GLUT2-
expressing cell types.  Necrosis of the surface enterocytes in the small intestine of a guinea pig 
receiving a 300 mg/kg dose of STZ (A).  Acute renal tubular necrosis is multifocally present in the cortex 
of the kidney from a guinea pig receiving an STZ dose of 300 mg/kg (B).  Associated with IP 
administration of STZ, there is capsular fibrosis and mild inflammation at the surface of the liver (C).  










Table 3.1. Summary of survival and rate of hyperglycemia with various STZ treatments. 










100 IP 4 100% 0% 
300 SQ 5 20% 20% 
300 IP 4 25% 0% 
50 x 6 IP 4 0% 0% 
200 SQ 4 100% 50% 
50 x 4 SQ 4 100% 0% 
250 SQ 4 75% 25% 
250 SQ 5 80% 40% 
250 AE SQ 5 100% 40% 
200 AE SQ 5 100% 20% 










While no significant differences in mortality were observed between IP and SC routes of 
administration, guinea pigs that received IP STZ in citrate buffer (pH 4.5) developed mild 
peritonitis and exuberant peritoneal and serosal fibrosis on visceral organs, precluding further 
use of this route of administration (Fig 3.2). 
 In contrast, guinea pigs receiving a single or multiple daily doses amounting to a total of 
200 mg/kg displayed much improved tolerance and survival, with 100% survival out to 30 days 
post-injection (Fig 3.1).  However, the hyperglycemia response rate was unacceptably low at 
this dose, with no conversion at 4 doses of 50 mg/kg (n=4) and only 50% with a single dose 
(n=4).  This rate of response was not improved upon by a slightly higher single dose of STZ at 
250 mg/kg (Table 3.1).  Coinciding with a low rate of STZ-induced hyperglycemia at 300 mg/kg, 
there was no histological evidence of beta cell death within pancreatic islets observed at this 
high dose.  However, acute cellular necrosis was evident within the islets of guinea pigs treated 
with 200 and 250 mg/kg doses of STZ and corresponded with aggregates of insulin protein 
presumably released from β-cell necrosis (Fig 3.3 and 3.10).      
 Because it is well demonstrated that the α-anomeric form of STZ is more biologically 
active and consequently, more likely to induce adverse toxicity, we evaluated the preparation of 
STZ as an equilibrated solution of α- and β-anomers previously shown to contain approximately 
56% β- and 44% α-anomer composition23-25.  The goal was to determine if, at an equivalent 
dose, the equilibrated solution of STZ is capable of producing a similar hyperglycemic response.  
At a dose of 250 mg/kg, both freshly prepared and anomer-equilibrated STZ induced non-
fasting hyperglycemia in 40% of treated guinea pigs (n=5 each), indicating a similar efficacy 
between both preparations (Table 3.1).  In these two groups, survival was minimally improved 
by administration of anomer-equilibrated STZ with 100% survival to day 21 in guinea pigs 












Figure 3.3. Pancreatic islet pathology is consistent with acute and chronic phases post-STZ and 
after long-term HFHC diet. (A) Normal guinea pig pancreatic islet, arrow. (B) Example of an islet from a 
guinea pig 24 hours after receiving a 250 mg/kg dose of STZ.  There is selective necrosis of some islet 
cells (arrow) while others remain morphologically viable, presumably representing the selective toxicity of 
STZ for β-cells over other islet cell populations. (C) Pancreatic islet from a guinea pig allowed to consume 
HFHC-diet for six consecutive months without receiving STZ.  The islets are confluent and are dissected 
by fibrosis (arrows). (D) Pancreatic islets of a guinea pig after 11 weeks of HFHC-diet and three weeks 





Rate of STZ-induced hyperglycemia is enhanced with antecedent use of an α2-
adrenergic receptor antagonist.   
 Since the success rate of achieving hyperglycemia in guinea pigs at mid-range doses of 
STZ remained low regardless of dose or route of administration (Table 3.1), additional 
adjunctive treatment was pursued to enhance the specific targeting of pancreatic β-cells.  
Previously, the α2-antagonist yohimbine was demonstrated to enhance the diabetogenic effects 
of STZ in mice26.  We evaluated the rate of hyperglycemia from anomer-equilibrated STZ 
treatment at 200 mg/kg in guinea pigs either pre-treated with yohimbine or mock-treated with 
normal saline.  Guinea pigs that were pre-treated with yohimbine (n=5) were 100% responsive 
to the STZ treatment as indicated by hyperglycemia present for the following seven-day period 
(Table 3.1, Fig 3.4).  In contrast, of the guinea pigs mock-treated with saline prior to 
administration of STZ (n=5), only 20% developed hyperglycemia.  Acute mortality did not occur 
at a dose of 200 mg/kg of anomer-equilibrated STZ.    
 
STZ-induced hyperglycemia in guinea pigs is transient with recovery from glucose 
intolerance in the absence of HFHC diet. 
 At STZ doses of 200 and 250 mg/kg (with or without yohimbine), where hyperglycemia 
was manifested in 25-100% of treated guinea pigs, elevated glucose was evident within 48 
hours.  In the course of daily random glucose sampling, non-fasted hyperglycemia persisted in 
the range of 200 to 400 mg/dl, for 7 to 10 days.  There was a consistent steady decline in the 
degree of hyperglycemia beginning around day 4 and extending through day 14 post-STZ 
treatment.  The reduction in glucose over time was best demonstrated in yohimbine pre-treated 
guinea pigs, which yielded hyperglycemia success rate of 100% (Fig 3.4).  This transient 















Figure 3.4. Random sampled hyperglycemia induced by STZ is transient. The average blood 
glucose trend measured without fasting is plotted through 11 days after STZ-treatment in guinea pigs 
treated subcutaneously with 250mg/kg of STZ and either mock pre-treatment or yohimbine pre-treatment. 
Regardless of the efficacy of the particular STZ-treatment in inducing hyperglycemia, random non-fasting 








hyperglycemia from STZ treatment.  Evaluation of glucose tolerance by OGTT in guinea pigs 
treated with STZ alone after 14 and 21 days demonstrated that glucose tolerance returned to 
normal over time, when compared to OGTT performed on day 7 after treatment where severe 
glucose intolerance was present (Fig 3.5).  
 
Guinea pigs fed an HFHC-diet are not obese but do develop dyslipidemia. 
 Weight change was monitored over time in guinea pigs fed either a normal guinea pig 
diet or the HFHC diet, and also for the three weeks following STZ treatment of HFHC-fed guinea 
pigs.  After eight weeks of consuming the HFHC diets, these guinea pigs weighed less than 
control guinea pigs fed a normal diet.  This difference in weight was apparent in the transition 
between normal and HFHC diets, within the first week of initiating the HFHC feeding (Fig 3.6).  
Subsequently, HFHC-fed guinea pigs gained weight at a rate consistent with, but, on average, 
did not exceed the weight of normal diet controls.  These data are consistent with the additional 
observation that HFHC-fed guinea pigs consumed a nearly equivalent caloric intake on a per 
weight, per day basis when compared to normal diet controls (Table 3.2).  However, HFHC/STZ 
guinea pigs with diabetic levels of glucose intolerance showed steady weight loss over the 
three-week period following STZ administration.  Average weights after the 11-week period are 
listed in Table 2.  After five weeks of initiating the HFHC diet, increased water consumption was 
observed on average in the HFHC-fed guinea pigs (Table 3.2), but in contrast to the 
HFHC/STZ-treated guinea pigs where all animals had detectable glucose in urine, glucosuria 
was present in only one out of the five urine samples evaluated from this group.   Both HFHC-
fed and HFHC/STZ guinea pigs had elevated fasting serum triglyceride levels.  However, 
elevations in total serum free fatty acids were present only in the HFHC/STZ guinea pigs (Fig 














Figure 3.5. Diabetic glucose tolerance progressively wanes in STZ-only guinea pigs after a period 
of 21 days. Glucose intolerance measured by OGTT in guinea pigs treated with yohimbine prior to a 250 
mg/kg dose of STZ. Severe glucose intolerance is evident seven days after STZ but steadily decreased 















Figure 3.6. HFHC Fat Fed guinea pigs are not obese but do develop dyslipidemia. (A) Weight trends 
of normal diet control guinea pigs compared to HFHC-fed and HFHC/STZ groups are compared (n=20).  
After an initial brief period of weight loss, the rate of weight gain is similar between normal diet controls 
and HFHC-fed guinea pigs, but HFHC-fed guinea pigs do not exceed normal diet controls.  However, 
significant weight loss occurs in the three-week period following induction of overt diabetes with STZ 
treatment. (B) After a six-hour fasting period, guinea pigs fed HFHC diet (n=15) and HFHC/STZ type 2 
diabetic guinea pigs (n=12) demonstrate hypertriglyceridemia, while (C) elevated total serum free fatty 


















Table 3.2.  Clinical parameters from guinea pigs subjected to diabetogenic treatments. 
ND = not detected, n/a = not measured, NS = not significant, BW = body weight (n=5) 
 
 Chow-Fed HFHC-Fed HFHC/STZ P-value 
  
 
   
Weight (g) 732.4 ± 50.5 619.6 ± 51.1 441.6 ± 42.4 <0.0001 
     
Water Consumption (ml) 65.3 ± 8.6 161 ± 19.6 n/a 0.001 
     
Diet Consumption 
(kcal/100g BW/day) 
40 ± 3.7 44.1 ± 5.2 n/a NS 
     
Urine Glucose ND 16.3 ± 36.5 90.2 ± 98.5 NS 











HFHC-fed guinea pigs demonstrate impaired glucose tolerance and response to insulin 
with glucose intolerance reaching diabetic levels in HFHC/STZ guinea pigs.   
 HFHC-fed guinea pigs were evaluated for evidence of insulin resistance based on oral 
glucose tolerance test.  No significant difference in the glucose response was observed 
between normal diet controls and HFHC-fed guinea pigs after two or four weeks on the diet.  
However, after 8 weeks of consuming the HFHC diet, impaired glucose tolerance was evident 
as increased average blood glucose at the 60-minute time point of the OGTT (n=20) (Fig 3.7).  
Significantly elevated fasting blood glucose was not ever observed in guinea pigs fed HFHC diet 
alone.  The development of fasting hyperglycemia and severely impaired glucose tolerance was 
only evident in HFHC/STZ guinea pigs.  These guinea pigs demonstrated significantly elevated 
blood glucose levels during OGTT, which persisted at 120 and 150 minutes after glucose 
administration (Fig 3.7).      
 
HFHC-fed guinea pigs display compensatory hyperinsulinemia, which is eliminated in 
HFHC/STZ guinea pigs.   
 Fasted serum insulin concentrations were compared along with fasting blood glucose 
from the same blood sample to determine if a compensatory response was present in HFHC-fed 
and HFHC/STZ guinea pigs.  Compared to normal diet controls, hyperinsulinemia was present 
in HFHC-fed guinea pigs after consuming the diet for 8 weeks (Fig 3.8).  However, the fasting 
glucose concentrations did not differ from those of normal diet controls.  Three weeks after STZ-
treatment, the serum insulin concentrations of HFHC guinea pigs were decreased to a level 


























Figure 3.7.  HFHC-fed guinea pigs are glucose intolerant and insulin resistant.  (A) Oral glucose 
tolerance test performed in HFHC-fed guinea pigs reveals delayed glucose clearance at 60 minutes post-
glucose administration in the OGTT after eight weeks of HFHC feeding (n=20). (B) HFHC guinea pigs 
were treated with 200 mg/kg STZ after eight weeks on the diet, and OGTT performed 20 days after STZ 
treatment.  A diabetic level of glucose intolerance is retained in these guinea pigs 20 days post-STZ 
treatment (n=20). (C) Insulin tolerance test performed in HFHC guinea pigs after 6 weeks of HFHC 
feeding.  Exogenous insulin failed to reduce blood glucose at a level comparable to normal diet controls 





Figure 3.8.  Guinea pigs fed HFHC diet for 8 weeks develop compensating hyperinsulinemia, 
which is lost after treatment with STZ.  (A) Fasting serum insulin concentrations, measured by direct 
ELISA, are significantly higher in HFHC (PreDM) guinea pigs compared to normal diet controls (NonDM) 
and HFHC/STZ guinea pigs (T2DM).  (B) Similar fasting glucose concentrations in HFHC guinea pigs 
compared to normal diet controls indicating a compensatory response by elevated insulin in HFHC guinea 
pigs. In contrast, compensation for insulin resistance is no longer present after STZ-induced reduction in 
insulin production, leading to fasting hyperglycemia. These fasting insulin and glucose levels are 
expressed as a ratio of glucose:insulin for each individual guinea pig to demonstrate elevated insulin and 
lower glucose in HFHC guinea pigs compared to lower insulin and elevated glucose typical of diabetic 
STZ/HFHC guinea pigs. *P<0.05, ***P<0.001(n=16 per group) 
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Islet cell hyperplasia accompanies HFHC-induced hyperinsulinemia and insulin-
production is retained in HFHC/STZ guinea pigs.   
 The pancreatic islets of HFHC-fed guinea pigs were, in general, larger in size and 
quantitatively more numerous per mm2 of total evaluated pancreatic tissue when compared to 
normal diet controls (Fig 3.9).  Immunofluorescent detection of proinsulin in the HFHC-guinea 
pigs revealed a high frequency of insulin producing cells in all islets, including those that were 
significantly enlarged (Fig 3.10).  In contrast, islet morphology was altered in HFHC/STZ guinea 
pigs with generally reduced islet size, and indiscernible, irregular margins (Fig 3.3).  
Immunofluorescent detection of proinsulin in the HFHC/STZ guinea pigs revealed a retention of 
insulin-producing β-cells, but these were significantly reduced in frequency compared to the 
normal diet controls and HFHC-fed guinea pigs (Fig 3.10).  
 
HFHC/STZ guinea pigs are non-insulin dependent and responsive to oral 
antihyperglycemic therapy.  
 Prior to initiation of oral antihyperglycemic therapy, three weeks after STZ treatment and 
11 weeks total of HFHC feeding, HFHC/STZ guinea pigs displayed a degree of glucose 
intolerance consistent with overt diabetes.  Complete reversal of diabetes-related glucose 
intolerance was evident in guinea pigs treated with a combination of both metformin and 
glipizide after 14 days of treatment (Fig 3.11).  Guinea pigs treated with metformin and glipizide 
in combination (n=4) displayed 100% survival out to 120 days while only a 25% survival rate 





Figure 3.9.  Islet cell hyperplasia is present in guinea pigs fed an HFHC diet.  Count of absolute 
numbers of pancreatic islets in HFHC-fed guinea pigs is, on average, 2.4-fold higher per cm2 compared 
to normal diet controls (upper panel). (A) High frequency of pancreatic islets (arrows) in HFHC-fed guinea 
pigs with significant variability in size. (B) Histology of the pancreas from normal diet control guinea pigs 















Figure 3.10. Insulin immunoreactivity is frequent in enlarged islets of HFHC-guinea pigs and 
retained in HFHC/STZ guinea pigs. Representative photomicrographs of insulin immunoreactivity of 
pancreatic tissue after various diabetogenic treatments. (A) Frequency of insulin producing cells in the 
islets of a normal diet control guinea pig. (B) Insulin producing cells are frequent within a significantly 
enlarged islet of an HFHC-fed guinea pig. (C) Destruction of normal morphology and aggregation of 
insulin in an islet 24 hours after receiving 250 mg/kg of STZ. (D) Insulin producing cells are significantly 
reduced but remain present in an HFHC guinea pig treated with 200 mg/kg of STZ. green = insulin, blue = 






















Figure 3.11. Oral antihyperglycemic therapy improves diabetic glucose intolerance to a level 
equivalent to non-diabetic controls.  (A) Guinea pigs with type 2 diabetes were treated with either 25 
mg/kg of metformin and 0.25 mg glipizide per os or mock-treated with oral water.  An oral glucose 
tolerance test was performed on diabetic guinea pigs 14 days after treatment and compared to untreated, 
non-diabetic control guinea pigs. Treatment with metformin and glipizide in combination improves glucose 
tolerance in diabetic HFHC/STZ (T2DM) guinea pigs to a level comparable to normal non-diabetic 
controls (NonDM). (B) Combination therapy with metformin and glipizide greatly improves survival in 
T2DM HFHC/STZ guinea pigs compared to diabetic guinea pigs left uncontrolled. (NonDM, n=2; T2DM, 










 In this study, we have developed a novel model of type 2 diabetes in the guinea pig 
through a combination of diet-induced glucose intolerance and subtotal β-cell cytotoxicity. In the 
process, we have identified critical factors necessary for improved survival, induction of 
hyperglycemia, and sustainable diabetic glucose intolerance induced with STZ in the guinea pig 
model.  The use of STZ to establish insulin-dependent hyperglycemia in mice and rats is well 
established.  The protocols for use of STZ in these rodents and in comparison to what has been 
identified in our guinea pig model demonstrates the wide variability in the response of multiple 
rodent species to STZ.  The rat model requires only a single low dose of STZ for nearly 
complete β-cell cytoxicity, while five consecutive doses of 50 mg/kg is generally accepted as the 
most effective dosing schedule for mice27.  Comparatively, we have demonstrated that the 
guinea pig generally requires higher doses of STZ as a single bolus.   
 It is quite apparent from this study that regardless of route of administration or if 
administered as a single or multiple doses of 50 mg/kg, a total dose of 300 mg/kg is not 
tolerated, yielding high mortality by day 10 post-administration.  In contrast, a much lower dose 
of 100 mg/kg is well tolerated by IP and SQ routes of administration for at least 30 days after 
administration, but this dose does not produce sustained hyperglycemia or glucose intolerance.  
Paradoxically, hyperglycemia also was not noted with the highest dose of 300 mg/kg while 
midrange doses of 200 and 250 mg/kg did produce hyperglycemia at varying levels.  The lack of 
hyperglycemia is further supported by an additional lack of islet lesions in these animals.  This 
could be explained by the level of acute toxicity seen at such a high dose, which precluded the 
establishment of diabetes due to failure to selectively target β-cells for cytotoxicity.  Additionally, 
the rapid clinical decline and mortality may have occurred at a rate preceding diabetogenic 
effects detectable by random glucose sampling or glucose tolerance test.   
 143 
 Regardless, the pathological lesions identified in guinea pigs suffering mortality post-
STZ treatment are most consistent with acute toxicity especially since all lesions were present in 
the major cell types expressing the GLUT2 solute transporter, including intestinal epithelium and 
kidney tubular epithelium, as well as pancreatic β-cells28.  The STZ molecule, a nitrosurea 
glucose analogue, enters cells through the GLUT2 transporter, which dictates it's selective 
cytotoxicity of β-cells, and induces DNA alkylation leading to cell death29, 30.  This also further 
supports the suggestion that guinea pig β-cells are similar to other rodent species, which are 
dominated by surface GLUT2 receptors and unlike human β-cells, which recently have been 
shown to utilize GLUT1 transporters in glucose sensing30, 31.      
 Although dose appears to significantly impact STZ tolerance and the development of 
hyperglycemia in the guinea pig, we have also demonstrated similar efficacy between anomer-
equilibrated STZ solution and STZ that is freshly prepared.  It is well demonstrated that rapid 
decomposition of STZ occurs due to instability in solution, leading to a reduction in α-anomer 
forms of the molecule and a higher proportion of β-anomer forms.  It has been suggested with 
frequency that the α-anomeric form is more diabetogenic than the β-anomer and, for this 
reason, it is often cited that STZ must be prepared fresh and administered immediately32, 33.  
However, a recent study demonstrated that an equilibrium is established between α- and β-
anomeric forms of STZ within two hours of dissolution, and this preparation leads to consistent 
hyperglycemia in mice with a significant reduction in mortality22, 34-36.  These findings are 
recapitulated in our guinea pig model, which demonstrates that anomer-equilibrated STZ is 
equally effective in inducing hyperglycemia in guinea pigs compared to an equivalent dose of 
freshly prepared STZ.  This study therefore provides additional support for the adoption of 
anomer equilibration in STZ chemical-induced animal models of diabetes in an attempt to 
improve reproducibility and reliability of studies between laboratories.   
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 The guinea pig is reportedly resistant to the diabetogenic effects of both STZ and 
alloxan.  However, previous studies administering alloxan, a β-cell toxin similar to STZ, directly 
into the pancreatic circulation have yielded uniform hyperglycemia in guinea pigs, in contrast to 
those receiving systemic administration, which were largely insensitive26.  Thus, the reported 
level of resistance to both alloxan and STZ in the guinea pig may not be a direct reflection of the 
β-cell itself, but rather the availability of the compound to the β-cells after systemic 
administration.  This is further supported by the fact that isolated pancreatic islets from the 
guinea pig are sensitive to the actions of both compounds in vitro37.   
 Protection against STZ-induced β-cell death by non-metabolizable glucose analogs 
indicates that competitive prevention of STZ uptake can prevent the toxic effects in other rodent 
species, but this protection is not afforded by the presence of high glucose33.  Previously it has 
been reported that extended fasting prior to STZ administration yields improved β-cell 
cytotoxicity in the guinea pig33.  However, this may not be due to the glucose lowering effects of 
starvation but rather, may be related to low insulin secretion present at the time of STZ 
administration or counter-regulatory mechanisms to prevent severe hypoglycemia.   
 In line with reports of resistance of guinea pigs to STZ, we experienced a rate of 
diabetes induction at doses of 200 and 250 mg/kg that was variable and incomplete33.  
However, also in line with the previously suggested difficulty associated with systemic 
administration, we were able to markedly improve the rate of STZ-induced hyperglycemia by 
treating guinea pigs with the α2-adrenergic receptor antagonist, yohimbine, prior to 
administering STZ.  This increased rate of hyperglycemia was associated with obvious selective 
islet cell death in islets of guinea pigs analyzed within 48 hours post-STZ administration.  It has 
been previously demonstrated that STZ-induced diabetes could be improved through the use a 
specific α2-adrenergic receptor antagonist but not through blockade of α1 receptors38, 39.  It is 
known that α2-adrenergic receptors are involved in glucose-sensing and insulin secretion from 
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the pancreatic β-cell27, 40, and that reduced circulating insulin in yohimbine-treated rats coincides 
with higher efficacy of STZ41.  Our data indicates that yohimbine also improves sensitivity of 
guinea pig β-cells to STZ; however, if this is due to manipulation of insulin secretion remains to 
be evaluated with our recently developed ELISA assay.  
 Previous use of STZ in the spontaneously hypertensive rat (SHR) model, which 
develops hyperinsulinemia and insulin resistance in the absence of obesity, demonstrated that 
hyperglycemia results from doses of STZ that have no impact on glucose metabolism in normal 
wild-type rats40.  This suggests that in the face of metabolic stress, compensating β-cells may 
be more susceptible to the cytotoxic effects of STZ.  This is further supported by our data, which 
demonstrates transient hyperglycemia and glucose intolerance with STZ alone but a greater 
and persistent impact when combined with pre-existing diet-induced glucose intolerance.  The 
transient hyperglycemic effect of STZ alone in guinea pigs suggests a significant compensatory 
or regenerative β-cell response in this species.  Under otherwise normal β-cell physiology 
without the stress of dyslipidemia-associated insulin resistance both rodent and human β-cells 
have substantial regenerative capacity42.  Therefore, this potential regenerative response in the 
guinea pig is not unexpected.  However, the persistent diabetic glucose intolerance generated in 
STZ-treated guinea pigs after diet-induced glucose intolerance indicates that the metabolic 
stress of the high fat, high carbohydrate diet may limit the β-cell recovery potential.  It is well 
documented that in the presence of insulin resistance, β-cells are limited in their proliferative 
capacity and are more prone to cell death43.  Additionally, the islet cell hyperplasia and 
hyperinsulinemia present in HFHC-fed guinea pigs in this study is in line with the typical 
response of other rodent models of type 2 diabetes and demonstrates further the proliferative 
and compensatory capacity of guinea pig β-cells44-46. 
 The primary amino acid sequence of guinea pig insulin, and insulin of other 
hystricomorph rodents, is highly divergent, having only approximately 65% homology to human 
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insulin.  In contrast, this sequence is generally highly conserved among other mammalian 
species47, 48.  As a result, our ability to detect insulin by commercial ELISA-based assays 
against mouse, rat or human was limited in the guinea pig (data not shown) and we have 
accordingly developed a direct insulin ELISA for the purpose of validating this model. 
Measurement of serum insulin with this ELISA assay showed significantly higher production of 
insulin in guinea pigs fed an HFHC diet, and when considered in combination with the normal 
fasting glucose concentrations in these animals, is consistent with a successful compensatory 
response to peripheral insulin resistance.  However, after treatment with STZ, HFHC guinea 
pigs had serum insulin concentrations similar to those of normal diet controls and developed 
both fasting hyperglycemia and severe glucose intolerance.  These data indicate that treatment 
with STZ was able to reduce β-cell insulin production sufficiently to eliminate the compensatory 
response, but did not completely abolish the β-cell population.  
 The STZ-induced models of diabetes are often regarded as an insulin-dependent form of 
diabetes due to an absolute insulin deficiency.  In contrast, we have shown that guinea pigs first 
fed an HFHC diet then subsequently treated with STZ develop hyperglycemia largely due to the 
presence of insulin resistance.  This is based on the fact that fasting hyperglycemia was evident 
only after the compensating hyperinsulinemia of HFHC-fed guinea pigs was abolished through 
STZ treatment.  We have also confirmed that insulin production and secretion is retained but at 
lower levels in HFHC/STZ guinea pigs both within the pancreatic islets and in serum.  
Therefore, we had hypothesized that HFHC/STZ guinea would not only respond to the oral 
antihyperglycemic therapy frequently used to treat type 2 diabetes and insulin resistance in 
humans, but also that this therapy would improve survival without requiring the use of 
exogenous insulin therapy.  We have demonstrated here that this model of type 2 diabetes in 
the guinea pig is not insulin-dependent because extended survival occurs in guinea pigs treated 
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with a combination of metformin and glipizide, at doses capable of reversing diabetic glucose 
intolerance.         
 Previously, the guinea pig model of STZ-induced hyperglycemia has been difficult to 
interpret due to a significant degree of variability in the literature regarding effective dose and 
route, responsiveness as indicated by hyperglycemic response, and high levels of reported 
mortality.  In summary, we recommend the induction of acute STZ-induced hyperglycemia in the 
guinea pig through use of yohimbine pretreatment and anomer-equilibrated STZ solution at 
doses of 200 or 250 mg/kg administered by subcutaneous route.  This combination of methods 
will minimize mortality and maximize the hyperglycemic response rate.  For persistent diabetic 
levels of impaired glucose tolerance, the guinea pig species requires an additional component 
of β-cell stress, which we have demonstrated can be successfully accomplished with a high fat, 
high carbohydrate diet.  
 This study describes the development a novel guinea pig model of type 2 diabetes 
through careful consideration of the hyperglycemic response of guinea pigs to STZ, 
identification of optimal dosing ranges and adjunctive methods for improving β-cell loss and 
hyperglycemic induction in the guinea pig, and also through enhancing the relative stability of 
the diabetic state in the guinea pig beyond what is induced with STZ alone.  Furthermore, we 
show that guinea pigs respond with more consistent and long-lasting diabetes when combined 
with an initial β-cell stressor, in this case a high-fat, high-carbohydrate diet, with the goal of 
replicating a natural progression in the typical pathogenesis of type 2 diabetes.  Overall, this 
guinea pig model demonstrates important similarities to human type 2 diabetes including 
glucose intolerance that precedes diabetic levels of hyperglycemia, altered lipid metabolism and 
reduced compensatory β-cell capacity.  The induction of diabetes in this model, which closely 
replicates the pathogenesis of human type 2 diabetes, will improve the future use of this species 
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Increased Severity of Tuberculosis in Guinea Pigs with Type 2 Diabetes: 
A Model of Diabetes-Tuberculosis Comorbidity2 
 
Rationale:  The association of TB with type 2 diabetes is becoming increasingly recognized in 
TB endemic countries.  In some regions, up to 30% of new TB diagnoses may be attributable to 
type 2 diabetes.  However, the mechanisms by which diabetes, in general, increases the 
susceptibility to TB are poorly understood and an appropriate model of type 2 diabetes that can 
be used to better understand the pathogenesis of this comorbidity has not been developed.  In 
the previous chapter, we developed a novel model of type 2 diabetes in the guinea pig, which 
develops the two characteristic features of type 2 diabetes, insulin resistance and reduced 
insulin secretory capacity.  We propose that this model will aid in better understanding the 
immunological and metabolic mechanisms that may lead to more severe TB disease in people 
with type 2 diabetes.  In this chapter, we use this guinea pig model of type 2 diabetes to 
characterize the impact on TB progression, bacterial growth and cellular immune response.  
 
Hypothesis:  Overt type 2 diabetes will further impair the control of bacterial growth and worsen 
TB disease, the impact of which will be more severe than that of non-diabetic hyperglycemia or 
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Impaired glucose tolerance and type 2 diabetes was induced in guinea pigs to model the 
emerging comorbidty of Mycobacterium tuberculosis (M. tuberculosis) infection and diabetes.  
Non-insulin dependent diabetes was induced by low dose streptozotocin in guinea pigs 
rendered glucose intolerant by first feeding a high fat, high carbohydrate diet prior to M. 
tuberculosis exposure. M. tuberculosis infection of diabetic guinea pigs resulted in severe and 
rapidly progressive tuberculosis (TB) with a shortened survival interval, more severe pulmonary 
and extrapulmonary pathology and higher bacterial burden compared to glucose intolerant and 
non-diabetic controls. Compared to non-diabetics, diabetic guinea pigs with TB had an 
exacerbated pro-inflammatory response with more severe granulocytic inflammation and higher 
gene expression for the cytokines/chemokines IFNγ, IL-17A, IL-8 and IL-10 in the lung as well 
as IFNγ, TNFα, IL-8 and MCP-1 in the spleen. TB disease progression in guinea pigs with 
impaired glucose tolerance was similar to non-diabetic controls in the early stages of infection, 
but was more severe by day 90.  The guinea pig model of type 2 diabetes-TB comorbidity 
mimics important features of the naturally occurring disease in humans. This model will be 
beneficial in understanding the complex pathogenesis of combined TB and diabetes and to test 











 Host susceptibility to Mycobacterium tuberculosis (M. tuberculosis) is influenced by a 
variety of chronic communicable and noncommunicable diseases, which increase the risk of 
infection and the development of active tuberculosis (TB) disease. Moreover, M. tuberculosis 
infected patients with concurrent diseases often have more severe TB, which further 
complicates treatment responses to conventional antimicrobial drugs. The risk factors most 
frequently linked to M. tuberculosis susceptibility are HIV infection, malnutrition, tobacco use, air 
pollution, alcoholism, extremes in age, chronic kidney disease and diabetes. The highest 
relative risk for TB is associated with profound immunosuppression associated with HIV 
infection. However, recent epidemiological evidence suggests that, in the face of a growing 
diabetes epidemic, the population-attributable risk of diabetes may be equivalent to or exceed 
that of HIV/AIDS.  In countries with the highest TB and diabetes incidence, type 2 diabetes in 
particular may account for up to 20% of active TB cases whereas less than 5% may be 
attributable to HIV1, 2.  
 Type 2 diabetes accounts for approximately 95% of diabetes cases and is associated 
with obesity, poor diet, and a sedentary lifestyle, all of which are often linked to urbanization. An 
estimated 371 million people were diagnosed with type 2 diabetes in 2012, with the 
overwhelming majority residing in low- and middle-income countries. Moreover, there is an 
additional 280 million people that are prediabetic, many of which have undiagnosed insulin 
resistance with non-diabetic hyperglycemia and impaired glucose tolerance3. Furthermore, the 
global incidence of type 2 diabetes is projected to rise to approximately 552 million by 20304.  
Evidence in human studies suggests that glucose control, more than any other feature of altered 
metabolism in diabetic patients, influences the susceptibility to M. tuberculosis infection, 
highlighting the importance of uncontrolled hyperglycemia in TB risk5.  The increased difficulty in 
controlling blood glucose levels in diabetic patients with TB, combined with poor responses to 
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antimicrobial drug treatment, has the potential to further hamper current TB control efforts 
worldwide6.  An animal model that more closely mimics the pathogenesis of this comorbidity in 
humans is essential for identifying more effective strategies for antimicrobial drug treatment and 
for control of blood glucose levels in diabetics with TB.  In addition, the influence impaired 
glucose tolerance and insulin resistance has on TB susceptibility and pathogenesis has not 
been adequately investigated.  
 Currently, the animal models most often used to study the pathogenesis of TB 
concurrent with diabetes are inbred strains of mice treated with high doses of the cytotoxic drug 
streptozotocin7, 8.  These models mimic chronic hyperglycemia resulting from total insulin 
deficiency as in human type 1 diabetes. While this strategy has provided valuable information 
on how absolute insulin deficiency and persistent hyperglycemia impact active TB disease, it 
fails to take into account a wide variety of other metabolic defects associated with impaired 
glucose tolerance and type 2 diabetes through dietary manipulation.  Unlike murine models, lipid 
metabolism in the guinea pig more closely resembles that of humans, making this species ideal 
for studying cardiovascular disease risks and other consequences of altered glucose and lipid 
metabolism associated with type 2 diabetes9.  Moreover, the majority of mouse strains used to 
model TB, including those previously used in diabetes-TB comorbidity studies, fail to respond to 
M. tuberculosis infection with the development of pulmonary and extrapulmonary granulomata 
with caseous necrosis as is typical in humans, as well as guinea pigs, non-human primates and 
rabbits10.  The value of the guinea pig TB model has been further validated recently in studies of 
natural transmission of M. tuberculosis from human TB patients to guinea pigs.  A subpopulation 
of guinea pigs exposed to aerosols from TB patients developed active TB disease and an array 
of clinical and pathological responses, which more accurately reflects the clinical variation of 
naturally occurring M. tuberculosis infection in humans11.     
 Clinical studies have shown that the increased susceptibility of people with diabetes to 
M. tuberculosis is accompanied by an altered host response to infection.  Diabetic patients with 
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active TB have higher bacterial burdens based on sputum culture and are refractory to first-line 
antimicrobial combination therapy with longer time to sputum conversion, and higher mortality 
rates during therapy12-14.  Diabetic patients often have atypical radiographic findings with more 
frequent involvement of lower lung lobes and some studies indicate a higher rate of cavitary 
disease, consistent with more severe pulmonary pathology15, 16.  However, the impact diabetes 
has on the development of extrapulmonary TB in humans is conflicting with some studies 
indicating a relative risk similar to, or less than that of non-diabetic individuals while others show 
a predisposition for extrapulmonary and even miliary disease patterns5, 17, 18.  In patients with TB 
and poorly controlled type 2 diabetes, an exaggerated innate and type 1 cytokine response has 
been demonstrated clinically19.  However, the impact insulin resistance alone has on the 
response to M. tuberculosis infection is unknown.  The goals of this study were to develop an 
animal model that more closely mimics the clinical and immunologic manifestations of diabetes-
TB comorbidity in humans.  
 
Materials and Methods. 
 
Induction and confirmation of glucose intolerance and type 2 diabetes.   
Sixty outbred Dunkin-Hartley guinea pigs, weighing between 300-400 g, were obtained 
from Charles River Laboratories (Wilmington, MA) and maintained in individual housing. Guinea 
pigs were divided into three groups; non-diabetic, impaired glucose tolerance, and type 2 
diabetic (n=20 per group).  Eleven weeks prior to infection with Mycobacterium tuberculosis, 
guinea pigs were fed a custom-formulated high fat, high carbohydrate (HFHC) diet (Dyets Inc., 
Bethlehem, PA) ad libitum to induce impaired glucose tolerance.   The diet consisted of 18% 
protein, 30% fat, and 52% carbohydrate with the carbohydrate portion consisting of 45% 
sucrose and 55% fructose.  The dietary fat composition consisted of equivalent kCal/kg of beef 
tallow and Primex vegetable shortening creating a fatty acid composition of 42% saturated, 50% 
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monounsaturated, and 8% polyunsaturated fatty acids. After 8 weeks of HFHC diet, type 2 
diabetes was induced in half of the guinea pigs with impaired glucose tolerance with a single 
subcutaneous injection of streptozotocin (STZ) to induce subtotal beta cell cytotoxicity20.  STZ 
treatment consisted of an optimized single dose of 200 mg/kg in citrate buffer (pH 4.5) after 
anomer equilibration at 4°C for 2 hours21 and 20 minutes after pre-treatment with an 
intramuscular injection of 0.5 mg/kg of the α2-adrenergic receptor antagonist, yohimbine22.  A 
standardized oral glucose challenge (oral glucose tolerance test, OGTT) was used to assess 
the severity of glucose intolerance by administering a 2 g/kg dose of D-glucose (0.5g/ml) after a 
12-hour fasting period and measuring glucose levels at times 0, 60, 90, 120 and 150 minutes 
post-administration with the Freestyle Lite glucometer (Abbot, Alameda, CA) validated for 
accuracy in the guinea pig against the glucose oxidase method, as previously described23.   
 
Infection with M. tuberculosis and euthanasia.   
Low dose aerosol exposure of guinea pigs to M. tuberculosis was performed using the 
Madison chamber aerosol generation device calibrated to deliver approximately 20 bacilli of the 
H37Rv strain of M. tuberculosis (TMC102, Trudeau Institute, Saranac Lake, NY) isolated during 
log phase growth in Proskauer-Beck media. The course of infection was evaluated in non-
diabetic, glucose intolerant and diabetic guinea pigs at the predetermined endpoints of TB 
disease progression, days 30, 60 or 90 of infection or to humane endpoints then euthanized 
(n=5 per group, per time point).  At day 30 of infection, 7 out of 20 diabetic guinea pigs 
remained and were euthanized due to declining clinical condition. Euthanasia was performed by 
anesthetic induction with ketamine (40 mg) and diazepam (1 mg) prior to intraperitoneal 





Histopathology and determination of lesion burden.   
To determine the impact impaired glucose tolerance and diabetes had on TB disease 
progression, histopathology was evaluated and lesion burden quantified on days 30, 60 and 90 
of M. tuberculosis infection.  Tissues were fixed in 4% buffered paraformaldehyde.  
Standardized sampling of the lung was performed by midsaggital sectioning of the left caudal 
lung lobe from each guinea pig at a predetermined anatomic location, irrespective of visible lung 
lesions.  The head of the spleen from each animal was also uniformly sectioned for 
histopathologic evaluation.  The tissues were paraffin embedded and 5 µm sections were 
stained with hematoxylin and eosin for histopathologic evaluation using routine methods.  
Morphometric analysis was performed using a Nikon 80i Eclipse microscope and 
StereoInvestigator software, version 10.02 (MBF bioscience, Williston, VT) with tissue area and 
lesion area estimated using the area fraction fractionator method and expressed as a percent 
ratio of lesion to total tissue area, as previously described24.   
 
Quantification of tissue bacterial burden.  
Lung, spleen, and liver were homogenized in 1 ml of PBS and plated in serial dilutions 
on nutrient 7H11 agar and incubated at 37°C for 3-6 weeks.  Colony forming units (CFUs) were 
log transformed and expressed as CFUs/g of tissue. In addition, the intrathoracic trachea was 
removed at necropsy, flushed with 1 ml of PBS, and plated on 7H11 agar undiluted.  Data was 
expressed as either positive or negative for M. tuberculosis growth.  
 
Quantification of serum lipids.   
Total serum triglycerides were quantified by sequential enzymatic conversion with 
lipoprotein lipase, glycerol kinase and glycerol phosphate oxidase followed by peroxidase 
mediated colorimetric change (Cayman Chemical, Ann Arbor, MI) measured 
spectrophotometrically at an absorbance of 450 nm. Total serum free fatty acids (FFAs) were 
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quantified by sequential enzymatic conversion with ascorbate oxidase and acyl CoA oxidase 
followed by peroxidase mediated generation of fluorescence (Cayman Chemical, Ann Arbor, MI) 
measured spectrophotometrically at excitation 530 nm, and emission 585 nm, as previously 
described23.   
 
Quantification of tissue and serum advanced glycation end-products.   
Lung tissue was mechanically homogenized in 1ml of PBS, centrifuged to remove 
insoluble material, and the supernatant used for AGE detection.  Serum and cell lysate from 
lung homogenate were assayed for total protein by the BCA method and diluted to 10 µg/ml for 
AGE detection by ELISA (Cell Biolabs, San Diego, CA). Quantification was performed by 
interpolation from a standard curve derived from AGE-modified BSA and data expressed as µg 
of AGE-modified protein per ml.  Antibodies utilized in this assay detect glycolaldehyde-derived 
AGEs including two of the most biologically prevalent, carboxymethyllysine (CML) and 
pentosidine. 
 
RNA isolation from lung tissue.   
The pulmonary circulation was perfused with RNasin RNase inhibitor (Promega, 
Madison, WI) (40 units/ml) in Hank's balanced salt solution (HBSS) at the time of necropsy.  
Perfused lung was collected in incomplete DMEM and maintained at 4°C unless otherwise 
indicated.  Tissues were digested with collagenase D (0.7 mg/ml) and DNaseI (100 units) at 
37°C for 30 minutes then pushed through a 70 µm cell strainer.  Viable cells were separated 
from necrotic cell debris using Ficoll-Paque Premium (GE Life Sciences, Pittsburg, PA), washed 
twice in HBSS, and 1ml of Trizol reagent (Life Technologies, Grand Island, NY) added to the 
recovered viable cells.  RNA isolation with Trizol was performed as instructed by the 
manufacturer followed by treatment with 10 units of DNaseI and recovery with an additional 
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phenol/chloroform separation and sodium acetate-ethanol precipitation.  RNA integrity was 
assessed using the Agilent Technologies RNA 6000 nano chip (Santa Clara, CA) and samples 
with an RNA integrity number (RIN) greater than five utilized for relative gene expression. 
 
Relative gene expression by quantitative RT-PCR.   
The influence of impaired glucose tolerance and diabetes on the immune response to M. 
tuberculosis infection was measured by relative gene expression of selected key cytokines.  
Following cDNA synthesis, quantitative RT-PCR was performed with SYBR green detection 
(BioRad, Hercules, CA) using the BioRad CFX-96 real time thermal cycler per manufacturer's 
instructions with each reaction containing 0.2 µM of each primer and 50 ng of cDNA template.  
Under these reaction conditions, primer design was optimized for equivalent amplification 
efficiencies. Gene expression was normalized to two reference genes, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) and TATA-box binding protein (TBP), both of which were 
validated for consistent expression under these experimental conditions.  The HPRT, IL-12p40, 
IFNγ, TNFα, IL-1β, TGFβ, and FoxP3 primer sequences used in this study are previously 
published 25-27.  TBP, IL-17A, IL-23, MCP-1 and IL-10 primers were designed using transcripts 
from the EMBL Ensembl annotated genome browser28 for the guinea pig with the aid of Primer3 
primer design software29 and primers targeting IL-4 were designed from the recently published 
sequence30.  The primer sequences are as follows: TBP (ENSCPOT00000001200) Forward 5'-
CCAAGCGGTTTGCTGCTGTA, Reverse 5' GGCTCCTGTGCACACCATCTT; IL-10 
(ENSCPOT00000009023) Forward 5'-GCCTTTGGCAGGGTGAAGAC, Reverse 5'-
GGCTTGGCASACCCAGGTAAC; IL-17A (ENSCPOT00000010600) Forward 5'-
AATGCCGTTACTCGGGCTGT, Reverse 5'-AGCGGGCAGTTCTGAGGTTC; MCP-1 
(ENSCPOT00000013601) Forward 5'-AGCAGCAGGTGTCCCCAAGA, Reverse 5'-
TCTCTGGTCCAGTTTGGCAATG; IL-23 (ENSCPOT00000015072) Forward 5'-
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GCAACCACCACACCTTGCAAGAAA, Reverse 5'-ATCAGCAAAGACGTCCGTGACCAGC; IL-4 
(NCBI NM_001257263) Forward 5'-GCAACCACCACACCTTGCAAGAAA, Reverse 5'-
ATCAGCAAAGACGTCCGTGACCAGC.  RNA isolates without reverse transcription were 
amplified for each animal to ensure a lack of contaminating genomic DNA and all assays 
performed included no-template controls.  Data was expressed as normalized fold expression 
on a log2 scale. 
 
Quantification of leukocyte phenotype in tissue by flow cytometry.   
Single cell suspensions from lung, tracheobronchial lymph node, and spleen were 
prepared as previously described31.  Cell suspensions were labeled with anti-guinea pig CD4-
RPE, CD8-FITC, Pan T-cell-APC, CD45-FITC, MIL4 (granulocytes), MR1 (macrophages) and 
MHC-II antibodies (AbD Serotec, Raleigh, NC) as previously described32.  Unconjugated 
antibodies were detected with a secondary anti-mouse IgG antibody conjugated with RPE 
fluorochrome for CD45 detection on CD8 T-cells, MHC-II and MIL4 antibodies; and FITC 
fluorochrome for the MR1 antibody.  Data acquisition was performed with the BD Biosciences 
LSR II flow cytometer and analyzed with FACSDiva software (San Jose, CA) using a minimum 
of 100,000 events.  Compensation for spectral overlap was performed as previously 
described32. 
 
Data analysis.   
Analysis was performed with SAS 9.3 software.  A one-factor analysis of variance was 
used for glucose tolerance test, morphometric microscopy, tissue bacterial culture and cytokine 
data with log transformation to correct for unequal variance and Tukey HSD used for pairwise 
comparisons.  A two-factor analysis was used on the log transformed flow cytometry data and 
Tukey HSD used for pairwise comparisons between groups at each time point.  To determine 
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differences between survival curves a Logrank test with Wilcoxon adjustment for multiple 




HFHC diet impairs glucose tolerance in guinea pigs.   
Guinea pigs fed a high fat, high carbohydrate diet for 8 weeks consistently developed 
impaired glucose tolerance as determined by OGTT. Delayed glucose utilization resulted in 
abnormally elevated blood glucose levels as early as 60 minutes after glucose challenge as 
expressed as a significant increase in total area under the curve (Figure 4.1, C and D) when 
compared to OGTT prior to initiating the diet (Figure4.1, A and B).  
 
HFHC diet combined with streptozotocin induces non-insulin dependent diabetes in 
guinea pigs.   
OGTT performed two weeks after STZ treatment of guinea pigs fed the HFHC diet 
showed fasting hyperglycemia and further exacerbation of impaired glucose tolerance with 
glucose levels remaining high at 150 minutes after glucose challenge (Figure 4.1, C and F) 
criteria consistent with human type 2 diabetes33.  The impact of diabetogenic treatments on 
serum biochemical parameters after a 12-hour fasting period is summarized in Table 4.1.  
Guinea pigs with impaired glucose tolerance fed the HFHC diet only for 11 weeks, as well as 
guinea pigs with 3 weeks of uncontrolled diabetes both had elevated fasting triglycerides prior to 
M. tuberculosis infection.  FFAs were significantly elevated only in the diabetic guinea pigs prior 




Infection with M. tuberculosis impairs glucose tolerance in non-diabetic, HFHC fed only 
and diabetic guinea pigs.   
At day 30 of infection, TB induced impaired glucose tolerance in non-diabetic guinea pigs with 
significantly higher levels at 120 minutes after glucose administration, and an overall increase in 
area under the curve compared to pre-infection glucose tolerance (Figure 4.2, A and B).  
Impaired glucose tolerance was more severe in HFHC fed animals and diabetic guinea pigs 
following M. tuberculosis infection with total area under the curve exceeding pre-infection, post-
diabetogenic treatment levels (Figure 4.2, A and B). While impaired glucose tolerance persisted 
in HFHC fed alone guinea pigs through day 60 and 90 of infection, total area under the curve 
was not significantly different from pre-infection glucose tolerance in non-diabetic guinea pigs at 
day 60 and 90 of infection (Figure 4.2, C-F).  However, despite minimal difference in total area 
under the curve, impaired glucose tolerance was evident at the endpoint of OGTT in non-
diabetic guinea pigs (Figure 4.2, E and F).  Infection with M. tuberculosis also markedly 
increased serum FFAs in all groups. Serum FFAs were highest at day 30 of infection and 
subsided as chronic infection was established (Table 4.1). 
 
AGEs accumulate when diabetes and TB are combined.   
Serum AGEs were elevated above preinfection levels by approximately 3-fold at day 30 
of infection only in diabetic guinea pigs while no difference was evident between non-diabetic 
and guinea pigs with impaired glucose tolerance at days 30, 60, or 90 of M. tuberculosis 
infection (Table 4.1).  Increased pulmonary tissue AGEs were present in M. tuberculosis-
infected non-diabetic, glucose intolerant and diabetic guinea pigs to a similar degree (Table 4.1) 




Figure 4.1. Glucose tolerance is impaired in guinea pigs with prediabetic impaired glucose 
tolerance and type 2 diabetes. Normal glucose tolerance in non-diabetic guinea pigs prior to initiating 
HFHC diet by oral glucose tolerance test (OGTT) (A) and corresponding area under the curve (AUC) (B).   
Feeding of high fat, high carbohydrate diet impairs glucose tolerance in guinea pigs fed the HFHC diet 
alone with reduced glucose disposal at 60 minutes of OGTT (C) and overall increase in AUC (D), 
compared to the same guinea pigs prior to initiating the diet.  A diabetic level of impaired glucose 
tolerance in diabetic guinea pigs 11 weeks after combined HFHC/STZ diabetogenic treatment (E) with 
marked increase in AUC (F). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; NonDM = non-diabetic, IGT = impaired 







Figure 4.2.  Infection with M. tuberculosis further impairs glucose tolerance in non-diabetic, HFHC 
fed only and diabetic guinea pigs.  OGTT at day 30 of infection (A) shows amplification of impaired 
glucose tolerance in non-diabetic, HFHC fed only and diabetic guinea pigs due to M. tuberculosis 
infection with increased AUC (B) compared to pre-infection values.  At day 60 of infection (C) glucose 
tolerance is comparable to pre-infection levels in non-diabetic guinea pigs while impaired glucose 
tolerance and increased AUC (D) remains in guinea pigs with pre-existing impaired glucose tolerance.  
Similarly, impaired glucose tolerance persists at day 90 of infection (E) in guinea pigs with pre-existing 
impaired glucose tolerance as indicated by elevated AUC (F) while overall glucose tolerance is 
comparable to pre-infection levels in non-diabetic controls although blood glucose remains elevated in 
this group 2 hours post-administration. */† P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; NonDM = non-diabetic, 






















Table 4.1.  Metabolic parameters from non-diabetic, glucose intolerant and diabetic guinea pigs 
prior to infection with M. tuberculosis (Day 0) and on days 30, 60 and 90 after infection.  TG = 
triglyceride, FFA = free fatty acid, AGE = advanced glycation end product, ND = not determined; * = 
compared to non-diabetic, † = compared to pre-infection levels, */† p≤0.05, ††† p≤0.001, †††† p≤0.0001 
 
 Day 0 30 60 90 
TG (mg/dl) 
NonDM 34.7 ± 9.4 58.4 ± 16.3 40.59 ± 19.3 ND 
IGT 93.1 ± 63.7* 66.9 ± 44.1 77.1 ± 42.1 ND 
T2DM 101 ± 47* 52.2 ± 13.9 ND ND 
FFA (µM) 
NonDM 132.3 ± 24.8 380 ± 46.2†††† 260.6 ± 8.6†† 252.7 ± 25.4†† 
IGT 146.6 ± 47.5 406.1 ± 84†††† 256.9 ± 19.2†† 240.3 ± 16.6†† 
T2DM 172.6 ± 47.4* 454.2 ± 90.7†††† ND ND 
AGE (µg/ml) 
NonDM 1.079 ± 0.181 1.266 ± 0.188 1.125 ± 0.179 0.956 ± 0.122 
IGT 0.973 ± 0.011 1.186 ± 0.273 1.007 ± 0.094 0.987 ± 0.14 











Diabetic guinea pigs develop rapidly progressive TB disease.   
Progression of TB was rapid in diabetic guinea pigs with 65% mortality before day 30 of 
infection and a median survival time of 25 days (Figure 4.3A).  Guinea pigs with impaired 
glucose tolerance showed intermediate, but not statistically significant, mortality compared to 
non-diabetic controls.  Mortality in guinea pigs with impaired glucose tolerance was 50% before 
termination of the study at day 145 with a median survival time of 95 days.  Guinea pigs with 
impaired glucose tolerance and infected with M. tuberculosis were euthanized due to respiratory 
distress and had developed marked cranial mediastinal and tracheobronchial lymph node 
enlargement with compression of primary bronchi.  No mortality occurred in non-diabetic guinea 
pigs prior to the terminal endpoint at day 145 of infection.      
 
M. tuberculosis infection in guinea pigs with diabetes accelerates bacilli dissemination 
and exacerbates TB disease severity.  
Pulmonary lesion burdens were markedly increased in diabetic guinea pigs with a 2.7-
fold increase in mean percent involvement over non-diabetic controls.  While pulmonary lesions 
were higher in guinea pigs with impaired glucose tolerance at day 30, this difference was not 
statistically significant and no significant differences were present on days 60 and 90 of infection 
between glucose intolerant and non-diabetic guinea pigs (Figure 4.3B).  In contrast to typical 
well-structured granulomas of non-diabetic and guinea pigs with impaired glucose tolerance 
(Figure 4.3D), diabetic guinea pigs had marked granulocytic inflammation that disrupted lung 
granuloma architecture often resulting in airway erosions (Figure 4.3E).  Splenic lesion burden, 
as a measure of extrapulmonary TB disease, was increased in diabetic guinea pigs at day 30 of 
infection, reaching as high as 97% involvement (Figure 4.3C).  In addition to extensive 
involvement, guinea pigs with diabetes had altered lesion morphology characterized by widely 





Figure 4.3.  TB is more severe in guinea pigs with type 2 diabetes.  Markedly reduced survival in 
diabetic guinea pigs and intermediate, but insignificant, susceptibility seen in guinea pigs with impaired 
glucose tolerance (A).  Approximately 3-fold increase in lung disease severity in diabetic guinea pigs on 
day 30 of infection as measured by lesion burden while no significant differences were present between 
glucose intolerant and non-diabetic controls (B).  Markedly increased spleen lesion burden in diabetic 
guinea pigs on day 30 of infection while no significant differences were present between glucose 
intolerant and non-diabetic controls (C).  When compared to normal granuloma morphology in the lung of 
non-diabetic guinea pigs (D), there was much higher granulocyte infiltration (arrows) and disruption of 
granuloma architecture in diabetic guinea pigs (E) (H&E, bar = 100µm).  When compared to typical large 
and discrete granulomas (arrow) in the spleen of non-diabetic guinea pigs (F), diabetic guinea pigs had a 
widespread miliary pattern of lesion dissemination in the spleen consisting of small and coalescing 
granulomas (arrows) (G) (H&E, bar = 100µm). * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001; NonDM = non-













when compared to non-diabetic controls (Figure 4.3F).  Progressive lesions developed within 
the lymph nodes draining the lungs in all guinea pigs regardless of their diabetic state. 
 
Diabetic guinea pigs have higher bacterial burden.  
At day 30 of infection, diabetic guinea pigs had approximately 2 log10 higher bacterial 
burdens in all tissues evaluated compared to non-diabetic controls and guinea pigs with 
impaired glucose tolerance (Figure 4.4A).  While no significant differences were present at day 
60 of infection (Figure 4.4C), the bacterial burden was lower in spleen and liver of non-diabetic 
guinea pigs at day 90 compared to guinea pigs with impaired glucose tolerance whose 
extrapulmonary burden remained elevated (Figure 4.4E).  The higher lung bacterial burden in 
diabetic guinea pigs was accompanied by increased shedding of bacilli into the upper airways.  
While M. tuberculosis could not be isolated from tracheal wash fluid of any non-diabetic controls 
(n=4) on day 30 of infection, M. tuberculosis was cultured from two of four guinea pigs with 
impaired glucose tolerance and five of eight diabetic guinea pigs (Figure 4.4B).  As chronic 
infection was established, the frequency of viable bacilli cultured from tracheal wash of guinea 
pigs with impaired glucose tolerance was reduced.  Tracheal washes were culture positive from 
one non-diabetic and glucose intolerant guinea pig on day 60 of infection (Figure 4.4D) but all 
were negative by day 90 (Figure 4.4F).  
 
Guinea pigs with impaired glucose tolerance and diabetes respond to M. tuberculosis 
infection with altered pro- and anti-inflammatory cytokine profiles.   
At day 30 of infection, elevations in cytokine and chemokine expression in the lungs of 
diabetic guinea pigs included IL-12p40 (2.3 fold), IFNγ (4.7 fold), IL-17A (4.3 fold), IL-8 (5.6 
fold), and IL-10 (12.6 fold) compared to non-diabetic controls (Figures 4.5-7).  In contrast, non-
diabetic guinea pigs and those with impaired glucose tolerance had similar cytokine profiles 




Figure 4.4.  Guinea pigs with diabetes have a higher bacterial burden.  Diabetic guinea pigs at day 
30 of infection have much higher bacterial burden in pulmonary and extrapulmonary organs (A).  Higher 
frequency of M. tuberculosis growth from tracheal wash fluid of diabetic guinea pigs, exceeding positive 
samples from guinea pigs with impaired glucose tolerance as compared to no growth in non-diabetic 
controls (B).  No significant differences in tissue bacterial burden on day 60 of infection between glucose 
intolerant and non-diabetic guinea pigs (C) and similar tracheal wash culture results, which have declined 
in guinea pigs with impaired glucose tolerance (D).  By day 90 of infection, extrapulmonary burden has 
declined in non-diabetic guinea pigs while it is persistently elevated in guinea pigs with impaired glucose 
tolerance (E).  All tracheal wash cultures from non-diabetic and glucose intolerant guinea pigs are 
negative at day 90 of infection (F). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; NonDM = non-diabetic, IGT = 








Figure 4.5.  Guinea pigs with type 2 diabetes respond to M. tuberculosis infection with a more 
robust type 1 cytokine response. Relative gene expression of cytokines promoting a Th1-biased T cell 
response was measured by qRT-PCR.  Lung IFNγ and IL-17 expression as well as spleen IFNγ was 
higher in diabetic guinea pigs infected with M. tuberculosis on day 30 of infection.  Elevated IFNγ was not 
seen in guinea pigs with impaired glucose tolerance until day 90 of infection.  No significant differences 
were observed in IL-12p40 or IL-23 expression at any time point evaluated. * P ≤ 0.05, *** P ≤ 0.001; 









Figure 4.6.  Guinea pigs with type 2 diabetes respond with an elevated innate chemokine/cytokine 
response early in M. tuberculosis infection.  Relative gene expression of innate cytokines and 
chemokines most involved in TB pathogenesis were measured by qRT-PCR. Elevated expression of 
neutrophil and macrophage chemokines IL-8 and MCP-1, respectively, as well as splenic TNFα 
expression are significantly elevated in guinea pigs with type 2 diabetes on day 30 of infection.  In 
contrast, elevated expression of IL-1β and TNFα occurred only at day 90 of infection in guinea pigs with 
impaired glucose tolerance. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; NonDM = non-diabetic, IGT = impaired 










Figure 4.7.  Increased IL-10 expression does not impair the inflammatory response in type 2 
diabetic guinea pigs.  Relative gene expression of cytokines and transcription factors that oppose the 
cell-mediated response during TB were measured by qRT-PCR.  A productive type 1 cytokine response 
persisted in diabetic guinea pigs despite elevated IL-10 expression on day 30 of infection with M. 
tuberculosis. IL-4 expression, as an indicator of Th2 T cell differentiation, or FoxP3 expression, as an 
indicator of regulatory T cell differentiation, did not differ between non-diabetic, insulin resistant or diabetic 
states at any time point evaluated.  * P≤ 0.05; NonDM = non-diabetic, IGT = impaired glucose tolerance, 








increase in TNFα (p=0.1) and IL-1β, respectively, at day 90 of infection in guinea pigs with 
impaired glucose tolerance compared to non-diabetic controls (Figure 4.6). Diabetic guinea pigs 
had elevated IFNγ (5.8 fold), TNFα (4.3 fold), and MCP-1 (11.0 fold) in the spleen at day 30 of 
infection while guinea pigs with impaired glucose tolerance had elevated TNFα (3.0 fold), 
compared to non-diabetic controls (Figures 4.5 and 4.6).  Differences in cytokine expression in 
the spleen at day 90 of infection were present in guinea pigs with impaired glucose tolerance 
with elevated IFNγ (4.4 fold), TNFα (4.5 fold), and TGFβ (6.2 fold) (Figures 4.5-7).  Expression 
of FoxP3, and IL-4 did not differ between any groups at any point throughout the study (Figure 
4.7). 
 
Guinea pigs with diabetes have higher levels of macrophage activation and neutrophil 
infiltration early in disease while innate immune cell phenotypes increase late in disease 
in guinea pigs with impaired glucose tolerance.  
Absolute quantification of immune cell phenotypes per gram of lung, lymph node and 
spleen is depicted in Table 4.2.  Diabetic guinea pigs responded to M. tuberculosis infection with 
higher total numbers of activated MHCIIhigh macrophages in lung, lymph node and spleen (Table 
4.2) as well as a greater proportion of activated macrophages out of all macrophage cells 
recovered from lung and lymph node compared to non-diabetic and glucose intolerant controls 
(Figure 4.8, G and H). This correlated with higher total numbers of activated CD45high CD4 T 
cells from the lymph node of diabetic guinea pigs although the percentage of activated CD45high 
T cells out of total CD4 T cells recovered did not differ (Figure 4.8, A-C).  In addition, diabetic 
guinea pigs had a higher proportion of granuloyctes in the lung at day 30 of infection compared 
to non-diabetic controls (Figure 4.8J).  In contrast, guinea pigs with impaired glucose tolerance 
had lower cell numbers of all phenotypes recovered from lymph node at day 30 of infection, but  
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Table 4.2.  Immune cell phenotypes in absolute number as measured by flow cytometry in lung, 
lymph node, and spleen on days 30, 60 and 90 of infection.  Results are expressed at 105 cells and 
normalized to per gram of tissue.  * = Compared to IGT, # = Compared to T2DM, */# P≤ 0.05, **/## P ≤ 
0.01, ***/### P≤ 0.001; MAC = macrophage, Gran = granulocyte, NonDM = non-diabetic, IGT = glucose 
intolerant, T2DM = diabetic 
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Figure 4.8. Activated macrophages and granulocytes are increased in diabetic guinea pigs at day 
30 of M. tuberculosis infection. Total CD4+ or CD8+ TCR+ T cells and MHCII low or high expressing 
macrophages were quantified by flow cytometry and normalized to per gram of tissue in lung, lymph node 
and spleen then expressed as percent activated based on proportions of CD45high CD4+ and CD8+ 
lymphocytes and MHCIIhigh macrophages.  The proportion of activated CD4 T cells decreases in non-
diabetic and glucose intolerant guinea pigs at day 60 of infection but is equally elevated at day 90 of 
infection in all organs in non-diabetic and glucose intolerant guinea pigs (A-C).  No differences in CD8 T 
cell activation at any time point between non-diabetic, glucose intolerant and diabetic guinea pigs (D-F).  
Higher proportions of activated macrophages are present in diabetic guinea pigs in lung and lymph node 
on day 30 of infection (G-I).  Granulocytes as a proportion of total leukocytes counted per gram of tissue 
are increased in the lung of diabetic guinea pigs (J-L). * P≤ 0.05; NonDM = non-diabetic, IGT = impaired 




higher numbers of activated MHCIIhigh macrophages as well as granulocytes were present at 
day 90 of infection.  An overall decrease in the proportion of activated CD45high CD4 T cells 
occurred in all organs in both non-diabetic guinea pigs and those with impaired glucose 
tolerance between day 30 and 60 of infection, but increased again at day 90 of infection (Figure 




 This study represents both the first model of non-insulin dependent diabetes in the 
guinea pig as well as the first description of M. tuberculosis infection in an animal model with 
diet-induced impaired glucose tolerance or type 2 diabetes.  The guinea pig model was chosen 
to better mimic the comorbidity of diabetes and TB in humans, based on the guinea pig 
response to M. tuberculosis infection and similarities to human glucose and lipid metabolism 
compared to mice or rats. The most common indicator of systemic insulin resistance in human 
patients is delayed utilization of glucose, referred to as impaired glucose tolerance, as 
measured by OGTT.  In this study, guinea pigs fed a HFHC diet developed impaired glucose 
tolerance evidenced by an elevated 1-hour post-load blood glucose during OGTT, a 
measurement recently shown to predict early insulin resistance and beta cell dysfunction in 
human patients34.  In addition, guinea pigs developed serum lipid alterations, including elevated 
fasting triglycerides and FFAs, consistent with insulin resistance similar to that seen in  
humans35.  In humans, the progression from prediabetic, impaired glucose tolerance and insulin 
resistance to type 2 diabetes is gradual and can take years36.  Consequently, the low-dose 
treatment with the cytotoxic drug STZ in these studies was included to accelerate the rate of 
beta cell loss in guinea pigs with impaired glucose tolerance. The combination of the HFHC diet 
and low-dose STZ consistently induces fasting hyperglycemia and blood glucose levels 
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exceeding 200 mg/dl in a 2-hour OGTT as early as 14 days after STZ treatment, data consistent 
with the diagnostic standards established for humans with type 2 diabetes33.  
 Severe systemic inflammation in non-diabetic individuals is often associated with 
hyperglycemia and impaired glucose tolerance mediated in part by proinflammatory cytokines, 
especially TNFα. The pathogenesis of cytokine-mediated hyperglycemia and impaired glucose 
tolerance is directly linked to the release of FFAs, which are potent mediators of insulin 
resistance37-39.  In this study, impaired glucose tolerance was induced by M. tuberculosis 
infection alone even in non-diabetic guinea pigs, as we have previously described23.  M. 
tuberculosis infection in diabetic as well as non-diabetic guinea pigs fed the HFHC diet only, 
further exacerbated impaired glucose tolerance.  This finding paralleled the marked elevations 
in serum FFAs in infected guinea pigs, which exceeded the modest elevations associated with 
diabetes induction prior to infection.  In addition, elevations in FFAs reflected increased cytokine 
expression during the early stages of infection, which subsided at day 60 of infection when 
innate cytokine expression was low. The relationship between cytokine expression and FFA 
concentrations was also reflected at day 90 of M. tuberculosis infection in guinea pigs with 
impaired glucose tolerance, which also correlated with increased TNFα and IL-1β expression.  
Impaired glucose tolerance and insulin resistance with hyperglycemia has been previously 
reported in human patients with active TB, which may be explained by elevated proinflammatory 
cytokines consistent with these data.  The clinical significance of impaired glucose tolerance 
and hyperglycemia induced by M. tuberculosis infection is that it further complicates both the 
diagnosis and treatment of diabetes in patients with TB 40-43. 
 Overt diabetes had a profound impact on TB progression in this study.  An overall 
increase in disease severity, characterized by a significantly higher bacterial load and more 
severe and rapidly progressive pulmonary and extrapulmonary disease contributed to 
decreased survival in diabetic guinea pigs with TB.  These findings are consistent with reports of 
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more severe pulmonary TB in human diabetic patients15, 16.  Despite the conflicting evidence in 
human patients5, 10, 17, 18, more severe and rapidly progressing extrapulmonary disease in 
diabetic guinea pigs was a consistent finding.  The altered pattern of lesion dissemination in the 
spleen of diabetic guinea pigs resembles miliary TB, a pattern of disease that is associated with 
increased mortality especially in severely immunocompromised human TB patients44. M. 
tuberculosis infection in diabetic guinea pigs also resulted in increased shedding of bacilli into 
the tracheal lumen at the predetermined endpoints. M. tuberculosis was cultured from tracheal 
washes of diabetic guinea pigs with greater frequency than non-diabetic guinea pigs and those 
with impaired glucose tolerance. The low frequency of animal-to-animal transmission of M. 
tuberculosis in normal guinea pigs is likely related to the failure to routinely develop open 
cavitary lesions, which typically harbor large numbers of bacilli10, 45.  Our data indicate that 
diabetes induction increases the frequency of airway shedding of M. tuberculosis, even in the 
absence of cavitation, which may be related to higher pulmonary bacterial load and/or an 
alteration in the diabetic airway microenvironment46, 47. With the increasing interest in natural M. 
tuberculosis transmission from humans to animals or between animals11, the diabetic guinea pig 
may represent a viable animal-to-animal transmission model, which warrants further 
investigation.   
 In contrast, impaired glucose tolerance in guinea pigs appeared to have little impact on 
TB disease progression in the early stages of disease.  Although the initial pulmonary burden 
was higher in guinea pigs with impaired glucose tolerance, the differences were not statistically 
significant and the number of activated CD45high lymphocytes in the lung as well as cytokine 
expression was comparable to non-diabetic controls.  Differences in response to M. tuberculosis 
infection in guinea pigs with impaired glucose tolerance were not seen until the chronic stages 
of infection.  On day 90, TNFα and IL-1β expression as well as the extrapulmonary bacterial 
burden in guinea pigs with impaired glucose tolerance was higher than non-diabetic controls.  
Recently, an increased prevalence of impaired glucose tolerance and insulin resistance has 
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also been recognized in TB patients, however it is unknown whether these metabolic alterations 
are a consequence of systemic insulin resistance mediated by M. tuberculosis infection48.  
These results provide the first experimental evidence that impaired glucose tolerance similar to 
a prediabetic state also increases TB disease severity, a finding that warrants further 
investigation in animal models and humans49.  While guinea pigs with impaired glucose 
tolerance did not develop TB disease that progressed as rapidly as in diabetics, active 
inflammation persisted, which accounted for more severe clinical disease in the chronic stages 
of infection.  In this study, the more severe TB disease in guinea pigs with hyperglycemia as a 
result of impaired glucose tolerance are similar to our previous studies showing that TB disease 
severity is increased even in non-diabetic guinea pigs with repeated post-prandial 
hyperglycemia 23.  Moreover, our results are similar to that described in diabetic humans and 
STZ treated mice with chronic hyperglycemia, which suggest that poor glycemic control is an 
important determinant of TB disease risk7, 19.   
 Aside from the increased severity of disease, the pathological features of M. tuberculosis 
infection in diabetic guinea pigs differed from that of non-diabetic controls. These changes may 
be related to the altered expression of particular cytokines and subsequent cellular response to 
M. tuberculosis infection. Increased IL-17, also described in humans with type 2 diabetes and 
TB50, as well as elevated IL-8 expression may be linked to more granulocytic infiltration and 
pathology seen in diabetic guinea pigs infected with M. tuberculosis.  A persistent IL-17 
response during TB contributes to excessive inflammation and is generally limited by IFNγ 
production although was not evident in diabetic guinea pigs in this study51, 52. We have shown 
that the accumulation of advanced glycation end products (AGEs) occurs as a result of M. 
tuberculosis-mediated inflammation but is further increased when combined with diabetes. This 
response was reflected by the marked increase in serum AGEs only in diabetic guinea pigs with 
TB. These byproducts of chronic hyperglycemia, combined with oxidative stress, induce a pro-
inflammatory response and may have contributed to the more severe inflammation and TB 
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disease in guinea pigs with type 2 diabetes53-55. A significant increase in MCP-1 expression in 
diabetic guinea pigs with TB correlated with the pattern of coalescing foci of tissue 
macrophages without granuloma formation in the spleen. Increased MCP-1 expression in 
human TB patients is a feature of pulmonary TB, however, the increased expression of this 
cytokine in diabetic guinea pigs may explain the more severe, miliary pattern of extrapulmonary 
spread to the spleen, which is prevalent in this species56.   
 It is generally accepted that a Th1-biased cytokine response is critical for protection 
during M. tuberculosis infection.  Guinea pigs with type 2 diabetes displayed higher macrophage 
activation, an appropriate response to the increased production of IFNγ. Despite this seemingly 
favorable response to M. tuberculosis infection, diabetic guinea pigs failed to limit bacterial 
growth.  A balance between the ability to limit bacterial growth and the development of 
damaging inflammation during active TB, may explain the increase in anti-inflammatory 
cytokines. The increased anti-inflammatory cytokine expression is likely a reciprocal response 
intended to prevent host injury from the exacerbated innate response to M. tuberculosis 
infection seen in diabetic guinea pigs.  In this study, the increase in IL-10 occurred despite, the 
counter regulatory effects of high IFNγ expression.  These findings suggest possible IFNγ-
mediated induction of IL-10 as has been previously described associated with a high M. 
tuberculosis burden57, 58.  Previously, a delayed onset of IFNγ production in response to M. 
tuberculosis infection was shown in STZ-treated mice with hyperglycemia, which also fail to 
control bacterial growth8. The contribution of rapid disease progression prior to onset of adaptive 
immunity to M. tuberculosis in diabetic guinea pigs will need to be determined in future studies 
that focus on the very early stages of diabetes-TB comorbidity. Previous studies have shown 
that the accumulation of regulatory T cells expressing FoxP3 during M. tuberculosis infection 
parallels the activation of a Th1-biased adaptive immune response and along with the Th2 
cytokine, IL-4, is thought to impair a productive Th1 lymphocyte response59.  However, in this 
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study, no differences were noted in FoxP3 or IL-4 expression suggesting that the over-
expression of immunosuppressive T cell subsets are not a major determinant in the increased 
severity of TB in guinea pigs with type 2 diabetes.  
 From this and other studies investigating diabetes-TB comorbidity, it is evident that the 
diabetic state impairs M. tuberculosis host defenses resulting in uncontrolled bacterial growth.  
In addition, altered cytokine expression and more severe pulmonary pathology indicative of a 
proinflammatory response to M. tuberculosis infection are consistent with features described in 
diabetes-TB comorbidity of humans. Moreover, these studies demonstrate that M. tuberculosis 
infection alone is associated with altered host lipid and glucose metabolism, which reveals the 
possibility of using antiglycemic drugs as an adjunct with antimicrobial drugs to treat TB.  
Because of the shared features of M. tuberculosis infection in diabetic humans and guinea pigs, 
this model will be valuable in testing new TB treatment and diabetes control strategies when 
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Impaired Transition from Innate to Adaptive Immunity in the Guinea Pig Model of 
Diabetes-Tuberculosis Comorbidity 
 
Rationale:  In the previous chapter, we demonstrated that more severe TB disease in diabetic 
guinea pigs presents as an exacerbated adaptive and innate immune response, which is 
accompanied by very high bacterial growth in lung and extrapulmonary tissue.  However, the 
mechanisms preventing the host from controlling this bacterial growth at a level similar to non-
diabetic animals is not yet understood.  In the typical pathogenesis of TB, it is well demonstrated 
that the ability of the host to orchestrate a successful transition from innate to adaptive immunity 
is essential for controlling the infection.  This process is highly dependent on timing since cells 
harboring bacteria early during infection have much more successful bactericidal capacity in the 
presence of a cell-mediated response.  Therefore, if the adaptive transition is delayed, effective 
control of bacterial growth may be hindered.  An early hyperactive innate response similar to 
what has been identified at day 30 of infection in diabetic guinea pigs, may lead to early host 
injury and impair successful T cell help at the site of pulmonary infection.  
 
Hypothesis:  The early immune response in diabetic guinea pigs is skewed toward production 
of inflammatory innate cytokines in the presence of rapid bacterial growth that promote a robust 










Diabetes increases the risk of developing active tuberculosis (TB) disease and clinical 
studies suggest that TB is more severe in diabetic individuals. We have developed a guinea pig 
model of type 2 diabetes-TB comorbidity, which closely replicates these features in the human 
comorbidity.  By day 30 of infection, diabetic guinea pigs have high bacterial growth and 
damaging neutrophilic inflammation despite the presence of cell-mediated immunity expected to 
control these manifestations.  Therefore, in this study, we evaluated the early response to 
Mycobacterium tuberculosis infection in diabetic guinea pigs, in order to identify innate and cell-
mediated factors that may influence the host's ability to contain bacterial growth and prevent 
progressive TB disease.  By day 10 of M. tuberculosis infection, diabetic guinea pigs 
demonstrated limited pulmonary inflammation, reduced inflammation of the pulmonary 
lymphatics and impaired transport of bacteria to lung draining lymph nodes, the site for 
development of a cell-mediated response.  Correlating with this, diabetic guinea pigs 
demonstrated a reduced antigen-specific IFNγ response and lower overall production of IFNγ in 
lung and lymph node on day 19 of infection.  However, bacterial growth did not differ between 
diabetic and non-diabetic guinea pigs at either day 10 or day 19 of infection.  This evidence of 
impaired antigen transport and delayed production of an antigen specific immune response may 
be related to the impact of early increased expression of the cytokine IL-6, which is known to 
impair Th1 immunity and migratory ability of antigen presenting cells by reducing the expression 
of the critical chemotactic receptor CCR7, which was also present in diabetic guinea pigs.  
These data indicate that bacterial growth is not enhanced in diabetic guinea pigs early in 
infection and that a delayed antigen-specific Th1 cell-mediated response may represent a 
central mechanism leading to the inability of diabetic guinea pigs to contain bacterial growth 





 Diabetes is a recognized risk factor for tuberculosis (TB) and the growing epidemic of 
type 2 diabetes, particularly in countries where TB is endemic, accounts for the majority of 
diabetes-associated TB1, 2.  Currently, 95% of the 262 million diabetic people worldwide have 
type 2 diabetes, and of these, up to 80% reside in TB endemic countries3.  Moreover, with a 
rapidly rising incidence of type 2 diabetes worldwide, it is estimated that this population will 
nearly double by the year 20304. Although a number of altered disease manifestations and 
immune response elements have been identified, the underlying mechanisms that make people 
with diabetes more likely to develop active TB disease remain poorly understood5-7.  
 Recently, we have described a guinea pig model of type 2 diabetes, which is preceded 
by progressive dietary-induced insulin resistance followed by reduced β-cell capacity, the two 
defining features of type 2 diabetes pathogenesis in humans8.  In response to infection with 
Mycobacterium tuberculosis, these diabetic guinea pigs develop more severe TB disease that is 
dominated by neutrophilic inflammation, higher bacterial burdens, and an exacerbated innate 
and cell-mediated immune response8.  These finding are in line with reported features in human 
clinical studies in type 2 diabetic patients with TB including radiographic evidence of more 
severe disease, higher bacterial burdens based on sputum culture, and higher innate and type 1 
cytokine production from stimulated peripheral blood mononuclear cells, including TNFα, IL-17, 
IL-10 and IFNγ9-14. These findings are also consistent with previous studies in a mouse model of 
diabetes characterized by total insulin deficiency and absolute hyperglycemia, where more 
severe disease manifests in the presence of high bacterial loads and inflammatory cytokines15.   
 Interestingly, despite a greater expression of the Th1 cytokine IFNγ and associated 
macrophage activation, both of which are linked to bactericidal activity in macrophages, diabetic 
guinea pigs were unable to contain the growth of M. tuberculosis.  However, the alterations in 
 192 
the immune response early in infection that allow for high bacterial growth are unknown.  Many 
alterations in immune function have been reported in diabetic patients, the most common of 
which include reduced phagocytosis and microbial killing through oxidative burst in neutrophils 
and macrophages, impaired neutrophil chemotaxis, and impaired generation of antigen-specific 
T cell responses17-21, all of which could account for more rapid growth of M. tuberculosis early in 
the course of infection.  However, few studies have emphasized the mechanisms that increase 
susceptibility to pathogen-specific diseases where diabetes has a demonstrated impact on the 
manifestation, progression, severity and treatment of the disease, as is the case with 
tuberculosis.  
 Among the most important stages of the response during TB in the mouse model is the 
transition from innate to adaptive immunity.  It is well known that a Th1 T cell response is critical 
for limiting progressive inflammation because it greatly enhances bactericidal capacity of M. 
tuberculosis infected macrophages, and corresponds with the stage of disease progression 
where bacterial growth is controlled22-24.  In the absence of IFNγ, the signature of a Th1 
response, bacterial growth continues and severe and fatal inflammation ensues25.  A 
requirement for timely development of a cell-mediated immune response is the transport of 
viable bacteria from the lung to the draining lymph node by dendritic cells for antigen 
presentation26.  The expedited transport of M. tuberculosis to the lymph node has consistently 
led to the development of earlier pulmonary cell-mediated immunity and better control of 
bacterial growth in animal models27-29.  Therefore, it is reasonable to expect that any impairment 
in the development of an antigen-specific response would lead to higher bacterial growth.  Such 
results have been demonstrated in the mouse model of diabetes, which develops a delayed 
adaptive immune response30.  However, whether this also occurs in the comorbidity with the 
guinea pig model of type 2 diabetes is unknown.  In this study, we aimed to identify whether 
altered early innate responses and transition to adaptive immunity account for rapid bacterial 
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growth and severe inflammation characteristic of type 2 diabetic guinea pigs later in the course 
of M. tuberculosis infection.  
 
Materials and Methods. 
 
Induction of type 2 diabetes in guinea pigs.   
Outbred Dunkin-Hartley guinea pigs, weighing between 250-350 g, were obtained from 
Charles River Laboratories (Wilmington, MA) and maintained in individual housing. Guinea pigs 
were divided into two groups, either non-diabetic controls or those that would receive treatments 
to induce type 2 diabetes.  The induction of type 2 diabetes was performed as previously 
described8.  Briefly, 11 weeks prior to infection with Mycobacterium tuberculosis, guinea pigs 
were fed a custom-formulated high fat, high carbohydrate (HFHC) diet (Dyets Inc., Bethlehem, 
PA) ad libitum to induce impaired glucose tolerance.  After 8 weeks of HFHC diet and 
confirmation of glucose intolerance by a 2g/kg oral glucose tolerance test, type 2 diabetes was 
induced with a single 200 mg/kg subcutaneous injection of anomer-equilibrated streptozotocin 
(STZ)31, approximately 20 minutes after intramuscular treatment with 0.5 mg/kg of yohimbine32.  
Diabetic glucose intolerance was confirmed by oral glucose tolerance at 14 and 21 days post-
STZ treatment.   
 
Infection with Mycobacterium tuberculosis.   
An aliquot of the H37Rv strain of M tuberculosis (TMC102, Trudeau Institute, Saranac 
Lake, NY), grown to log phase in Proskauer Beck medium, was diluted to 1 x 106 CFU/ml for 
delivery to guinea pigs by low dose aerosol exposure using the Madison chamber aerosol 
generation device calibrated to deliver approximately 20 bacilli per guinea pig.  The course of 
infection was evaluated in non-diabetic and diabetic guinea pigs at the predetermined endpoints 
of days 10 and 19 of infection (n=4 per group, per time point).  Prior to euthanasia, blood was 
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collected under isoflurane anesthesia by venipuncture of the cranial vena cava accessed by 
intrathoracic collection at the junction of the manubrium and first rib.  Euthanasia was performed 
by anesthetic induction with ketamine (40 mg) and diazepam (1 mg) prior to intraperitoneal 
injection of an overdose of sodium pentobarbital (1.5ml/kg) and followed immediately by 
necropsy and tissue collection.  
 
Histopathology and determination of lesion burden.  
Tissues collected at day 10 and 19 of infection were fixed in 4% buffered 
paraformaldehyde and 5 µm sections of paraffin embedded tissues were stained with 
hematoxylin and eosin for histopathologic evaluation using routine methods.  Morphometric 
analysis was performed using a Nikon 80i Eclipse microscope and StereoInvestigator software, 
version 10.02 (MBF bioscience, Williston, VT) with tissue area and lesion area estimated using 
the area fraction fractionator method and expressed as a percent ratio of lesion to total tissue 
area, as previously described33, 34.   
 
Quantification of tissue bacterial burden.  
Lung, spleen, and liver were homogenized in 1 ml of PBS, plated in serial dilutions on 
nutrient 7H11 agar and incubated at 37°C for 3-6 weeks.  Colony forming units (CFUs) were log 
transformed and expressed as CFUs/g of tissue.  
 
RNA isolation and relative gene expression by quantitative RT-PCR.   
The pulmonary circulation was perfused with RNasin RNase inhibitor (Promega, 
Madison, WI) (40 units/ml) in Hank's balanced salt solution (HBSS) at the time of necropsy.  The 
right cranial lung lobe and head of the spleen at days 10 and 19, and one third of the 
peribronichial lymphnodes at day 19, were collected for RNA isolation and homogenized in RNA 
Later solution (Ambion).  RNA isolation from lymph node at day 19 was not possible due to size 
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and consequently, all tissue was used for bacterial culture.  Preserved lung and spleen tissues 
were incubated at 4°C overnight then frozen at -80°C until processed for RNA isolation. RNA 
isolation with Trizol reagent (Life Technologies, Grand Island, NY) was performed as instructed 
by the manufacturer followed by treatment with 10 units of DNaseI and recovery with an 
additional phenol/chloroform separation and sodium acetate-ethanol precipitation.  The early 
immune response was evaluated by relative gene expression of selected key cytokines, 
chemokines and receptors.  Following cDNA synthesis, quantitative RT-PCR was performed 
with SYBR green detection (BioRad, Hercules, CA) using the BioRad CFX-96 real time thermal 
cycler per manufacturer's instructions with each reaction containing 0.2 µM of each primer and 
50 ng of cDNA template.  Under these reaction conditions, primer design was optimized for 
equivalent amplification efficiencies. Gene expression was normalized to two reference genes, 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) and GAPDH, both of which were 
validated for consistent expression under these experimental conditions.  The HPRT, GAPDH, 
IL-12p40, IFNγ, TNFα, IL-1β, MCP-1, IL-10, IL-23 and IL-17A primer sequences used in this 
study are previously published8, 35-37.  IL-12p35, IL-6, CCR7, CCL19 and CCL21 primers were 
designed using transcripts from the EMBL Ensembl annotated genome browser28 for the guinea 
pig with the aid of Primer3 primer design software29.   
 The primer sequences are as follows: CCR7 (ENSCPOT00000012440) Forward 5'-
TGCTGACCCTTCCCTTCTGG, Reverse 5'-CATGCCGCTGAAGAAGCTCA; IL-12p35 
(ENSCPOT00000000016) Forward 5'-CTGAGGGCGGTGAACAGTGA, Reverse 5'-
GGCTTTCACGGTGCTGGTTT; IL-6 (ENSCPOT00000002030) Forward 5'-
TCCAGATGCCACCCTGCTGG, Reverse 5'-TCTTCAAGGCGCTGAAGGACGA; CCL19 
(ENSCPOT00000002661) Forward 5'-CCCTCAGCCTGCTGGTTCTC, Reverse 5'-
TCACGATGTTCCCAGGGATG; CCL21 (ENSCPOT00000005489) Forward 5'-
CCCTCTGCATCACCCAGACA, Reverse 5'-CTGCGGACGACCTTGTAGGG.  RNA isolates 
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without reverse transcription were amplified for each tissue isolate to ensure a lack of 
contaminating genomic DNA and all assays performed included no-template controls.  Data was 
expressed as normalized fold expression on a log2 scale. 
 
IFNγ  release assay by relative gene expression.  
Prior to euthanasia on days 10 and 19 of infection, 1 ml of peripheral blood was 
collected in EDTA anticoagulant from non-diabetic and diabetic guinea pigs.  Peripheral blood 
mononuclear cells were isolated from whole blood using Polymorph Prep (Cosmo Bio, 
Carlsbad, CA), which yields a population of lymphocytes and monocytes of greater than 95% 
purity from guinea pig blood based on cytologic evaluation (data not shown).  The collected 
whole blood was layered on top of 1.5 ml of Polymorph Prep and centrifuged at 400 x g for 30 
minutes at room temperature to separate PBMCs from granulocytes and erythrocytes.  PBMCs 
were isolated and washed in 5 ml of Hank's Balanced Salt Solution, then plated at a cell density 
of 100,000 cells per well of a 48-well tissue culture plate in RPMI-1640 with 5% fetal calf serum.  
Cells from each animal were stimulated with a combination of immunodominant antigens ESAT-
6 and CFP-10, concanavalin A as a non-specific mitogen, or ovalbumin as a non-specific 
antigen and negative control. Cells were cultured under these conditions for 24 hours then RNA 
isolated using methods outlined above, cDNA synthesized, and the relative expression of IFNγ 
transcripts measured by qRT-PCR.  All data was normalized to the IFNγ expression levels in 









The rate of bacterial growth is not altered by type 2 diabetes, but dissemination from the 
lung is delayed.    
Bacterial loads were assessed from lung, lymph node, spleen and liver on days 10 and 
19 of infection.  Bacterial growth was similar in both diabetic and non-diabetic lung at day 10 of 
infection and as expected, no extrapulmonary dissemination to spleen or liver was evident at 
day 10 of infection (Figure 5.1).  However, the frequency of cultivatable bacilli did differ in the 
lymph node early in infection on day 10.  In non-diabetic guinea pigs, 3 out of 4 had viable bacilli 
in the lymph node ranging from 2 to above 3 log10 CFU per gram of tissue.  In contrast, only 1 
out 4 type 2 diabetic guinea pigs contained viable bacilli in the lymph node on day 10 of 
infection.  The one remaining diabetic guinea pig had a lymph node bacterial load consistent 
with non-diabetic guinea pigs (Figure 5.2).  By day 19 of infection, extrapulmonary 
dissemination and bacterial loads in the lung in diabetic guinea pigs was not statistically 
different from non-diabetics (Figure 5.1), including similar bacterial load in the lung-draining 
lymph node (Figure 5.2).  As a result, the average rate of growth between days 10 and 19 of 
infection in non-diabetic and type 2 diabetic guinea pigs was similar, although minimally higher 
in type 2 diabetic guinea pigs at both time points evaluated.  
 
Development of an antigen-specific IFNγ  response is delayed in type 2 diabetic guinea 
pigs. 
At day 10 of infection, there was no detectable induction of IFNγ by the immunodominant 
antigens ESAT-6 or CFP-10 when compared to non-specific ovalbumin controls (Figure 5.3).  
However, non-specific expression of IFNγ was induced by the mitogen concanavalin A,  
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Figure 5.1. Pulmonary and extrapulmonary bacterial burdens do not differ early in M. tuberculosis 
infection. Bacterial burdens in the lung (A) on day 10 and 19 of infection are minimally higher in type 2 
diabetic guinea pigs but no significant change in the rate of M. tuberculosis growth can be demonstrated 
between these two infection time points.  As would be expected, no bacteria were cultured from spleen 
(B) or liver (C) on day 10 of infection, which precedes the stage of extrapulmonary dissemination. By day 
19 of infection, extrapulmonary burdens in spleen and liver are similar although minimally higher in type 2 













Figure 5.2. Arrival of viable bacteria to the lung draining lymph node is delayed in type 2 diabetic 
guinea pigs. (A) At day 10 of infection, a time when bacterial transport to the lymph node is expected, 
three of four non-diabetic guinea pigs had cultivatable organisms in the lung draining lymph node.  In 
contrast, bacilli were cultured from the lymph node of only one of four diabetic guinea pigs.  (B) By day 
19, lymph node bacterial burdens were similarly elevated in both non-diabetic and diabetic guinea pigs. 


















Figure 5.3. Development of antigen-specific cell-mediated immunity is delayed in type 2 diabetic 
guinea pigs. IFNγ expression was measured in PBMCs in response to specific antigen stimulation, non-
specific mitogen stimulation, and in the presence of a non-specific antigen (A) On day 10 of infection, 
prior to onset of adaptive immunity, there is no antigen specific induction of IFNγ in either non-diabetic or 
diabetic guinea pigs.  However, mitogen stimulated induction was equivalent in both groups. (n=4 per 
group)  (B) By day 19 of infection, inducible IFNγ production by ESAT-6 and CFP-10 antigens is evident 
in non-diabetic guinea pigs while diabetic guinea pigs remain unresponsive.  Similar to day 10, mitogen 
stimulation is equivalent in both groups. (n=4 per group)  All gene expression data is normalized to 







the response to which was similar between both non-diabetic and type 2 diabetic guinea pigs.  
However, by day 19 of infection, the production of antigen inducible IFNγ was detected in 
cultured PBMCs of non-diabetic guinea pigs (Figure 5.3).  In contrast, type 2 diabetic guinea 
pigs did not demonstrate any significant inducible IFNγ expression even at day 19 of infection, 
which was significantly different from the induction present in non-diabetic guinea pigs.  
However, mitogen stimulated IFNγ expression, induced by concanavalin A was similar between 
both diabetic and non-diabetic guinea pigs on day 19 of infection.  The ESAT-6/CFP-10 
inducible IFNγ expression in the non-diabetic guinea pigs correlated with an elevation in IFNγ in 
the lungs overall when compared to type 2 diabetic guinea pigs.  Similar elevation in total IFNγ 
was also present in the lymph node of non-diabetic guinea pigs on day 19 of infection compared 
to lymph nodes of type 2 diabetics (Figure 5.4).   
 
Disease severity does not differ early in disease but lymphatic lesion development is 
impaired in diabetic guinea pigs. 
 In non-diabetic and type 2 diabetic guinea pigs at day 10 of infection, there was minimal 
detectable lesion within the pulmonary parenchyma.  These areas consisted of infrequent and 
small aggregates of macrophages with rare neutrophils.  These lesions were present in 2 of 4 
guinea pigs in both non-diabetic and type 2 diabetic groups.  However, significantly different 
lesion manifestations were observed in the peribronchial tissue where aggregates of 
macrophage type cells surrounded, invaded and filled peribronchial lymphatic vessels.  These  
changes were present in all four of the non-diabetic guinea pigs with multiple sites in each lung 
section.  In contrast, only one of four type 2 diabetic guinea pigs displayed this lymphatic lesion, 
which consisted of a single small aggregate of cells (Figure 5.5).  Interestingly, this single 
animal was also the only diabetic guinea pig to contain cultivatable bacilli in the lung draining 










Figure 5.4. Expression of IFNγ  is reduced in the lung and draining lymph nodes of type 2 diabetic 
guinea pigs. Total expression of IFNγ was measured in the lung on day 10 and 19 of infection and 
draining lymph nodes on day 19 of infection.  IFNγ expression is reduced in diabetic guinea pigs on day 










Figure 5.5. Early development of pulmonary lymphangitis is greatly reduced in type 2 diabetic 
guinea pigs. Images from day 10 of infection are representative of pulmonary pathology present in the 
non-diabetic and type 2 diabetic guinea pigs.  (A, B) Non-diabetic lungs have consistent and larger 
inflammatory lesions surrounding and involving the peribronchial lymphatic vessels (arrow).  (C) In 
contrast, type 2 diabetic guinea pigs, in general, lack this lesion (arrow) or (D) in one animal, displayed a 










By day 19 of infection, early granuloma structures were present with central areas of 
neutrophil infiltration and loosely arranged peripheral walls of macrophages.  This lesion 
morphology was present in both diabetic and non-diabetic lung.  Lesion area was measured in 
the lung of both diabetic and non-diabetic guinea pigs.  Although 2 of 4 diabetic guinea pigs 
displayed higher total lesion area, no significant differences were present between non-diabetic 
and diabetic groups (Figure 5.6). 
 
Type 2 diabetic guinea pigs have reduced expression of critical chemokines and 
receptors.  
 Because lymphatic lesions were slow or failed to form in the type 2 diabetic guinea pigs 
at day 10 of infection, we investigated the chemokine signals known to be critical for migration 
of dendritic cells. CCR7 chemokine receptor transcripts were measured in lung and lymph node 
as well as the corresponding chemokine signals, CCL19 and CCL21.  In the lymph node at day 
19 of infection, relative expression of CCL19 and CCL21 were similar with slightly higher, but 
not statistically significant, expression in the type 2 diabetic guinea pigs (Figure 5.7).  Although 
less biologically relevant, the CCR7 receptor expression was also measured in the lymph node 
and again, no significant differences were identified between non-diabetic and type 2 diabetic 
guinea pigs.   However, in contrast, the relative expression of the CCR7 receptor was reduced 
in the lungs of type 2 diabetic guinea pigs early at day 10, which persisted with a more 
significant reduction by day 19 of infection (Figure 5.8).  An additional chemokine signal 
measured responsible for recruitment of inflammatory macrophages was MCP-1 (CCL2).  
Although no significant differences were identified in the lung at day 10 of infection, by day 19, 
the expression of MCP-1 was significantly reduced in diabetic guinea pigs.  














Figure 5.6. Severity of pulmonary disease does not differ between diabetic and non-diabetic 
guinea pigs.  Disease severity was measured by proportional lesion area based on total pulmonary TB 
lesions as a fraction of total lung area.  Although two diabetic guinea pigs display higher lesion burden in 



















Figure 5.7. Expression of chemokines for dendritic cell migration is not altered in lymph node of 
type 2 diabetic guinea pigs. The chemokines CCL19 and CCL21, responsible for recruitment of 
activated dendritic cells, were measured on day 19 of infection in the lung draining lymph nodes.  There is 
no significant difference in the expression of either chemokine between non-diabetic and diabetic guinea 




















Figure 5.8. The expression of dendritic cell chemokine receptor, CCR7, is reduced in the lung of 
type 2 diabetic guinea pigs. The chemokine receptor CCR7, required for migration of dendritic cells to 
the draining lymph node for antigen presentation, is reduced on day 10 of infection in diabetic lung and 
more significantly reduced by in diabetic guinea pigs by day 19 of infection.  There is no significant 








The early innate pulmonary cytokine profile is shifted in type 2 diabetic guinea pigs. 
 Cytokines that mediate a pro-inflammatory response, or the transition from innate to 
Th1-biased cell mediated immunity were evaluated.  At day 10 of infection, few significant 
differences were identified between non-diabetic and type 2 diabetic guinea pigs (Figure 5.9).  
At day 10 of infection, IL-8 expression and IL-1β expression were both elevated in type 2 
diabetic guinea pigs at 6.4- and 6.1-fold higher relative expression, respectively.  No significant 
differences were noted at day 10 of infection in TNFα, IL-6, IFNγ, IL-12p40, IL-12p35, IL-23 or 
IL-17.  In contrast, by day 19 of infection, there were multiple significant differences in the innate 
cytokine expression profile of type 2 diabetic guinea pigs (Figure 5.10).  Although no significant 
changes were identified in the expression of the heterodimeric cytokine IL-12, as indicated by 
equivalent IL-12p40 and IL-12p35 expression, the expression of IL-23 (IL-12p19) was 52.3-fold 
lower in diabetic guinea pigs, which corresponded with a 40.2-fold reduction in expression of its 
induced cytokine, IL-17.  Also reduced in type 2 diabetic guinea pigs was the relative expression 
of TNFα by 3.1-fold (P=0.11).  In contrast, the cytokines IL-6 and IL-8 (P=0.1) were elevated in 




 Previously we had investigated the course of TB progression and immune response in 
diabetic guinea pigs at day 30 of infection, a time when the cell-mediated immune response was 
strongly evident based on high IFNγ production, presence of activated CD45high CD4 and CD8 T 
cells, and a distinguishable population of activated MHCIIhigh macrophages8.  At this time in the 
course of infection, diabetic guinea pigs responded with what typically would be interpreted as 
an appropriate cell-mediated response with Th1 skewed IFNγ-expression and a higher 











Figure 5.9. Cytokine profiles at day 10 of infection are indicative of a pro-inflammatory response in 
the lung of diabetic guinea pigs. Select cytokines that function in macrophage activation and 
bactericidal activity or promotion of a Th1 skewed cell-mediated response as well as chemokines for 
neutrophil and macrophage recruitment was measured by relative gene expression qRT-PCR.  
Alterations in early innate cytokine expression on day 10 of infection are limited to elevations in pro-
















Figure 5.10. The inflammatory profile in the lung of diabetic guinea pigs at day 19 of infection is 
dominated by atypical cytokines. The same activating and Th1 cytokines were measured on day 19 of 
infection in lung.  Expression of IL-6 and IL-8 (P=0.1) are elevated in diabetic guinea pigs while TNFα 
(P=0.11), MCP-1 (P=0.1), IL-23 and IL-17 are all reduced in diabetic guinea pigs compared to non-







favorable response, diabetic guinea pigs were unable to control the bacterial growth and in 
contrast, to non-diabetic guinea pigs, manifested with a pro-inflammatory response involving 
heightened innate cytokine expression and damaging suppurative inflammation.  However, it 
was not apparent whether this severe manifestation of TB in diabetic guinea pigs occurred only 
after onset of adaptive immunity or if such a response was consistent throughout infection in 
diabetic guinea pigs; or what factors may have contributed to such high bacterial growth. In this 
study, we targeted day 10 and day 19 of infection as predetermined endpoints to evaluate 
disease progression because this spans the initiation of transitional innate and adaptive 
immunity in the lymph node and the earliest onset of antigen-specific cell-mediated immunity in 
the lung in guinea pigs, inferred from previous histopathological and immnunohistochemical 
analyses in the guinea pig and immunological investigations in mouse models38-41. 
 The induction of a Th1 dominated cell-mediated immune response is a critical factor in 
the progression of TB disease because it both limits bacterial growth and progressive 
inflammation.  It is well documented that disease progression is limited after the onset of IFNγ 
production in M. tuberculosis infection and recently an anti-inflammatory function of IFNγ has 
been attributed to limiting the neutrophilic inflammatory response42.  Additionally, IFNγ 
generously promotes the production of nitric oxide in infected macrophages and greatly 
enhances their bactericidal capacity43.  Therefore, with an assumed protective function of this 
key cytokine, it was surprising to identify more severe TB disease in the face of high IFNγ 
expression in diabetic guinea pigs and we hypothesized that the response may be exacerbated 
by the significantly higher bacterial burdens present in diabetic guinea pigs. 
 Among the most critical factors in the establishment of a cell-mediated immune response 
during M. tuberculosis infection is the timing of this response.  In any circumstance, the earlier 
generation of cell-mediated immunity, either through BCG-induced memory response after 
immunization44, or through the use of mutated and less virulent M. tuberculosis strains, has 
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resulted in earlier pulmonary cell-mediated immunity and consequently, better control of 
bacterial growth27, 45, 46.  Consistent with previous data in the mouse model, we have identified a 
significant delay in the onset of antigen-specific cell-mediated immunity in diabetic guinea pigs 
measured based on IFNγ transcription in response to stimulation with ESAT-6 and CFP-10, two 
immunodominant antigens of M. tuberculosis, which serve as the basis of human IFNγ release 
diagnostic assays30, 47.  However, in contrast to previous studies in human patients, PBMCs of 
diabetic guinea pigs did not display reduced non-specific IFNγ production in response to 
mitogen stimulation48. This delayed response may represent a fundamental underlying 
mechanism of diabetic susceptibility to TB by allowing bacterial growth to continue unopposed 
until finally, when pulmonary adaptive immunity arrives, effector T cells must respond to a very 
high antigen load.   
 The potential involvement of delayed cell-mediated immunity in impaired control of 
bacterial growth in diabetic guinea pigs is further supported by the observation that pulmonary 
bacterial growth in diabetic guinea pigs did not differ significantly from non-diabetic controls out 
to day 19 of infection, indicating no difference in the rate of growth between the groups.  
Additionally, by day 19 of infection, bacterial growth in non-diabetic had reached a level similar 
to what was also observed previously at day 30 of infection.  This suggests that while bacterial 
growth is controlled after onset of cell-mediated immunity in non-diabetics, the growth continues 
in diabetic guinea pigs in the absence of T cell help.  However, an additional consideration for 
bacterial growth in diabetics is the excess availability of both lipid and carbohydrate nutrients.  
Previously, we had shown that exogenous dietary supplementation with sucrose increases 
bacterial growth in the guinea pig model of TB, but the impact of this on immune function is 
unknown.   
 This delayed adaptive response in diabetic guinea pigs was evident at day 19 of 
infection, a point in the course of infection where pulmonary cell-mediated immunity is being 
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initiated and suggests that the development of this response is fundamentally delayed at the 
level of antigen presentation in the lymph node.  This interpretation is supported by the fact that 
IFNγ production was lower at day 19 of infection not only in the lung of diabetic guinea pigs, but 
also in lung-draining lymph node.  In contrast, non-diabetic guinea pigs demonstrated higher 
IFNγ production in both sites, which correlated with an antigen-inducible response in PBMCs 
stimulated in vitro.   
 Lymphatic pathology, characterized by lymphangitis due to infiltration with macrophage-
type cells, is one of the earliest characteristic lesions to form in the guinea pig model of TB and 
the inflammatory involvement of the lymph node is also well-documented in human TB, 
particularly in children38, 49.  This highlights the importance of cell migration to lymphatics and 
subsequent development of lymphadenitis in this model species, which closely reflects the 
lesion morphology and progression in human TB.  In this study, we observed a generalized lack 
of early pulmonary lymphangitis in diabetic guinea pigs on day 10 of infection, which suggests 
impaired migration of antigen presenting cells to the draining lymph node; however, this finding 
would be better supported by additional phenotypic identification of the cells and a larger 
sample size to account for low sensitivity of the histopathological approach to tissue sectioning.  
However, impaired migration is further supported by the observation that cultivatable bacilli in 
the lung draining lymph node were isolated from only 25% of diabetic guinea pigs on day 10 of 
infection, in contrast to 75% of non-diabetics.  Previously, it has been shown that transport of 
viable bacilli to the lymph node by pulmonary dendritic cells is required for the timely 
establishment of an adaptive immune response to TB41, 50, and our data suggests that impaired 
migration of antigen presenting cells may underlie the delayed development of adaptive 
immunity in diabetic guinea pigs.  
 We have identified several potential factors in this study that may contribute to impaired 
antigen presenting cell migration and delayed antigen-specific Th1 immunity.  Perhaps the most 
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important, and a potential driving force in the diabetic susceptibility to TB, is the early increased 
expression of IL-6 in the lungs of diabetic guinea pigs.  IL-6 is a pleiotropic cytokine whose role 
in the response to M. tuberculosis infection is not well understood, but has a documented role in 
the inflammatory pathogenesis of type 2 diabetes51-53.  Many cell types, beyond immune cells, 
have the capacity to produce IL-6, including pulmonary epithelium54. The production of IL-6 is 
not limited to immune cells and in a state of insulin resistance, the majority of IL-6 is produced 
by adipose, liver, and skeletal muscle.  The induction of IL-6 is dispensable for control of M. 
tuberculosis growth and antigen specific immunity, but its absence leads to progressive 
inflammation early in disease55-57.  However, when present in high concentrations, IL-6 impairs 
the induction of a productive Th1 response58.  More recently, a reduced Th1 effector response 
has been demonstrated in SOCS3 deletion mice lacking the primary suppressor of IL-6 
signaling, wherein it was hypothesized that persistently high IL-6 impairs IL-12 production and 
therefore generation of Th1 biased immunity from the critical IL-12-IFNγ axis59.  A reduced 
production of IL-12 has also been demonstrated during in vitro M. tuberculosis infection of 
PBMCs from type 2 diabetic human patients, linked to the oxidative stress of diabetes and lower 
concentrations of intracellular reduced glutathione (GSH)60.  Although IL-12 is required for 
dendritic cell migration and T cell priming61, our data does not reflect the conclusions of these 
two studies because IL-12, measured as relative expression of both IL-12p35 and IL-12p40 
components of the cytokine, did not differ between non-diabetic and diabetic guinea pigs.   
 Equivalent expression of IL-12 and the observation of delayed arrival of M. tuberculosis 
bacilli at the regional lymph nodes led us to investigate other potential contributions to a delayed 
onset of cell-mediated immunity.  Chemokines play an important role in the transition from 
innate to adaptive immunity during M. tuberculosis infection and because of the lack of 
lymphatic lesions in diabetic guinea pigs, we investigated the expression of chemokines and 
their receptor implicated in dendritic cell migration to the lymph node during infection62.  CCL19  
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and CCL21 are chemokines produced in the lymph node and provide a gradient for the 
migration of activated dendritic cells expressing the chemokine receptor, CCR762, 63.  In this 
study, we show that the expression of CCL19 and CCL21 in lung-draining lymph nodes is not 
impaired in diabetic guinea pigs and actually is slightly elevated, suggesting that the migratory 
signal is not involved in delayed delivery of viable bacilli to the lymph node.  However, we 
observed a significant reduction in the CCR7 receptor in the lung on both days 10 and 19 of 
infection, which may have an impact on the migratory responsiveness of dendritic cells to 
CCL19 and CCL21. It should be noted however, that CCR7 is also expressed on lymphocytes 
and this reduction may not be entirely reflective of the dendritic cell population.  Previously, 
suppressive effects of IL-6 on dendritic cell function have been demonstrated by impairing 
migratory capacity through reduction of surface CCR7 expression64.  Our data of high 
pulmonary IL-6 in the presence of low CCR7 expression are consistent with the findings of this 
study and suggest that diabetes-induced IL-6 may play a central role in the delayed 
establishment of Th1 cell-mediated immunity in diabetic guinea pigs.   
 Other factors may also be involved in the early diabetic response to infection.  TNFα has 
been shown to make a large contribution to the overall early innate response to M. tuberculosis 
infection65.  In the absence of TNFα, early bacterial control is impaired and Th1 immunity is 
reduced.  Additionally, TNFα contributes significantly to the fate of macrophages containing 
intracellular bacilli66.  When TNFα is blocked or induced in excessive concentrations, the 
induction of apoptosis associated with TNFα is reduced67.  Apoptosis is a critical mediator in the 
development of cell-mediated immunity by increasing the acquisition of bacilli and subsequent 
activation of pulmonary dendritic cells45.  We have identified here that TNFα expression is 
reduced in diabetic guinea pigs early in infection.  Interestingly, high IL-6 is known to reduce 
TNFα expression68-71, further implicating the role of IL-6 in diabetic susceptibility to TB.   
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 In stark contrast to our previous evidence of high IL-17 in diabetic guinea pigs at day 30 
of infection, which may support a damaging neutrophilic inflammatory response72, we show here 
that early in infection, the opposite is true of diabetic guinea pigs where expression of both IL-17 
and its inducing cytokine, IL-23 are markedly reduced in diabetic guinea pigs.  The role of this 
amidst the other immunological alterations identified early in the course of diabetic infection is 
uncertain.  IL-23 promotes early IL-17 production by γδT cells early during M. tuberculosis 
infection and recruits neutrophils to the site of infection, a cell type also shown to be important in 
the development of adaptive immunity46, 73.  However, in mice, the adaptive response develops 
adequately in the absence of IL-12p19, the component defining the IL-23 heterodimeric 
cytokine, as long as IL-12p70 is present44, 74.  Considering these studies, our data showing that 
expression of IL-12p70 components was unaltered questions the importance of low IL-23 in the 
pathogenesis of tuberculosis-diabetes comorbidity in our guinea pig model.  
 Although this study is limited by low sample size, we have identified some important 
alterations in early immune function with statistical differences. From this study, it is apparent 
that a delayed cell-mediated immune response may represent a fundamental pathway leading 
to more severe TB disease in diabetic guinea pigs. We have learned that bacterial growth does 
not occur earlier or more rapidly in diabetic guinea pigs but rather, bacterial burdens reach 
higher levels before they can be controlled, which may be a direct result of delayed cell-
mediated immunity.  It is anticipated that the severe TB disease in diabetics is in response to 
this high bacterial growth, but determining the role of antigen load requires further investigation.   
In order to improve the timing of the cell-mediated response that occurs due to diabetes, a 
better understanding of the underlying mechanisms for this delay will be necessary.  We have 
identified factors that could contribute to delayed immunity in diabetic guinea pigs, all of which 
have been previously linked to the over production of IL-6. Therefore, further investigation of the 
role for this cytokine in more severe TB disease in diabetic guinea pigs will help to identify novel  
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pathways and therapeutic targets to reduce the burden of TB disease in patients with diabetes. 
In conclusion, we have demonstrated that severe disease and damaging inflammation is not a 
continual process in diabetic guinea pigs but instead, occurs after a delayed onset of adaptive 
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Final Discussion and Future Directions 
 
 Less than 10% of individuals exposed to M. tuberculosis will develop active TB disease.  
The active form of TB, whether developing upon exposure or as reactivation from the latent form 
of M. tuberculosis infection, is often associated with a factor of susceptibility intrinsic to the host 
or from an acquired risk factor1.  The previous epidemic and ongoing association of HIV with M. 
tuberculosis infection highlights the impact that a particular risk factor can have on TB 
incidence2.  In the 1990's HIV-associated TB had nearly doubled the incidence of TB in some 
areas of subsaharan Africa where HIV was most prevalent, and during this time, TB emerged as 
the most important opportunistic infection and cause of death in HIV patients3-5.  In hindsight, 
more controlled and dedicated efforts to diagnose and treat HIV-TB comorbid individuals may 
have limited the impact of this epidemic on the overall control of TB2.  
 A primary contributing factor to this comorbidity was the convergence of the HIV 
epidemic on countries in Africa already having high endemic prevalence of TB.  Now, TB 
endemic countries are faced with a growing epidemic of non-communicable diseases, perhaps 
the most important of which is diabetes, a known risk factor for TB6.  Although at the individual 
level, diabetes has a lesser impact than that of HIV, there is a much larger and rapidly growing 
diabetic population, which creates a population attributable risk for TB that is approximately 
equivalent to HIV7.  Reflecting on lessons learned from the HIV-TB epidemic, a collaborative 
framework has already been established recognizing the importance of early detection and 
treatment in diabetes-TB comorbidity and has defined a research agenda to reduce the impact 
of diabetes on TB control8, 9.   
 However, the mechanisms by which diabetes predisposes to the development of active 
TB still remain poorly defined.  A better understanding of this pathogenesis will contribute  
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greatly to the prioritized agenda to identify the most successful approaches for diagnosing and 
treating TB in the face of diabetes and vice versa.  However, investigations using animal models 
to gain further insight into TB pathogenesis, efficacy of new treatment strategies and evaluation 
of preventive strategies are infrequently modeled in the context of TB risk factors, including 
diabetes, which we have shown in these studies can have a significant impact on the response 
to infection with M. tuberculosis10.    
 In the previous chapters, we have identified a number of important conclusions, which 
have led to the development of novel hypotheses, a theoretical model for how diabetes leads to 
more severe TB disease, as well as new therapeutic targets to improve the course of TB and 
response to treatment, both in diabetes-TB comorbidity and in the absence of diabetes as a risk 
factor.   
 The model chosen to study any disease, including tuberculosis, should be carefully 
selected to have the greatest translational potential for application to human disease.  
Unfortunately, an exact replicate of human TB disease is not provided by any animal species, 
and all have their advantages and disadvantages11.  Although the non-human primate is 
arguably the most reflective animal model of TB, the use of this species in TB studies is 
cumbersome and expensive.  In our work, the guinea pig model was chosen because this 
model closely reflects the pathology and progression of active TB in humans and has been 
relied upon with frequency for the evaluation of new treatment and preventive strategies.  
During these studies, we developed the first model of type 2 diabetes in the guinea pig, which 
develops diet-induced glucose intolerance and reduced β-cell mass based on a design to 
closely mimic the pathogenesis of insulin resistance and subsequent type 2 diabetes in humans.  
 Evaluating this model in the context of type 2 diabetes and TB comorbidity, we learned 
that type 2 diabetic guinea pigs infected with M. tuberculosis develop many of the reported  
clinical features of TB in diabetic human patients including high bacterial burdens, more 
numerous and severe TB lesions, and a dysregulated immune response involving higher innate 
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and type 1 cytokines10, 12-14.  Using this model, we have shown that despite strong Th1 cell-
mediated immunity, which is known to be critical for the control of TB, diabetic guinea pigs 
infected with M. tuberculosis develop a high lung and extrapulmonary bacterial burden 
accompanied by an unfavorable inflammatory response predominated by neutrophilic 
infiltration10.  These data indicate that in diabetic guinea pigs, early immune responses are 
unable to contain bacterial growth, which leads to exacerbated immunopathology.  
 The observation that diabetic guinea pigs developed more severe disease in the 
presence of a bacterial burden nearly 100-fold higher than non-diabetic guinea pigs led us to 
investigate the early immune factors that might allow for such exuberant bacterial growth.  We 
had originally hypothesized that an exacerbated immune response would be present from early 
on in the course of infection, rationalized based on the robust inflammatory response identified 
in our type 2 diabetic guinea pig model and also reported in the human comorbidity13, 14.  
However, we have now linked the severe TB disease manifested in diabetic guinea pigs to 
generally hyporesponsive innate immunity early in the course of disease, highlighted by reduced 
involvement of the pulmonary lymphatic system and draining lymph nodes, which is the site of 
antigen presentation and development of the cell-mediated immune response15, 16.  
Furthermore, diabetic guinea pigs had delayed development of antigen-specific cell-mediated 
immunity, the timing of which is critical for the effective control of bacterial growth in the lung 
and extrapulmonary sites because the production of IFNγ by antigen-specific T cells is generally 







From these conclusions we have generated a hypothetical model of the pathogenesis of 
tuberculosis in diabetic guinea pigs, depicted in the following figure, that ultimately leads to 




Figure 6.1. Proposed pathway leading to delayed cell-mediated immunity and more severe TB 
disease in diabetic guinea pigs. IL-6 is a proposed central mediator, which may be the result of AGE-
induced RAGE signaling on respiratory epithelium and macrophages. IL-6 serves as a survival signal to 
macrophages by activation of STAT3, leading to decreased apoptosis, and also impairs dendritic cell 
migration by reducing CCR7 expression. In turn, a delayed cell-mediated response occurs because of its 
dependence on apoptosis and bacterial transport to the lymph node for timely initiation.  This delay allows 
for substantial bacterial growth in the lung such that, upon encounter by a Th1 response, the severity of 





 It is recognized in both humans and mice that the onset of adaptive immunity is delayed 
normally in M. tuberculosis infection, even in the absence of known risk factors15, 18, 21, 22. This 
delay allows for bacteria to replicate to a high level, such that upon arrival of the cell-mediated 
response in the lung, the bacterial growth can only be controlled but not eliminated.  We have 
demonstrated in these studies that cell-mediated immunity is further delayed under the influence 
of diabetes.  We propose that this additional delay allows for continued growth of M. 
tuberculosis in the lung to an extent that exceeds the burden typical of a guinea pig without 
diabetes.  This is further supported by the observation that the rate of bacterial growth is not 
accelerated in our type 2 diabetic guinea pig model compared to non-diabetic guinea pigs.  
Instead, we propose that bacterial growth is simply allowed to go unopposed for a longer period 
of time in diabetics because of prolonged absence of Th1-based IFNγ production.   
 Because plateaued growth of M. tuberculosis corresponds with the presence of antigen-
specific Th1 immunity in the lungs17, and diabetic guinea pigs did not develop severe disease 
until after Th1 immunity was evident in the lung, we suspect that this delay in adaptive immunity 
is a critical feature mediating the development of severe TB disease, which is driven by high 
antigen load. In support of this interpretation, these findings closely mimic immune reconstitution 
inflammatory syndrome (IRIS), where an injurious IFNγ response to excessive bacterial growth 
occurs upon restitution of immune function in end-stage HIV and M. tuberculosis co-infected 
individuals23. Individuals with TB-HIV IRIS develop severe and atypical neutrophilic 
inflammatory responses that are also manifested in the mouse model of IRIS and are very 
similar to the exacerbated neutrophilic response identified in the guinea pig model of type 2 
diabetes24.   
 The underlying mechanisms that lead to the severe disease associated with IRIS remain 
unknown but one fundamental requirement is the presence of antigen-specific T cells, indicating 
that this is an exacerbated innate response to T cell help24, which we hypothesize also occurs in 
229 
	  
response to high antigen load in diabetic guinea pigs.  Previous research indicates that IFNγ 
may be involved in this process but these results contradict the normal regulatory and beneficial 
function assigned to this molecule in TB pathogenesis25. In future studies, it will be important to 
determine the role of CD4 T cells, and IFNγ itself, in the uncontrolled growth of bacteria in the 
lung and an exacerbated response to high antigen load.  Conversely, it will also be important to 
determine if high bacterial growth in diabetic guinea pigs is what contributes to over-production 
of IFNγ and leads to severe and damaging inflammation.   
       It is known that insulin resistance is mediated by inflammation and as a result, type 2 
diabetes can be classified as an inflammatory disease26.  Consequently, it is possible that 
preexisting low-grade inflammation from type 2 diabetes may impact the response to infection. 
We have identified two potential pre-existing inflammatory factors that could have an early 
impact on the host response to M. tuberculosis infection; IL-6 and the interaction of advanced 
glycation end products (AGEs) with their receptor RAGE.  The source of IL-6 in diabetes 
pathogenesis is not limited to inflammatory cells.  Many cell types are capable of producing IL-6 
and are involved in obesity-associated inflammation including adipocytes, hepatocytes, and 
skeletal myocytes27, 28.  The RAGE receptor is over expressed in diabetes due to transcriptional 
activation by its own signaling pathway29.  
 In diabetic guinea pigs, we have identified increased expression of the RAGE receptor in 
lung, which normally has the highest expression of all organs, and also increased pulmonary 
expression of IL-6, which may be epithelial derived30, 31.  Linking these together, we have also 
confirmed that IL-6 is a major product of RAGE signaling in the presence of AGE ligands, using 
guinea pig macrophages. Since IL-6 is, (1) a major product of RAGE signaling32; (2) is known to 
impair a cell-mediated immune response in TB33; and (3) was shown to be significantly 
increased early in M. tuberculosis infection of diabetic guinea pigs, it will be important in future 
studies to identify the role that IL-6 may have in the delayed adaptive immune response of 
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diabetic guinea pigs.  IL-6 is known to impair dendritic cell function by reducing CCR7 
expression and inhibiting migration34, data that is consistent with our observations made during 
early M. tuberculosis infection of diabetic guinea pigs.  Additionally, IL-6 may promote survival of 
macrophages through STAT3 transcriptional activation.  The STAT3 transcriptional factor is 
constitutively activated in type 2 diabetes and has previously been shown to inhibit macrophage 
apoptosis in obesity-associated inflammatory disease35, 36.  Both dendritic cell migration and 
macrophage apoptosis are critical components in the transition from innate to adaptive immunity 
and the generation of a Th1 cell-mediated immune response37, and will be investigated further 
in future studies.  
 In both diabetic and non-diabetic guinea pigs, we have shown that glucose intolerance 
and hyperglycemia exacerbates the progression of TB disease and leads to the formation of 
advanced glycation end products (AGEs)38. AGEs, a pathologic and unregulated byproduct of 
non-enzymatic glycation, function as pattern recognition molecules to promote a sustained pro-
inflammatory host response by signaling through the receptor for AGEs (RAGE)39, 40.  AGE-
RAGE signaling and oxidative stress mediated by AGEs are fundamental pathogenic 
mechanisms directly linked to the high morbidity and mortality associated with the complications 
of uncontrolled diabetes39-42; however, the role of this interaction in diabetic susceptibility to 
infections, including M. tuberculosis, is unknown.  The direct relationship between 
hyperglycemia and glycation in the pathogenesis of diabetic complications, the evidence that 
uncontrolled hyperglycemia is a greater risk factor for TB than individuals with controlled 
diabetes, and the presence of a dysregulated inflammatory response in diabetic, M. tuberculosis 
infected guinea pigs that accumulate AGEs, implicates AGE-RAGE signaling in the 
pathogenesis of diabetes-TB comorbidity.  Studies investigating the role of AGEs in diabetes as 
well as RAGE in other infectious diseases have been performed previously using inhibitors of 
AGE formation as well as high-affinity RAGE inhibitors, and also through the therapeutic use of 
the decoy receptor for RAGE ligands known as soluble RAGE (sRAGE)43-45.  These techniques 
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could be employed in future studies to evaluate the role of AGE-RAGE signaling in the 
development of severe TB disease in diabetic guinea pigs.  
 Up to this point, I have described a proposed pathogenesis for diabetic susceptibility to 
TB that revolves around immunological mechanisms.  However, an alternative hypothesis that 
certainly deserves consideration is the contribution of host-derived nutrient availability to the 
bacterium. In these studies we identified that M. tuberculosis infection, by itself, is capable of 
inducing severe metabolic disturbances in both glucose and lipid metabolism, resembling insulin 
resistance and diabetes.  As a result, we have established the guinea pig as an ideal animal 
model to study interventions on the TB-associated metabolic disturbances that mimic what had 
been reported in humans years ago46, 47.  It is well known that TB disease results in a catabolic 
syndrome historically known as "consumption", leading to cachectic wasting of muscle and fat, a 
process that is likely a result of the metabolic disturbances that we identified in the guinea pig.  
Results from this study suggest that increased nutrient availability may significantly impact TB 
disease either at the host or bacterial level because exogenous feeding of sucrose enhanced 
bacterial growth and led to more severe TB pathology.  Whether immune defects were present 
in these sucrose-fed, non-diabetic guinea pigs is unknown, but based on these results, a 
reasonable hypothesis to pursue is that excess nutrient availability, whether exogenous or host-
derived, contributes to the growth and persistence of M. tuberculosis in the host.   
 It is anticipated that that the host metabolic derangements are an adaptive response of 
the host to chronic inflammation but that the M. tuberculosis bacterium benefits from host 
nutrient availability.  At this point, the impact of excess host metabolites on immune function and 
host response to the infection is unknown.  However, lipid sequestration and cholesterol 
accumulation within chronic granulomatous lesions of M. tuberculosis infected animals as well 
the frequent use of PET-CT imaging to identify experimental tuberculous lesions are indicative 
of altered metabolism in the host inflammatory response48, 49.  Additionally, recent emphasis has 
been placed on metabolism of the organism itself and its utilization of host derived molecules.  
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Although the pool of carbon sources utilized by M. tuberculosis bacilli are not fully understood, 
those that are most readily used are fatty acids and cholesterol, which may be host derived and 
contribute to lipid accumulation within the bacteria that is characteristic of bacilli in a dormant or 
persistent state, as well as changes in cell wall lipid constituents50-52.  Additionally, recent 
evidence suggests that bacilli may also use glucose in vivo to establish a persistent infection53, 
which is likely to be readily available in a state of uncontrolled diabetes.     
 The hypothesis that derangement of host metabolism is a treatable response to infection 
has emerged from this study, where an improvement in glucose and lipid metabolism would be 
targeted to improve both the host response to infection and also the severity and progression of 
wasting associated with this disease. It would therefore be important to know the impact of 
limiting host-derived nutrients on the viability and metabolic state of TB organisms. The course 
of antimicrobial treatment for TB is exceedingly long and is complicated by adverse toxicity in 
human patients, especially in multidrug resistant TB cases, where treatment regimens may 
reach years in duration.  Alternative and adjunctive therapies are greatly needed to reduce the 
length of treatment required with antimicrobials alone, and the implementation of metabolic 
interventions, by repurposing FDA-approved drugs for the treatment of type 2 diabetes, to target 
the metabolic disturbances associated with chronic inflammation of TB, may represent one such 
alternative approach.   
 The guinea pig model will serve as an excellent starting point to investigate these 
alternative treatment strategies.  Ideally, first a better understanding of the degree of insulin 
resistance that occurs during TB and the pathogenesis leading to altered lipid metabolism 
should be identified.  Using multiple therapeutic strategies to reduce glucose load, promote 
retention of adipose lipid content and reduce lipolysis, and interfere directly with the signaling 
mechanisms related to the pathogenesis of altered lipid metabolism in type 2 diabetes, 
represents an ideal approach to translating the manifestations of metabolic syndrome and type  
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2 diabetes to that of TB-related chronic inflammation.  Based on the demonstrated alterations in 
glucose and lipid metabolism, we have a series of therapeutic targets that can be addressed to 
further clarify the pathogenesis of TB-associated metabolic disease and identify novel 
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